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DNA topoisomerase IIβ is an enzyme that manipulates DNA topology. Its mechanism of action 
involves introduction of transient breaks in the DNA phosphodiester backbone enabling the 
passage of another DNA strand through the break. TOP2β has been suggested to be implicated in 
chromosomal translocations associated with development of secondary malignancy induced by 
anti-cancer drugs that targeting TOP2 enzymes. TOP2β also plays a role in transcriptional 
regulation, possibly via the introduction of transient DNA breaks at promoters enabling local 
remodelling of chromatin. 
To investigate the isoform-specific contribution of TOP2β in cytotoxicity and genotoxicity of 
TOP2 targeting drugs, a Nalm6 cell line previously knocked out for TOP2β and its parent cell line 
were utilised in this study. Their response to drugs idarubicin or daunorubicin alone or in 
combination with Ara-C has been investigated. 
Gene expression was investigated by RNA-seq of the Nalm6 cell lines. Analysis showed that 
expression of a number of genes was altered and this was confirmed by RT-qPCR on the same cell 
line. To be sure which genes changed a new Nalm6 TOP2β knockout was generated by CRISPR 
cas9. In the newly created knockout, RT-qPCR was carried out to confirm which genes still had 
altered gene expression. Strikingly, CBR1, a gene implicated in doxorubicin-induced 
cardiotoxicity, was found to be down regulated in both Nalm6 TOP2β knockout lines. Chip 
followed by RT-qPCR confirmed that TOP2β was involved in regulating CBR1 transcription. 
I also generated several TOP2β knockout clones in further two cell lines (K562 and SH-SY5Y) 
using CRISPR. The response of wild type and three knockout SH-SY5Y clones to retinoic acid 
was compared in a number of ways including neurite outgrowth and RT-qPCR. Differential gene 
expression pattern was investigated using RNA-seq followed by IPA analysis. Results showed 
reduced level of ATRA-induced differentiation in the knockout cells compared with wild type. 
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1 Chapter One: Introduction 
1.1 Structure and organization of the human genome 
1.1.1 Chromatin architecture  
In humans, the genetic material (genome) is a deoxyribonucleic acid (DNA) double helix (Watson 
and Crick, 1953b; Watson and Crick, 1953a) packaged inside the nucleus as a polymer of DNA-
protein complex called chromatin (McGhee and Felsenfeld, 1980). The chromatin is progressively 
organized across levels ranging from to the lowest scale (nucleosome core particle) to the highest 
scale (chromosome) organization (McGinty and Tan, 2014). The basic structure of chromatin is a 
repeating unit called a nucleosome (Bradbury, 1976; Kornberg, 1977; Luger et al., 1997).  
Each nucleosome has a nucleosome core which is an octamer histone protein (consisting of two 
copies of 4 core histones namely H3, H4, H2A, and H2B) (Kornberg and Lorch, 1999) wrapped 
by 145–147 base pairs of the DNA duplex (~1.65 times) (Luger et al., 1997; McGinty and Tan, 
2014). The DNA segment between each two nucleosome cores is called linker DNA. Another 
histone molecule H1 acts as a linker histone. H1 is added to the four histone cores which wrap 20 
more base pairs of linker DNA, resulting in a total of ~166 base pairs of DNA wrapped around 
histone (~ 2 turns). The nucleosome core together with the linker histone H1 form a chromatosome. 
The chromatosome with the rest of linker DNA is called nucleosome (McGhee and Felsenfeld, 








Figure 1-1 Nucleosome components 
Figure shows nucleosome core, chromatosome, and nucleosome wraps DNA (blue line). This figure was  
reproduced from (McGinty and Tan, 2014) with permission. 
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The four core histones arranged as two H2A–H2B heterodimers with each heterodimer interacting 
with one half of the H3-H4 tetramer (Bradbury, 1976; Luger et al., 1997; Kornberg and Lorch, 
1999). These core histones have terminals (tails) of amino acid residues that expends between 
adjacent DNA gyres and around nucleosomes  and are subjected to posttranslational modifications 
such as methylation, acetylation, phosphorylation, and ubiquitination (Luger et al., 1997; Kornberg 
and Lorch, 1999; Wu and Grunstein, 2000).  
Arrays of nucleosomes with the DNA at this level of chromatin organization have been described 
as fibres of “beads on a string” due to their appearance in electron micrographs (Oudet et al., 1975; 
Kornberg and Lorch, 1999). These arrays of nucleosomes (11 nm wide) joined by DNA represent 
the primary structure of chromatin and occur in interphase and mitosis (McGinty and Tan, 2014).  
Similar to protein structure, chromatin primary structure can be further organised to form higher 
levels of organization (McGinty and Tan, 2014). Linker histone H1 represents a scaffold for 
molecular interaction between the 11 nm fibres to reversibly form higher levels of chromatin 
organization into larger fibres of approximately 30 nm width (McGinty and Tan, 2014; Hansen et 
al., 2018) (Figure 2.1). Despite the extensive research over the past decades, there is no agreement 
upon the structure of the 30 nm fibres (McGinty and Tan, 2014). The 30 nm fibres represent the 
secondary structure of chromatin. These fibres can further interact with other secondary structures 
to form tertiary chromatin structures (Luger et al., 2012). 
Further levels of chromatin organization are represented by folding of fibres to form array of loops 
that are structurally attached to the nuclear matrix or chromosomal scaffold components (Figure 
2.1). These chromatin loops were first recognized as domains of supercoiled DNA with individual 
























Figure shows hierarchical arrangement of chromatin inside the nucleus. This figure was reproduced from 
(Berezney, 2002) with permission. 
 
With the advent of three dimensional fluorescence microscopy and quantitative computer imaging, 
studies of sites of DNA replication showed that these chromatin loops organized into distinct 
replication sites consisting of ~1 Mbp of DNA. These replication sites were shown to be unchanged 
during the cell cycle and remain preserved in the further cell generations as chromatin domains 
(CDs) with each domain containing 5-6 of the previously recognized chromatin loops (Ma et al., 
1998; Berezney, 2002).  
Subsequently, further microscopic and biochemical studies have recognized these CDs as essential 
units of higher chromatin assembly (Berezney, 2002). The development of the chromatin 
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conformation capture (Hi-C) technique at a whole-genome scale with high resolution led to the 
identification of similar chromatin domains called topologically associated domains (TADs) 
(Dixon et al., 2012; Nora et al., 2012; Sexton et al., 2012). Generally, TADs and the previously 
described 1 Mbp chromatin domains (CDs) are considered as the same chromatin structure (Dixon 
et al., 2016). It is widely accepted now that interphase chromosomes encompassed distinct 
chromatin domains called topological domains or the more widely used term TADs (Dixon et al., 
2016). These TADs have been shown to be invariable among different cell types and conserved 
among species (Dixon et al., 2012; Dixon et al., 2016). Therefore, it has been suggested that these 
TADs function as a folding unit for chromosomes (Dekker, 2014). 
TADs represent distinct genome compartments that are physically “insulated” from each other such 
that interaction between regions within one TAD is more frequent than interaction with another 
TAD (Dixon et al., 2012; Nora et al., 2012; Sexton et al., 2012). It is well established that CCCTC-
binding factor (CTCF) and cohesin have a key role in the formation and maintaining of TADs 
(Gómez-Díaz and Corces, 2014; Rao et al., 2017).  
CTCF is a zinc finger protein that is involved in modulation of chromatin architecture, chromatin 
insulation, and transcription regulation via its sequence specific binding activity (Ohlsson et al., 
2001; Kim et al., 2007). Cohesin is a conserved protein complex composed of three subunits 
(RAD21, SMC1, and SMC3). Due to its ring-shaped structure (Gruber et al., 2003) which can 
encircle chromatin fibres in a sequence-specific manner, cohesin plays a major role in various 
genome organization activities such as mediation of sister chromatid cohesion, gene clustering, 
promoter-enhancer interactions, chromatin insulation, and gene regulation (Kagey et al., 2010; 
Watrin et al., 2016). A number of mechanisms for TAD formation have been proposed with the 
loop extrusion model being the most attractive. Briefly, according to this model, a chromatin fibre 
becomes loaded with and extruded through a cohesin ring which continues to move along the fibre 
until it encounters a DNA-bound CTCF on both sides of the growing ring. This explains the high 
frequency of co-occurrence of both CTCF and cohesin at TAD boundaries (Alipour and Marko, 
2012; Dekker and Mirny, 2016; Fudenberg et al., 2016; Vian et al., 2018).     
Given that TADs are physically insulated chromatin units, it is sensible to suggest that they 
represent functionally insulated units. This is apparent from two aspects: coordinated gene 
expression of genes within the same TAD, and suppression of expansion of activities such as 
transcription between neighbouring regions of the genome (Dixon et al., 2016).        
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Figure 1-3 DNA supercoiling 
1.1.2 DNA and chromatin supercoiling  
DNA is a dynamic double-stranded helical molecule where each strand turns (coils) around the 
other, this occurs once per 10.5 bp of DNA in the relaxed state. Supercoiling (also called torsional 
stress) is the transition of the double helix from the relaxed state to either the over-wound (<10.5 
bp) or the under-wound (>10.5 bp) state, termed positive or negative supercoiling respectively 
(Figure 1.3). Mathematically, this feature corresponds to a constant called the linking number (Lk). 
LK is calculated by the formula (Lk = Tw+Wr), where Tw (twist) is the number of times one strand 
turns around the other, and Wr (Writhe) is the number of times the duplex crosses itself (Figure 
1.3). In a linear DNA duplex constrained by topological barriers or in a closed circular DNA 
molecule (as in plasmid or prokaryote DNA), Lk does not change upon transition in coiling state 
(twist, writhe, or both) unless one (or more) strand is cut, passed over the other, and rejoined again 







Orange bars are barriers preventing from spreading of coiling state. This figure was reproduced from 
(Corless and Gilbert, 2016) under the terms of the Creative Commons CC-BY license. 
(https://creativecommons.org/licenses/by-nc/4.0/legalcode).  
 
This concept of twist and writhe is further complicated and less clear in the case of chromatinized 
DNA partly because the majority of DNA is bound to nucleosome core units. The writhe (or 
supercoil) of the DNA in the chromatin exists in two states constrained and unconstrained. The 
constrained supercoil (nucleosome core bound) is maintained in an under-wound state while the 
unconstrained supercoil (nucleosome-free regions such as linker DNA) have the ability to undergo 
a transition in winding state and become under-wound (Corless and Gilbert, 2016; Corless and 
Gilbert, 2017).    
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Supercoiling is a fundamental feature of genome organization and function and has a key role in 
regulation of gene expression. Supercoiling results from separation of DNA strands from each other 
due to activities of DNA-binding proteins such as RNA polymerases (transcription), DNA 
polymerases (replication), helicases, and chromatin modelers (Bates, 2005).  
A well established mechanism of generation of supercoiling is the twin domain model. According 
to this model, as RNA polymerase move along the transcribed DNA duplex, it generates a positive 
supercoiling ahead of it and a negative supercoiling behind of it (Liu and Wang, 1987; Wu et al., 
1988). These supercoiling patterns can be resolved via the action of topoisomerase enzymes. As 
supercoiling is dynamically generated during cellular activities, it is crucial to be finely tuned by 
the coordinated actions of both polymerases and topoisomerases (Pommier et al., 2016) (see 
section 1.2.1.3 for further details on topoisomerases role).     
1.2 Human DNA Topoisomerases 
DNA Topoisomerases are a group of enzymes that are necessary for living cells because of their 
ability to modulate DNA topology by catalysing the passage of single or double DNA strand 
through another. These enzymes generate a transient break in the DNA backbone, form a covalent 
phosphodiester bond between their tyrosine residue and one end of the broken strand, allowing 
another DNA molecule to pass through the break, and then rejoin the broken strand. Therefore, 
these enzymes resolve topological problems such as torsional stress, DNA concatenates and knots 
that arise from cellular activities such as DNA replication and transcription (Wang, 1996; 
Champoux, 2001; Wang, 2002; Pommier et al., 2016).  
Generally, DNA topoisomerases are classified into type I or II families (according to the ability to 
break one or two DNA strands respectively) and are further classified into A or B subfamilies 
according to which strand is bound by the enzyme in the covalent phosphodiester state (5′ or 3′ 
phosphate respectively) (Wang, 1996; Champoux, 2001; Wang, 2002).  
Human cells have six topoisomerase enzymes TOP2α, TOP2β, TOP3α, TOP3β, TOP1, and the 
most recently characterized mitochondrial TOP1 (TOP1mt)(Zhang et al., 2001; Pommier et al., 
2016). Each topoisomerase has both specialized and shared roles with others (Champoux, 2001; 






Topoisomerase Family Subunit structure Substrate and activity 
ATP 
requirement 
TOP1 IB Monomer Resolve supercoiling 
(negative and positive) 
No 
TOP1mt IB Monomer No 
TOP2α IIA Homodimer Resolve supercoiling 
(negative and positive), 
concatenates, and knots. 
Yes 
TOP2β IIA Homodimer Yes 
TOP3α 1A Monomer Resolve supercoiling (negative only) 
No 
TOP3β 1A Monomer hypernegative supercoiling No 
 
Table 1-1 Human DNA topoisomerases 
 
1.2.1 DNA Topoisomerase II (TOP2) enzymes 
DNA topoisomerase II (TOP2) enzymes are vital for cell survival because of their role in 
replication, transcription, and chromosomal segregation during mitosis (Padget et al., 2000). TOP2 
allows the formation of a transient DNA double-stranded break (DSB) in one DNA segment where 
another DNA segment can pass through as part of its catalytic cycle. During this catalytic action, 
TOP2 binds covalently to two double-stranded DNA segments, allowing formation of an enzyme-
enclosed double-stranded break, then religates the DSB after passing of the other DNA segment 
(Larsen et al., 2003; Deweese and Osheroff, 2009). This process is crucial for maintaining genome 
integrity by preventing deleterious effects of accumulation of torsional stress and unresolved 
concatenates and knots. The catalytic reaction involves the formation of an intermediate TOP2-
DNA covalent complex (Figure 1.5). This complex can be targeted by a group of drugs called 
TOP2 poisons that interfere with the catalytic cycle of TOP2, blocking the religation step leading 
to a cytotoxic DSB that initiates a series of molecular events culminating in ends with cell death 
(apoptosis) (Kaufmann, 1998; McClendon and Osheroff, 2007; Cowell and Austin, 2012) (refer to 
chapter 3 introduction for an extensive review).  
The essential role of TOP2 enzymes and the ability of a group of compounds to target them and 
preventing their normal catalytic action contributes to their importance as a target for many 
chemotherapeutic agents (Wilstermann and Osheroff, 2003).  
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However, targeting TOP2 enzymes in chemotherapeutic protocols is related to the development of 
a secondary leukaemia called therapy-related leukaemia (t-AL) typically acute myeloid leukaemia 
(t-AML) (Kayser et al., 2011) as well be described in chapter three introduction.        
1.2.1.1 DNA TOP2 Structure and mechanism of action 
DNA topoisomerase II (TOP2) plays a crucial role in modulating DNA topology during replication, 
transcription, and chromatin condensation (McClendon and Osheroff, 2007; Chen et al., 2013; 
Pommier et al., 2016). TOP2 enzymes are divided into two groups: TOP2α and TOP2β based on 
their structure and sequence (Wang, 1996; Austin et al., 2018).  
TOP2 enzymes are homodimeric enzymes with each monomer subdivided into three domains on 
the basis of sequence homology with the bacterial type II DNA gyrase. These domains are: N-
terminal domain, the central domain, and the C-terminal domain (Figure 1.4A) (McClendon and 
Osheroff, 2007). The N-terminal domain (1-670 amino acids) is the ATPase domain; it is 
homologous to the B-subunit of DNA gyrase (GyrB) and contains the ATP binding site and 
hydrolysis.  
The central domain (~ 671-1200 amino acids) is homologous to the A-subunit of DNA gyrase 
(GyrA) and contains the active site tyrosine (amino acid 805 for TOP2α and amino acid 821 for 
TOP2β) which is necessary for cleavage and ligation of DNA. The C-terminal domain (~ 1201-
1521 amino acids for TOP2α and ~ 1201-1621 for TOP2β) is most variable in sequence between 
the two enzyme isoforms and among organisms (Figure 1.4A) (McClendon and Osheroff, 2007). 





















(A) TOP2 domains; the N-terminal domain (contains ATP binding site), the central domain (contains the active site 
tyrosine (Y) which is necessary for DNA cleavage and ligation), and the C-terminal domain which is highly variable 
and contains the Nuclear Localization Sequences (NLS) and phosphorylation sites (PO4). The amino acid sequence 
here is for TOP2β isoform. This line diagram was adapted from (Wu et al., 2011) with permission. (B) General TOP2 
elements; ATPase domains include [the GHKL (for Gyrase, Heat-shock protein 90, histidine Kinase and MukL) 
subdomain (yellow) and transducer subdomain (orange)]. Two 5Y-CAP (catabolite gene activator protein) domains 
(shown in green) and a pair of toprim folds (shown in red) form the DNA gate. The tower (shown in light blue). C-
gate (shown in dark blue). C-terminal domain (shown in purple). Figure was reproduced from (Schoeffler and Berger, 
2005) with permission. 
 
    
The catalytic cycle of DNA topoisomerase II begins when the toprim and the 5Y-CAP domains 
that form the DNA gate bind to a double-stranded DNA segment, referred to as the gate segment 
(G-segment). Another DNA segment referred to as the transfer segment (T-segment) is bound to 
the ATPase domains [which consist of the GHKL (Gyrase, Heat-shock protein 90, histidine Kinase 
and MukL) and transducer subdomains] following dimerization of the ATPase domains induced 
by binding of two ATP molecules. ATP hydrolysis and release of Pi induce opening of the DNA 
gate and cleavage of the G-segment; this is followed by passage of the T-segment through the gap. 
Opening of the C-gate allows the T-segment to release. Ligation of the G-segment and release of 
the hydrolysis product triggers opening of ATP gate, then the enzyme enters another cycle (Figure 
1.5) (Schoeffler and Berger, 2005; Cowell and Austin, 2012). 
Figure 1-4 TOP2 structure 
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Figure 1-5 TOP2 Catalytic Cycle 
 












Domains are coloured as figure 1.1B. The toprim and 5y-CAP domains which form the DNA gate bind to the G-
segment (pale green) (step one). T-segment is bound to the ATPase domains after their dimerization with two ATP 
molecules (step two). ATP hydrolysis and release of Pi induce opening of DNA gate and cleavage of G-segment 
allowing T-segment to pass through the gap formed (step three). Releasing of T-segment upon C-gate opening (step 
four). Then, opening of ATP gate due to religation of G-segment and releasing of hydrolysis product allow the enzyme 
to enter the cycle again (Schoeffler and Berger, 2005). 
 
 
1.2.1.2 TOP2 Isoforms 
Human type II topoisomerases are divided into two isoforms; TOP2α and TOP2β. These isozyme 
forms are encoded by separate genes located on 17q21-22 and 3p34 for TOP2A and TOP2B 
respectively (Chung et al., 1989; Austin and Fisher, 1990; Jenkins et al., 1992; Tan et al., 1992). 
Although the two isozymes differ in the molecular weight (170 kDa for α and 180 kDa for β), they 
have about (70 %) homology in the amino acid sequence (Austin et al., 1993b; Austin and Marsh, 
1998; McClendon and Osheroff, 2007). The amino acid sequence variability is very high in the C-
terminal region where the amino acid identity is only 34 % (Austin et al., 1993b; Austin and Marsh, 
1998). These isoforms have specific immunological patterns because of the divergence in CTDs, 
which allows the production of antibodies specifically recognizes each form (Padget et al., 2000).  
TOP2α and TOP2β have different patterns of expression over the cell cycle (Padget et al., 2000; 
Austin et al., 2018). TOP2α is highly expressed during proliferation with its protein level 
significantly increased during S phase and maximized at G2/M phase (Adachi et al., 2000; Padget 
et al., 2000).  
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Furthermore, studies have shown that TOP2α protein is not detected in confluence-arrested cells 
or following serum deprivation (Padget et al., 2000), whilst TOP2β regulation has been shown to 
be less dependent on the cell cycle stage and generally it is expressed in proliferating and non-
proliferating cells (Zandvliet et al., 1996; Austin and Marsh, 1998; Padget et al., 2000; Austin et 
al., 2018).  
However, there is a controversy in the data available for TOP2β expression patterns among 
different cell lines (Padget et al., 2000). Quantitative immunoblotting analysis of TOP2α and 
TOP2β expression in several cell lines has shown that TOP2β is expressed in comparable levels to 
TOP2α in CCRF-CEM, Raji, Molt-4, and K562 cell lines when they are in their exponential phase 
and the decatenation activity of TOP2β was higher than TOP2α in the exponentially growing 
human Raji leukaemia cells (Padget et al., 2000). In addition, another study has shown that TOP2β 
level is increased in exponential cells (Turley et al., 1997). Regulation of TOP2 protein levels over 
the cell cycle could be a result of changing in transcription/translation rate, mRNA or protein 
stability or a combination of all of these processes (Austin and Marsh, 1998). 
While both isoforms have similar ATP-dependent strand-passing activities in vitro (Austin et al., 
1995), they have been shown to have different cellular roles. TOP2α is involved in cell division 
processes such as DNA replication, chromatin condensation and segregation. TOP2α remains 
associated with chromosomes in mitosis while TOP2β separates form chromosomes in mitosis 
(Deweese and Osheroff, 2009). The physiological role of the TOP2β enzyme is less clear than 
TOP2α but it has been shown to be involved in transcriptional regulation and to be required for 
neuronal differentiation (Austin et al., 2018; Madabhushi, 2018) (refer to introduction of chapters 
4 and 6 for extensive TOP2B review).  
In vivo expression patterns have been reported for both isoforms. It has been shown that TOP2α is 
highly expressed in proliferating tissues such as spleen, bone marrow, thymus, and testis while 
TOP2β is ubiquitously expressed in tissues including post mitotic cells. Both isoforms showed 
higher expression levels in neoplastic than normal cells (Giovanni Capranico and Zunino, 1992; 
Watanabe et al., 1994; Zandvliet et al., 1996; Turley et al., 1997; Harkin et al., 2016) (see chapter 




The intracellular location of TOP2α and TOP2β over the cell cycle has been reported. TOP2α is 
primarily found in a nuclear location in both the nucleoli and the nucleoplasm during the interphase 
(Rattner et al., 1996; Meyer et al., 1997). During mitosis, TOP2α remains associated with 
metaphase chromosomes (Rattner et al., 1996; Warburton and Earnshaw, 1997). TOP2β is 
primarily in the cytoplasm during mitosis, while its localization during interphase is less clear but 
there is an agreement that it has a nuclear location (Austin and Marsh, 1998; Austin et al., 2018).   
1.2.1.3 TOP2 cellular roles 
1.2.1.3.1 DNA replication and chromosomal segregation 
DNA replication starts at various regions on the chromosome called origins. These regions are 
primed in advance at the G1 phase. Replication is performed by a complex containing DNA 
polymerase with numerous proteins collectively called a replication fork (RF). Upon separation of 
the DNA strands by DNA helicases, two RFs are established at each origin region and move along 
the duplex in opposite directions. Advancing RFs along the DNA generates positive supercoiling 
ahead of RFs and precatenanes behind it (Peter et al., 1998; Branzei and Foiani, 2010). 
In the cellular environment, DNA is flanked by topological barriers such as nuclear matrix or 
insulators which hinders free rotation of DNA duplex around its axis. As a result, the generated 
supercoiling cannot be dissipated by diffusion along chromatin fibres. Hence, the accumulation of 
the supercoiling blocks replication progression unless it is actively removed by topoisomerase 
activity. Both TOP1 and TOP2 enzymes facilitate relieving of supercoiling ahead of the replication 
fork (RF). TOP2 also removes precatenanes behind the (RF) which affect proper chromosomal 
segregation if not resolved before mitosis (Lucas et al., 2001; Pommier et al., 2016) (Figure 1.6). 
This is especially important at the termination of replication where merging of the two RFs 
generates interlocked replicons (catenanes) (Sundin and Varshavsky, 1980; Sundin and 
Varshavsky, 1981) which are removed by TOP2 activity to allow chromosomal segregation 








According to the ‘twin domain model’, moving of the transcription machinery (RNA polymerase, 
polymerase-associated proteins, and nascent transcript with associated proteins such as ribosomes) 
along the transcribed DNA molecule generates positive supercoiling in front of the transcription 
machinery and negative supercoiling behind it (Liu and Wang, 1987; Wu et al., 1988; Tsao et al., 
1989) (Figure 1.6). A mechanism for generation of supercoiling according to this model has been 
proposed. The large and complex nature of the transcription machinery hinders its relative rotation 
while moving along the helical DNA molecule (which is also tethered to cellular components). 
Therefore, unwinding of DNA strands by the advancing replication machinery induces torsional 
stress positively and negatively ahead and behind the transcription machinery respectively (Liu and 
Wang, 1987; Koster et al., 2010). Unless actively resolved by topoisomerases (Figure 1.6), positive 
supercoiling ahead of the transcription machinery hinders the progression of transcription. This is 
supported by studies showing that transcription significantly accumulates supercoiling upon 
depletion of topoisomerases (Wu et al., 1988)}(Tsao et al., 1989; Krasilnikov et al., 1999). In 
addition, positive supercoiling significantly reduces mRNA level in a yeast system with mutated  
TOP1 and TOP2 (Gartenberg and Wang, 1992). Other studies showed that positive supercoiling 
can even block the initiation of transcription (Revyakin et al., 2004).    
Furthermore, studies have shown that TOP2 is particularly required for transcription of 
chromatinized DNA in vitro. One study conducted by (Mondal and Parvin, 2001) showed that 
TOP2 activity is necessary for transcription of chromatin templates but not for naked DNA 
templates. They showed that TOP2 inhibition by etoposide or ICRF-193 blocked transcription and 
addition of purified TOP2 recovered transcription repression. Subsequently, it has been shown that 
resolving of positive supercoiling is the reason for topoisomerases requirement for transcription 
elongation on chromatin templates (Mondal et al., 2003). Another study showed a requirement for 
TOP2 enzymes to facilitate RNA polymerase pause-release activity at the transcription start site of 







Figure 1-6 TOP2 roles in DNA replication and transcription 
This figure shows torsional stress generated during replication and transcription according to the twin 
supercoiling domain model (Liu and Wang, 1987) and role of TOP2 in the relaxation of supercoiling and 
resolving precatenanes formed during replication. Figure was reproduced from (Vos et al., 2011) with 
permission.     
 
 
In addition to the global effect of TOP2 on transcription through supercoiling-relieving activity, 
the TOP2β isoform has been shown to further play a regulatory role on a narrower gene category, 
including ligand inducible and developmentally regulated genes with particular role in neuronal 
development (refer to introduction of chapters 4 and 6 for detailed review). In this study, the 
cellular and regulatory role of TOP2β was investigated (TOP2α isoform was also included in the 






• Investigate the isoform-specific contribution of TOP2α and TOP2β as a target for cancer 
treatment by determining cytotoxicity and genotoxicity of TOP2 targeting drugs in three 
cell lines Nalm6WT, Nalm6B-/-, and Nalm6A+/- (chapter 3). 
• Investigate the effect of (daunorubicin+Ara-C) combination at different dose ratio and/or 
treatment order in cancer treatment (chapter 3). 
• Determine the role of TOP2β isoform in whole gene expression in Nalm6 cell line using 
RNA-seq analysis and RT-qPCR (chapter 4). 
• Confirm the TOP2β-regulated genes in newly knockout model generated by CRISPR 
(chapter 5). 
• Select candidate gene(s) to further study TOP2β recruitment to gene promoter by chromatin 
immunoprecipitation (ChIP) protocol (chapter 5). 
• Investigate the role of TOP2β in gene expression and differentiation of neuronal cells 












2 Chapter Two: Materials and methods 
2.1 Drugs and chemicals 
Daunorubicin and idarubicin (Sigma-Aldrich, UK) were dissolved in deionized water as a 10 mM 
stock solution and stored at -20°C until used. Cytarabine (Sigma-Aldrich, UK) was dissolved in 
deionized water as a 50 mM stock solution and stored at -20°C until used. Methyl methanesulfonate 
(MMS) (Sigma-Aldrich, UK) was dissolved in Dimethyl Sulfoxide (DMSO) as a 100 µM stock 
solution and stored at -20°C until used as a positive control in the micronucleus tests. Rutin (Sigma-
Aldrich, UK) was dissolved in Dimethyl Sulfoxide (DMSO) as an 80 mM stock and stored at -
20°C until used. All-trans retinoic acid (ATRA) from (Sigma, UK, Cat. R2625) and vitamin D3 
(Sigma, UK, Cat. D1530) were dissolved in ethanol as a 10 mM stock and stored as aliquots at -
20°C until use. Puromycin (Sigma, UK, Cat. P9620) used for selection of cells transfected with 
PX459 vector was a ready-to-use 10 mg/ml solution (as puromycin dihydrochloride). Main stock 
was divided into aliquots and stored at -20°C until used.  
2.2 Cell culture 
2.2.1 Cell lines  
Nalm6 is a human pre-B leukaemia cell line derived from the peripheral blood of a 19-year-old 
man with acute lymphoblastic leukaemia (ALL) in relapse. Nalm6 (wild type) and its genetic 
modified cell lines; TOP2B knockout cell line Nalm6B-/- and heterozygous knockout of TOP2A 
(Nalm6A+/-) were kindly provided by (Noritaka Adachi) and were generated as described in (Adachi 
et al., 2008b). K562 is a human myelogenous leukaemia cell line derived from a 53-year-old female 
patient with chronic myelogenous leukaemia in blast crisis.  
SH-SY5Y is a human neuroblastoma cell line derived from the original SK-N-SH line which was 
established from the bone marrow of a four-year-old female with neuroblastoma in 1970. SK-N-
SH was cloned as SH-SY. SH-SY was further subcloned as SH-SY5 which was in turn subcloned 
to generate SH-SY5Y (Biedler et al., 1973; Ross et al., 1983)       
2.2.2 Cell line maintenance  
All Nalm6 and K562 cell lines were maintained in (Roswell Park Memorial Institute (RPMI) 1640 
medium (Gibco by Life Technologies, Invitrogen, UK) containing 10% v/v heat-inactivated foetal 
bovine serum (FBS) (Gibco by Life Technologies, Invitrogen, UK) and 1% v/v Penicillin and 
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Streptomycin solution (10,000 units/ml penicillin, 10,000 mg/ml streptomycin, Gibco by Life 
Technologies, Invitrogen, UK) and incubated at 37°C and 5% CO2 under standard humidity. Cells 
were maintained at growing phase and kept at a density of ~1-2*106 cell / ml. 
All SH-SY5Y clones were maintained in a 50:50 mixture of Minimum Essential Medium (MEM) 
and F12 (Hams) medium (Gibco by Life Technologies, Invitrogen, UK) containing 10% v/v heat-
inactivated foetal bovine serum (FBS) (Gibco by Life Technologies, Invitrogen, UK) and 1% v/v 
Penicillin and Streptomycin solution (10,000 units/ml penicillin, 10,000 mg/ml streptomycin, 
Gibco by Life Technologies, Invitrogen, UK). SH-SY5Y cells were maintained at 75-80 % 
confluency and subcultured by trypsinization with 0.05 % Trypsin-EDTA (Gibco by Life 
Technologies, Invitrogen, UK) at 37°C for 5 minutes, then trypsin was neutralised with media. 
Cells were then pelleted by centrifugation for 5 minutes at 1000 rpm and the supernatant was 
discarded. Cells were then resuspended in media and a cell count was done to calculate the volume 
required to set a new culture. Cells were incubated at 37°C and 5% CO2 under standard humidity.  
2.2.3 Cryopreservation and thawing of cell lines 
Exponentially growing cells were centrifuged at 1000×g for 5 minutes (Harrier 15/80 MSE) and 
the supernatant medium was discarded. Cells were resuspended with fresh medium at half the final 
required volume (about one third the original volume). An equal volume of freezing medium 
containing 20 % DMSO was added and mixed. The cell suspension was then aliquoted in 1.5 ml 
cryogenic vials (Greiner, Bio-One GmbH, Germany) and labelled with the cell line name, passage 
number, date, and name of operator. Vials were cooled overnight at -80°C in a polystyrene box 
then transferred on the following day to liquid nitrogen storage at -192°C. 
Cryogenic vials were removed from liquid nitrogen and immediately thawed at 37°C in a water 
bath for few minutes then 10 ml of fresh medium was added to the cells and they were centrifuged 
at 1000×g for 5 minutes. The supernatant was discarded and the pellet was resuspended with 10 ml 
of fresh medium and transferred into a small cell culture flask and incubated at 37°C and monitored 
for growth and subcultured.  
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2.3 Western blotting    
2.3.1 Whole cell extraction 
The whole cell extraction method was adopted from (Mirski et al., 1993). Briefly, an adequate 
number of cells (~ 1×107 cells per each cell line) were centrifuged at 1000×g for 5 minutes and the 
media was removed and the cells were resuspended with cold phosphate buffered saline (PBS) and 
pelleted again to either use them directly for extraction or to store them at -80°C until use. 
Depending on their volumes, pellets were resuspended with 4 packed cell volumes of extraction 
buffer (10 mM MgCl2, 50 mM Tris-HCl, pH 7.4, 4 mM DTT, and 0.05 % of protease inhibitor (PI) 
cocktail [AEBSF HCl, Aprotinin, E-64, Bestatin, Leupeptin and Pepstatin]) and mixed. Then SDS 
was added to 0.25 % with mixing. DNase I was added to 50 µg/mL and the suspension was 
incubated on ice for 10-30 minutes. Once the viscosity disappeared from the suspension, an equal 
volume of solubilisation buffer (2% SDS, 20% glycerol, 5% β-mercaptoethanol, 0.6M Tris-HCl, 
pH 7.2) was added and the mixtures were heated at 68°C for 10 minutes. Then samples were either 
used for protein estimation and western blotting or stored as aliquots at -80°C until use.  
2.3.2 Estimation of protein concentration 
Bradford assays were used to estimate protein concentrations in the whole cell extracts (WCEs) 
using a standard curve of Bovine Serum Albumin (BSA). Samples were assayed in 96-well plates 
with BSA as a standard and DW as a blank. As samples contain solubilisation buffer which 
interferes with absorbance, BSA stock (2mg/mL) was firstly 1:1 diluted with solubilisation buffer 
then all samples were serially 1:1 diluted with DW to provide a range of concentrations for 
measurement. Then 250 µL of Bradford 1x Dye Reagent (BIO-RAD) was added to each well and 
incubated for 5-10 minutes at room temperature. Plate(s) were read at 595 nM on a plate reader 
(Bio-Rad Microplate reader 550). Standard curve(s) were created and used to determine protein 
concentrations of the samples. 
2.3.3 SDS-acrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE (Tris-HEPES NH 4-20 %, NuSep, USA) were used with 1×Tris-HEPES-SDS running 
buffer (NuSep, USA) for electrophoresis. The marker (Western sure pre-stained chemiluminescent 
protein ladder, Li-CoR, USA) was used to analyse the molecular weight of the proteins. Samples 
were mixed with an equal volume of sample buffer (TruSep SDS, NuSep, USA) and heated at 68°C 
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(Stuart Scientific test tube heater SHT 2D) for 5-10 minutes, then the gel was run at 120 V for 1.2 
hours.  
2.3.4 Gel transfer 
The transfer tank was filled with transfer buffer (25 mM Tris, 192mM glycine, 20% v/v methanol) 
and cooled with an ice block. Gels were transferred to nitrocellulose membranes (BIO-RAD, 
Germany) at 100 V and 500 mA for 1 hour.  
2.3.5 Immunoblotting 
Membranes were blocked with blocking solution (5 % (w/v) milk powder in Tris buffered saline 
(TBS) and 0.1 % TWEEN20 (TBS-T) for 1 hour, then incubated on a shaker with primary Antibody 
(Table 2.1) diluted in blocking solution either for 1 hour at room temperature or overnight at 4°C. 
Membranes were then washed with TBS-T (2× 1 minute + 1× 15 minutes) twice. Membranes were 
then incubated on a shaker with an HRP-congugated secondary antibody (Table 2.1) diluted in 
blocking solution either for 1 hour at room temperature or overnight at 4°C followed by washing 
with TBS-T (2× 1 minutes + 1× 15 minutes) twice. 
2.3.6 Imaging 
Blots were visualised by enhanced chemiluminescence (ECL) detection with enhancer solution 
(Clarity western ECL substrate, BIO-RAD, USA). Membranes were incubated with ECL reagent 
for 5 minutes then imaged using C-DiGid bllot scanner (Li-CoR, UK).  
2.3.7 Stripping membranes 
Where applicable, membranes were stripped to remove antibodies and blotted with another 
antibody or with an anti-actin antibody (Table 2.1) as a loading control. Briefly, membranes were 
washed with PBS or TBS-T then incubated with stripping buffer (Thermo Scientific, USA) for 7-
15 minutes at room temperature with shaking. Stripping buffer was then removed and the 
membranes were washed with PBS or TBS-T then blocked with blocking solution for 30-60 
minutes. 
2.4 Immunofluorescence 
Cells were harvested at a volume that contained approximately 2×105 cells for each slide. Samples 
were centrifuged at 1000×g for 5 minutes and resuspended with cold PBS and applied to Poly-L-
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Lysine slides (VWR, UK). Cells were fixed with 4% paraformaldehyde (0.7 mL per slide) for 10 
minutes, washed twice with PBS, and permeabilized with 0.8 mL KCM-T (120 mM KCl, 20 mM 
NaCl, 10 mM Tris-HCl, pH8.0, 1 mM EDTA, 0.1% (V/V) Triton X-100) for 15 minutes to each 
slide to allow for cell permeabilisation. Slides were incubated in blocking solution (KCM +T, 2% 
bovine serum albumin (BSA), 10% dried milk powder) for 1 hour then incubated with primary 
antibody (Table 2.1) for 1 hour at room temperature.  
Slides were then washed with KCM-T for 3 × 10 minutes and incubated with secondary antibody 
(Table 2.1) for 1 hour at room temperature in the dark. Slides were further washed with KCM-T 
for 3 × 10 minutes in subdued light. Vectashield mounting medium with DAPI (Vector laboratories, 
USA) was added to each slide and the coverslips were fixed by sealing with nail polish. 
Immunofluorescence imaging was performed using an Olympus IX-81 microscopic imaging 
system and the integrated FITC fluorescence per nucleus was determined using (Volocity software 
V6.3, PerkinElmer, UK) and analysed using (Graphpad Prism software (v4.0), Graphpad, Inc., 
USA) as described by (IG et al., 2011). Exposure time was optimized using autoexposure of the 
control samples.   
2.5 Antibodies 
















(1) Raised to Full C-Terminal domain (CTD) of TOPA (residue 1244-1531 of full TOP2A protein) Human TOP2A-
GST fusion (2) Raised to Full C-Terminal domain (CTD) of TOPB (residue 1263-1621 of full TOP2B protein) Human 
TOP2B-GST fusion (3) Raised to Full C-Terminal domain (CTD) of TOPB (residue 1296-1621 of full TOP2B protein) 
Human TOP2B-GST fusion (4) Raised to the last third of C-Terminal domain (CTD) of TOPB (residue 1296-1621 of 
full TOP2B protein) Human TOP2B-GST fusion (5) Raised to the Final 116 amino acids of CTD Human TOP2B-
GST fusion (6) Raised against amino acids 75-160 of USF-1 of human origin (7) Raised to a region within amino acids 
296-346 of Human USF2 (8) Raised against amino acids 1-238 representing full length GFP of Aequorea victoria 
origin (9) Raised against amino acids 1-262 of c-Myc of human origin (10) Raised to human Histone H3 acetylated at 
the N-terminus  












Rabbit polyclonal to human 
topoisomerase II alpha In house 




Rabbit polyclonal to human    
topoisomerase II beta In house 




Rabbit polyclonal to human    
topoisomerase II beta In house 




Rabbit polyclonal to human    
topoisomerase II beta In house 1:1000 for western blotting 
TOP2B5 
(3535) 
Rabbit polyclonal to human    
topoisomerase II beta In house 5 µg per IP for ChIP 
TOP2B Human/Mouse monoclonal to  human topoisomerase II beta    
R&D Systems, 
USA (MAB6348) 1:500 for western blotting 




2 µg per 500 µg of total protein 
per IP for ChIP 
USF27 Rabbit polyclonal to human  upstream stimulatory factor 2 
Abcam, UK  
(ab125184) 
5 µg per 1000 µg of total 
protein per IP for ChIP 




2 µg per 500 µg of total protein 
per IP for ChIP 
C-Myc9 Rabbit polyclonal to human C-Myc 
Santa Cruz, 
Germany (sc-764) 
5 µg per 1000 µg of total 
protein per IP for ChIP 
MAX Mouse monoclonal to Human MAX 
Abcam, UK 
(ab53570) 
5 µg per 1000 µg of total 
protein per IP for ChIP 
Ac-H310 Rabbit Polyclonal to acetyl-Histone H3 
Millipore, UK  
(06-599B) 5 µg per IP for ChIP 
Actin Mouse monoclonal to Actin Abcam, UK (ab3280) 1:2000  for western blotting 
beta-Actin Mouse monoclonal to beta-Actin Novusbio, UK  (NB600-501) 1:5000  for western blotting 














rabbit IgG  
Anti-rabbit IgG horseradish 
peroxidase linked whole antibody 
GE healthcare, UK 
(NA934) 1:5000  for western blotting 
Anti-
mouse IgG 
Anti-mouse IgG horseradish 
peroxidase linked whole antibody 
GE healthcare, UK 
(NXA931) 1:5000  for western blotting 
Anti-rabbit 
IgG 
Alexa fluor®488 goat anti-rabbit 
IgG (H+L) 
Life Technologies, 
USA (A11008) 1:400 for  immunofluorescence 




Immunophenotyping was performed to determine the effect of vitamin D3 on expression of number 
of cell surface markers in Nalm6 cells. All reagents used and the protocol for cell preparation for 
FACS analysis are described in (Table 2.2). 
    

























Sample 2 × 10
5 
cells 
2 × 105 
cells 
2 × 105 
cells 0.5 × 10









Washing PBS (1% FBS) 






























CD10  Clone  




CD19  Clone  




CD38  Clone  






























Incubation 30 min at 4 ⁰C 
Washing PBS (1% FBS) 
Resuspension 0.5 ml PBS (1% FBS) 
Dead cells 
exclusion DAPI for 5 minutes to stain dead cells. 
FACS (Fortessa x20) machine , 20000 events/sample were measured at slow rate 
 







2.7 Determination of growth curves and doubling time of cell lines   
Cell lines were seeded at a log phase and grown for up to 120 hours and cell counting was 
performed using the TC20 (BIO-RAD, USA) cell counter at different time points to determine 
growth curves. Data from 3 independent replicates were used to set up the growth curves for each 
cell line.  
Doubling times for cell lines was determined using the following equation: 
𝐃𝐃𝐃𝐃𝐃𝐃𝐃𝐃𝐃𝐃𝐃𝐃𝐃𝐃𝐃𝐃 𝐩𝐩𝐃𝐃𝐩𝐩𝐃𝐃𝐃𝐃𝐩𝐩𝐩𝐩𝐃𝐃𝐃𝐃𝐃𝐃 =  
𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳 (𝑵𝑵𝑵𝑵 𝑵𝑵𝑵𝑵⁄ )
𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳 (𝟐𝟐)
      
Where; (Nt) is the number of cells at given time, (Nc) is the initial cell number. 
Doubling time (𝑇𝑇d) =  𝑡𝑡 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 𝑝𝑝𝐷𝐷𝑝𝑝𝐷𝐷𝐷𝐷𝑝𝑝𝑡𝑡𝐷𝐷𝐷𝐷𝐷𝐷⁄  
Where; (t) is the time at which cells were counted. 
Doubling time at different time points were taken and averaged. 
2.8 Cytotoxicity assays 
The sensitivity of cell lines (Nalm6WT, Nalm6B-/-, and  Nalm6A+/-) to daunorubicin, idarubicin, and 
cytarabine as single agents and in combination were determined by cell counting and viability 
assays using the trypan blue exclusion method and the dose-response curve was established as 
Relative Increase in Cell Count (RICC) using the following formula (Fellows et al., 2008): 
RICC = Increase in number of cells in treated cultures (final−starting)
Increase in number of cells in control cultures (final−starting)
 × 100    
The dose response curves for single agents and in combination were analyzed and created using 
(Graphpad Prism software (v4.0), Graphpad, Inc., USA). Furthermore, the efficiency of drug 
combinations was determined for synergy analysis using CompuSyn software (ComboSyn, Inc). 
The CompuSyn program uses the Chou-Talalay method for drug combination analysis which is 
based on the median-effect equation derived from the mass-action law (Chou and Talalay, 1984; 
Chou, 2006; Chou, 2010) to determine the combination index (CI) which quantitatively indicates 
whether the combination is synergistic (CI<1), antagonistic (CI>1), or additive (CI=1) (Chou, 
2006). 
XTT assays were performed as follows: cells were treated with drug and incubated for 120 h. on 
the day of measurement, 50 μl XTT reagent (50:1 XTT reagent to electron coupling reagent, XTT 
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Cell Proliferation kit, Roche, UK) was added per well and cells were incubated for a further 4 hrs. 
A Bio-Rad 550 Microplate Reader (Bio-Rad, USA) was used to measure absorbance values and 
the data were analysed using (Graphpad Prism software (v4.0), Graphpad, Inc., USA). Growth 
inhibition values were determined by setting the values obtained with no drug as 100%. 
2.9 Micronuclei assay 
Micronucleus assays were used to assay the genotoxicity of drugs. In vitro Micronuclei test by 
FACS is based on flow cytometric counting of micronuclei (MN) stained fluorescently with a 
nucleic acid dye (CYTOX green). This protocol also allows for efficient determination of relative 
survival, using counting beads which can be stained and scored by the flow cytometer. The number 
of healthy nuclei per bead can be determined. The nuclei-to-bead ratio for the control and the 
treated samples can be used to determine the relative survival. The procedure was followed 
according to micronuclei kit (MicroFlow, Litron Laboratories, USA) instructions along with the 
OECD guideline (OECD, 2010) and was as follows: 
Working reagents were prepared as recommended by the (MicroFlow, Litron Laboratories, USA) 
kit instructions and outlined in (Table 2.3). Cells were allowed to grow for (1.5-2) normal cell cycle 
period after drug exposure with a density of no more than 1*106 cell / ml at harvesting time. In 
addition, it was taken into account that the cytotoxicity should be no more than 50 % at the time of 
harvest as this would interfere with MN endpoint and give false positive results. 
Exponentially growing cells were harvested after 48 hours continuous drug exposure. Each control 
and treated sample was mixed to achieve homogenous suspension then a consistent volume 
(estimated to provide 1*106 cell/ml of negative control) of each sample was transferred into 










Table 2-3 Working reagents preparation for Micronuclei (MN) test 
*Volumes were scaled up depending on number of samples 
The supernatants were discarded and the pellets were resuspended by tapping gently and placing 
on ice for 20 minutes then 300 µl of Ethidium Monoazide (EMA) (Dye A) working solution was 
added to each sample tube and the tubes were left opened to a direct light source 15 cm above the 
samples and submerged in about 2 cm in ice for 30 minutes. This step is required for the EMA 
stain to covalently bind DNA upon photoactivation. Counting beads (6 micron microspheres) were 
added to the 1× buffer solution (1 drop per 10 ml) and mixed well. The light was switched off and 
3 ml of 1× buffer solution with beads was added to each tube. The 1× buffer solution was mixed 
between samples and light exposure was limited from this step onwards by covering tubes with 
foil. Samples were then centrifuged at 300×g for 5 minutes and the pellet were resuspended by 
tapping gently then immediately preceding to the next step.  
1x Buffer Solution 
Number of 
samples* Volume of dH2O 
Volume of 10x 
Buffer Volume of FBS 
1 3.6 ml 0.4 ml 0.08 ml 
After the required volumes were added and mixed, the mixture was sterilised by 
filtration with b Millipore filter and refrigerated.  
Nucleic Acid Dye A Working Solution 
Number of samples* Volume of 1x Buffer Solution 
Volume of Nucleic Acid 
Dye A 
1 0.33 ml 3.3 μl 
The required volumes were added and mixed in a polypropylene vessel and stored on 
ice protected from light until used. 











1 0.55 ml 2.2 μl 2.75 μl 
The required volumes were added and mixed in a polypropylene vessel and stored at 
room temperature protected from light until used. 
Complete Lysis Solution 2 
Number of samples* Volume of Incomplete Lysis Solution 2 
Volume of Nuclei Acid 
Dye B 
1 0.55 ml 2.2 μl 
The required volumes were added and mixed in a polypropylene vessel and stored at 
room temperature protected from light until used. 
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500 µl of complete lysis solution 1 was added to the first sample and this was vortexed on low to 
medium speed for 5 seconds and this was repeated for all samples. All samples were incubated 
with complete lysis solution 1 for 1 hour at room temperature and away from light. Complete lysis 
solution 2 (500 µl  was added and the previous step was repeated for all samples then the samples 
were incubated for 30 minutes with complete lysis solution 2 at room temperature and away from 
light. The samples were then transferred into flow cytometric tubes for analysis or stored for up to 
24 hours at room temperature or 72 hours at 4°C.  
BD fluorescence-activated cell sorting (FACS) CantoTM II cytometer (BD Biosciences, New 
Jersey, USA) was used for data acquisition. Samples were Excited by a 488 nm laser and Cytox 
Green and EMA fluorescence were collected by 585/42 and 530/30 filters of the flow cytometer 
respectively. The parameter Settings and gating were confirmed with both positive control methyl 
methanesulfonate (MMS) and negative control (DMSO and H2O). The analysis was performed 
using (BD FACSDiva (v8.0), Biosciences, New Jersey, USA) software. 
The stopping gate was set as 30,000 healthy nuclei counted so that for each sample, 30,000 nuclei 
events were counted and the relative survival was determined by the nuclei-to-beads ratio. The 
following parameters were calculated: 
 
Relative survival= (nuclei−to−beads) ratio of treated samples 
(nuclei−to−beads) ratio of control samples
 × 100 
Micronuclei (%) = no.  of micronuclei  
no.  of healthy nuclei 
 × 100 
Micronuclei fold change = micronuclei (%) of treated sample  
micronuclei (%) of control
 
Apoptotic (EMA positive) cells (%)= no.  of EMA events of treated samples 
no.  of EMA events of control 
 × 100 
Apoptotic cells fold change = Apoptotic (EMA positive)cells (%) of treated sample  






2.10 Cell cycle analysis 
Micronuclei kit (MicroFlow, Litron Laboratories, USA) allows for cell cycle analysis by studying 
histograms of nucleic acid dye (CYTOX green) fluorescence. These histograms represent the DNA 
content of the cell populations. DNA content histograms created by FACS were analysed using 
(Flowjo software (v7.6), FlowJo, LLC, USA) to quantitatively determine cell cycle phase 
distribution in control and treated samples. 
2.11 Electroporation 
Electroporation was used to transfect the cell lines with small interfering RNA (siRNA) 
oligonucleotides (ON-TARGET plus SMART pool, Thermo Scientific, USA) to knockdown 
TOP2A and TOP2B (Table 2.4). Briefly, cells were grown to a density sufficient to adjust to the 
required cell concentration. Appropriate volume of cell suspension was centrifuged at 300×g for 5 
minutes and resuspended with 300 µl culture medium per sample such that the final density of each 
sample is 5*107 cell/ml. Sample cell suspension from above was transferred into an electroporation 
cuvette (Eurogenetic, UK) and the required volume of siRNA stock (20µM) was added to the cell 
suspension and the cuvette was briefly swirled to mix. The cuvette was transferred into the 
electroporator (Fischer EPI2500, Germany) and the electroporation was performed at 10 mSec and 
the voltage generally was (300-370) V depending on the cell line. After electroporation, cuvette(s) 
with cell suspension were incubated for 15 minutes at room temperature. Cell suspension was 
transferred into a small culture flask with 5.7 ml of fresh medium such that the final cell 
concentration was 2.5*106 cell/ml and incubated at 37°C and 5% CO2 under standard humidity. 









siRNA Target sequence Molecular weight 
(g/mol) 
ON-TARGET plus non-
targeting siRNA - SMART 
pool, 20 nmol 
Negative control siRNA with at least 4 
mismatches to any human, mouse, or rat 
gene. 
13400 
ON-TARGET plus human 
TOP2A (7153) siRNA – 





ON-TARGET plus human 
TOP2B (7155) siRNA – 





ON-TARGET plus human 
CBR1 (873) siRNA – 






Table 2-4 Oligonucleotides used for siRNA knockdown 
 
2.12 Agarose gel electrophoresis     
The size of the amplification products was verified using agarose gel electrophoresis by mixing 20 
µl of each PCR reaction with 5 µl of 6×DNA loading dye (Thermo Scientific). The mixtures were 
then loaded on 1.6% agarose gel in 1×TBE buffer with GelRed (Biotium) staining (10µl per gel) 
and a DNA ladder (Thermo Scientific) was used for comparison. Gels were run at 100 volts 
(Northumbria Biologicals Limited power pack) for 1 hour and visualised using (Gel-Doc EZ 





2.13 PCR primers 
All PCR primers listed in (Tables 2.5 and 2.6) were designed either by myself (M.K.) or from 
published data as stated. Target sequences were obtained from UCSC browser and primers were 
designed using the web tool (Primer3web version 4.0.0) and checked for specificity using both (In-
Silico PCR web tool, UCSC browser) and Basic Local Alignment Search Tool (BLAST). Primers 
were then synthesized by Integrated DNA Technologies (IDT, Glasgow, UK). All primers were 
supplied from the manufacturer as a stock solution of 100 µM in a TE buffer (pH 8.0) which were 
used to prepare the (Forward+Reverse) working solution of 10 µM. All primers were then checked 
for PCR efficiency using agarose gel as detailed in section 2.12.     
Generally, the following criteria were followed in designing the primers: Primer length 19-25 
nucleotides (nt), GC content of 45-60% and a single amplicon size of 75-350 base pairs (bp). 
Melting temperatures were between 55-63°C per primer pair. 
Genomic DNA primers are listed in (Table 2.5) and primers for Reverse Transcription Polymerase 




































Size (bp) Application Design 
TOPKO1 TOPKO1-1F F CTAGGAGTGCGGCGAGTG 18 66.7 193 CRISPR M.K. TOPKO1-1R R CCAGCCACTTACCACCCAG 19 63.2 
TOPKO19 TOPKO19-2F F CGCGGAGTGTGAGAAGGA 18 61.1 511 CRISPR M.K. TOPKO19-2R R GACCAGCCACTTACCACC 18 61.1 
GAPDH-P1 GAPDH-P1F F TACTAGCGGTTTTACGGGCG 20 55 166 ChIP Millipore (cat. 17-408) GAPDH-P1R R TCGAACAGGAGGAGCAGAGAGCGA 24 58.3 
CBR1-C1 CBR1-C1F F GAAGAAAACCCCTCAGAGAACC 22 50 189 ChIP M.K. CBR1-C1R R CTCGCCGGGGTGCGGAGCAGGCGG 24 83.3 
CBR1-P2 CBR1-P2F F ACACTCACTTTGAAACCATGCA 22 40.9 172 ChIP M.K. CBR1-P2R R GAGAATTGCTTGCTTGAACCC 21 47.6 
CBR1-P3 CBR1-P3F F CACAACTAAGGCATGTCTTCCA 22 45.5 160 ChIP M.K. CBR1-P3R R TGGGTCTTGATTCTGGTGGT 20 50 
CBR1-P4 CBR1-P4F F TATGTTCCCACCCCAATCCC 20 55 193 ChIP M.K. CBR1-P4R R TTGAACGACTCTCCTCAGGG 20 55 





















                Continued→ 
Table 2-6 RT-qPCR primers 






Size (bp) Design 
PP1A PP1A-1F F TCCTAAAGCATACGGGTCCTGGCAT 25 52 166 (Feart et al., 2005) PP1A-1R R CGCTCCATGGCCTCCACAATATTCA 25 52 
CBR1 CBR1-2F F AGCTGGACATCGACGATCTG 20 55 187 M.K. CBR1-2R R GTGCACACATCTCGGGTAC 19 57.9 
MTMR1 MTMR1-2F F GACACCTACCCTGCCATCAT 20 55 176 M.K. MTMR1-2R R CAGCGCTTATCATTGGGACC 20 55 
YOD1 YOD1-2F F CTCCCCAAGTGTCATCCCTT 20 55 222 M.K. YOD1-2R R CTGTGCTTACCAGAACCGTG 20 55 
TOP2B TOP2B_1F F ACCTGGGTGAACAATGCTGC 20 55 212 (Song et al., 2012) TOP2B_1R R ACCTCCCTGCAATTCATTCCT 21 47.6 
ZNF43 ZNF43-8F F TGGCCAAAAGTCTTGGGTAA 20 45 110 (Neff et al., 2012) ZNF43-8R R TGATCACCTGTCTGGAGCAA 20 50 
PRKACB PRKACB-1F F TGGATTGGTGGGCATTAGGA 20 50 74 (Domhan et al., 2008) PRKACB-1R R TGGTTGGTCTGCAAAGAATGG 21 47.6 
ZSCAN18 ZSCAN18-4F F GGATGGTCTCGGGTTCTTCC 20 60 162 M.K. ZSCAN18-4R R CACCTTGTCCCTGGCTAGAC 20 60 
ARMCX5 ARMCX5-3F F GAGCACAGTGATCCCGAAGT 20 55 172 M.K. ARMCX5-3R R GCCTCCCTCAATCAACATGG 20 55 
ZNF512B ZNF512B-1F F AGTTCTGAGAGTGGCGTCAA 20 50 244 M.K. ZNF512B-1R R CCTTGTCTCTGCATCCTGGA 20 55 
ZNF626 ZNF626-6F F CCCTCAGTGAGCTTCCTTCAA 21 52.4 115 M.K. ZNF626-6R R GCAGACATTTGTGCGTCCC 19 57.9 
ZNF573 ZNF573-1F F GCCTTCAGTCGTGCTTCAAA 20 50 193 M.K. ZNF573-1R R TGTGGGCTGTCTGATGATGA 20 50 
FLT2 FLT2-2F F TCCCTTATGATGCCAGCAAGT 21 47.6 79 (Andersson et al., 2010) FLT2-2R R CCAAAAGCCCCTCTTCCAA 19 52.6 
EMP2 
EMP2-1F F TCCTCTCCACCATTCTCT 18 50 
80 (Wadehra et al., 2008) EMP2-1R R AAACCTCTCTCCCTGCTTCA 20 50 






















ME3 ME3-1F F TGAAGAAGCGCGGATACGA 19 52.6 101 (Bragoszewski et al., 2007) ME3-1R R GATTAGGCCGTGGATTCCAAG 21 52.4 
IL1B IL1B-3F F AGATGAAGTGCTCCTTCCAGG 21 52.4 73 (Laddha et al., 2014) IL1B-3R R TGGTCGGAGATTCGTAGCTG 20 55 
GZMA GZMA-2F F GAAGAGACTCGTGCAATGGA 20 50 80 (Maertzdorf et al., 2011) GZMA-2R R AAGGCCAAAGGAAGTGACC 19 52.6 
LILRB1 LILRB1-3F F GTGACGTATGCCGAGGTGAA 20 55 136 M.K. LILRB1-3R R CAGCAGCCTCAGTGTCCATC 20 60 
CYP26A1 CYP26A1-1F F GCAGCCACATCTCTGATCACT 21 52.4 109 (Zuchegna et al., 2014) CYP26A1-1R R TGTTGTCTTGATTGCTCTTGC 21 42.9 
RARB RARB-2F F GCAGAGCGTGTAATTACCTTGAA 23 43.5 145 (Poulain et al., 2009) RARB-2R R GTGAGATGCTAGGACTGTGCTCT 23 52.2 
RET RET1F F GCTCCACTTCAACGTGTC 18 55.6 158 (Ohshima et al., 2010) RET1R R GCAGCTTGTACTGGACGTT 19 52.6 
CRABP2 CRABP1-F1 F TCAAAGTGCTGGGGGTGAAT 20 50 168 Ian Cowell CRABP1-R1 R TCTGCTCCTCAAACTCCTCCC 21 57.1 
USF1 USF1-1F F CACCACGGATTAGAGGTCGT 20 55 397 (Bussiere et al., 2010) USF1-1R R GAGCATCACCTGTCAGCAAA 20 50 
USF2 USF2-1F F GATCCAAAATCCCTTCAGCA 20 45 395 (Bussiere et al., 2010) USF2-1R R CTTTACTCGCTCCCGTCTTG 20 55 
C-Myc Myc-1F F AATGAAAAGGCCCCCAAGGTAG 22 50 112 (Wang et al., 2018) Myc-1R R GTCGTTTCCGCAACAAGTCCT 21 52.4 
MAX MAX-2F F AGGTGGAGAGCGACGAAGAG 20 60 69 (Miao et al., 2015) MAX-2R R GTGCATTATGATGAGCCCGTTT 22 45.5 
BCL2 BCL2-3F F GATTGTGGCCTTCTTTGAG 19 47.4 232 (Zucchini et al., 2005) BCL2-3R R CAAACTGAGCAGAGTCTTC 19 47.4 
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2.14 RNA methods 
2.14.1  RNA extraction   
Total RNA samples were extracted and purified using silica membrane technology (RNeasy Mini 
kit, Qiagen, USA) according to the kit instructions. Briefly, 4*106 cells per sample were harvested 
by centrifugation at 300×g for 5 minutes then the pelleted cells were disrupted by adding 350 µl of 
RLT buffer and mixed by pipetting. The resulting lysate was homogenized by pipetting directly 
into a QIAshredder spin column placed in a 2 ml collection tube, and centrifuging at 10000×g for 
2 minutes. Then one volume of 70% ethanol was added to the homogenized lysate and mixed well 
by pipetting. Up to 700 µl of the mixture was transferred into an RNeasy spin column placed in a 
2 ml collection tube, and centrifuged at 8000×g for 15 seconds, then the flow-through was 
discarded and the collection tube was reused for the next step.  
The spin column membrane was washed by adding 700 µl RW1 buffer and centrifuged at 8000 ×g 
for 15 seconds, then the flow-through was discarded and the collection tube was reused for the next 
step. The membrane of the RNeasy spin column was washed again with 500 µl RPE buffer and 
centrifuged at 8000 ×g for 2 minutes; then the flow-through was discarded and the collection tube 
was reused for the next step. The RPE washing step was repeated, then the RNeasy spin column 
tube was placed in a new 1.5 ml collection tube and 50 µl of RNase-free water was added directly 
to the spin column membrane and centrifuged at 8000 ×g for 1 minute to elute the RNA. The 
purified RNA samples were stored at -70°C for up to 1 year. 
2.14.2 RNA sequencing (RNA-Seq) 
2.14.2.1 RNA quality and quantity measurement 
The total RNA concentration and RNA integrity number (RIN) of samples were determined using 
the (Agilent 2100 Bioanalyzer System, Agilent Technologies, Germany) with (Agilent RNA 6000 
Nano kit, Agilent Technologies, Germany) according to the kit user manual. An example 
Electropherogram summary of a total RNA sample analysis using (Agilent 2100 Bioanalyzer 






Figure 2-1 Example electropherogram of a total RNA sample analysed 













2.14.2.2 Library preparation and sequencing platform  
For Nalm6 cell lines (Chapter Four), samples of total RNA were sent to the (Institute of Genetic 
Medicine, Newcastle University) for Library preparation and Sequencing. TruSeq Stranded Total 
RNA with Ribo-Zero Globin kit (Illumina) was used which removes both cytoplasmic and 
mitochondrial ribosomal RNA (rRNA) as well as globin-encoding messenger RNA (mRNA). For 
library preparation, the High-Throughput protocol of (TruSeq® Stranded Total RNA Sample 
Preparation Guide, Illumina) was followed. The input RNA for library preparation was 1000 ng 
per sample. Sequencing was performed using (NextSeq 500, Illumina) sequencing system. A High 
output flow cell was used and 75 bp Paired End (PE) sequencing was performed. 
For SH-SY5Y cell lines (Chapter Six), samples of total RNA were sent to the (Institute of Genetic 
Medicine, Newcastle University) for Library preparation and Sequencing. TruSeq Stranded mRNA 
kit (Illumina) was used which selects only poly-A containing mRNA molecules using poly-T oligo 
attached magnetic beads. For library preparation, the High Sample (HS) Protocol of (TruSeq® 
Stranded mRNA Sample Preparation Guide, Illumina) was followed. The input RNA for library 
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preparation was 1500 ng per sample. Sequencing was performed using (NextSeq 500, Illumina) 
sequencing system. High output flow cell was used and 75 bp single End (SE) sequencing was 
performed. 
2.14.2.3 Analysis and interpretation of results 
For Nalm6 data (Chapter Four), raw sequencing data was analysed by the (Bioinformatics Support 
Unit, Newcastle University). Enrichment analysis was performed in the differentially expressed 
genes (by > 1 log2 fold change, padj < 0.05) in Nalm6 cell line using (R software, version 3.4) as 
described below, as well as using Database for Annotation, Visualisation and Integrated Discovery 
(DAVID) web tool (version 6.7) as described by (Huang et al., 2008; Sherman et al., 2008). The 
multiple testing correction was performed using Benjamini method with a cut-off of 0.05 as a 
threshold of significance of over-representation of (GO) terms. 
For SH-SY5Y data (Chapter six), all analysis was performed by myself under the supervision of 
John Casement from the (Bioinformatics Support Unit, Newcastle University). Briefly, raw 
sequencing files (FASTQ files) were firstly checked for sequence quality using FASTQC software. 
Then quantification of transcripts count was performed using Salmon, a tool that quantifies 
transcript expression via read abundances and it uses a gene annotation source (I used GENCODE 
gene sets). The following steps were performed using (R software, version 3.4). The Principal 
Component Analysis (PCA) was performed using DESeq2 package. Quantification data files were 
read using (tximport package) and analysed for differential gene expression using (DESeq2 
package). Gene annotation was then added using (annotables package) with GENCODE release 29 
(GRCh38.p12) as reference annotation.  
Venn diagrams were generated using (gplots package). Differentially expressed genes (DEGs) 
were tested for biological functions and canonical pathways enrichment using QIAGEN’s 
Ingenuity Pathway Analysis (IPA, Spring release 2019, GIAGEN Redwood City, USA, 
www.qiagen.com/ingenuity) using subscription provided to (Bioinformatics Support Unit, 
Newcastle University). IPA analysis were performed for genes which showed > 1 log2 fold change 
and < 0.05 padj. Analysis species parameter was set to human and apart from that IPA default 
parameters were used. Analysis involved downstream effects evaluation of DEGs for biological 
function annotations and canonical pathways. Also, analysis includes a prediction of upstream 
factors that may have caused the effects observed in the datasets. 
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IPA algorithm uses right-tailed Fisher's exact test to calculate the p-values for biological 
annotations or pathways. The p-value here reflects the likelihood that the association between 
DEGs in an experiment and a given function or pathway is due to random chance. Mathematically, 
it reflects robustness of overlapping between DEGs in user experiment and total number of genes 
allocated to the biological function or pathway. IPA then calculates the corrected p-value (padj) 
using Benjamini-Hochberg multiple testing correction method.  
In addition to evaluation of over-representation of a biological function or pathway within a group 
of genes, IPA also offers a prediction of effect direction (activation or inhibition) as a value of 
activation score (z-score). Z-score is based on prior knowledge stored in IPA database of expected 
relationship between a gene and a given biological function. IPA tests genes from a user dataset 
that are assigned to each biological function or pathway and compares their relative expression 
change to what is predicted from the literature. When the noticed change direction is consistent 
with a biological function activation state (activation or inhibition), IPA makes a prediction for 
activation state of this function (as activation or inhibition).  
An activation state of a biological function is inferred as a z-score value. This is based on the 
literature-based information about the relationship between genes and function within a molecular 
network. Based on differential gene expression of a gene (up or down), the activation state of a 
biological function is inferred from the direction of the effect correlated with (gene-function) 
relationship. For example, given the (gene-function) relationship is (activating), IPA makes an 
activation prediction for this function upon gene upregulation and an inhibition prediction upon 
gene downregulation. Conversely, if the (gene-function) relationship is (inhibition), IPA makes an 
inhibition prediction for this function upon gene upregulation and an activation prediction upon 
downregulation. In the biological context, a single function is associated with more than one gene. 
IPA creates a prediction for each single gene associated with that function and generates an overall 
activation state as a value of z-score. If the predicted activation state of a function is consistent for 
all genes associated with this function, IPA makes a prediction for that function a value of z-score.  
Mathematically, overall z-score of a function or pathway is a value of whether a given function or 
pathway has more activation predictions than inhibition predictions such that the overall z-score of 
positive value indicates overall increase in function or pathway activity, while overall z-score of 
negative value indicates overall decrease in function or pathway activity. If activation and 
inhibition predictions of a given function are equal then the z-score value of the function is zero. 
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However, even if genes from an experiment dataset were significantly enriched for a given function 
or pathway, Qiagen IPA makes direction prediction score only for the pathways that are eligible 
for z-score calculations. For a full list of pathways eligible for z-score scoring (refer to the website: 
http://qiagen.force.com/KnowledgeBase/articles/Basic_Technical_Q_A/Eligible-Pathways-List). 
IPA describes this as follows: “QIAGEN curators assigned the molecules that should be in a 
particular known state when the pathway is activated…. then, the curator determined the states of 
additional molecules in the pathway based on the causal relationships among the connected 
pathway nodes, avoiding setting nodes in states that conflict with each other (again, considering 
the pathway in the active state). Some pathways are not amenable to being described in a single 
activated state, and will therefore not be eligible for z-score calculations”. In this case, IPA labels 
the function or pathway differently indicating that this function or pathway is “currently ineligible 
for a prediction”.  
IPA also calculates the percentage of overlap between DEGs in a dataset of an experiment and the 
total number of genes assigned to a given pathway. Moreover, IPA provides molecule activity 
prediction (MAP) service as part of analysis to show downstream and upstream effects of 
regulation of a given gene on the related molecules within a pathway and present this as an 
activation or inhibition effect with labels on the pathway graph.           
2.14.3 Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR)  
2.14.3.1 RNA samples 
RNA samples used for RT-qPCR were either extracted and purified using (RNeasy Mini kit, 
Qiagen, USA) as described in section 2.10.1 or prepared directly from fresh cell lysates using 
(SingleShot Cell Lysis, Bio-Rad) kit according to manufacturer instructions. Briefly, fresh cell 
suspensions containing the appropriate cell number (around 1×105 cells per well) were transferred 
into a 96-well PCR plate. Cells were centrifuged at 750×g for 5 minutes and the supernatant(s) 
were removed. Cells were then washed with 125 µl per well with PBS and centrifuged again at 
750×g for 5 minutes and the PBS was removed.  
For adherent cells, media was removed and cells were washed with 125 µl PBS then the protocol 
was completed similarly for both cell types. To each well, 50 µl of SingleShot cell lysis master mix 
(containing 48 µl SingleShot cell lysis buffer, 1 µl proteinase K solution, and 1 µl DNase solution) 
was added and complete resuspension was ensured by pipetting up and down. Complete lysis was 
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then performed by incubating the PCR plate for 10 minutes at room temperature followed by 5 
minutes at 37°C and then 5 minutes at 75°C using MyiQ Single colour dual time PCR detection 
system (Bio-Rad). Cell lysates were then kept for up to 2 months at -20°C or for up to 12 months 
at -80°C. 
2.14.3.2 Protocol 
Gene expression analysis was performed by real-time one-step RT-PCR using SYBR Green I 
detection method. For this purpose, (QuantiNova™ SYBR Green RT-PCR Kit, QIAGEN, Cat. 
208154) kit was used according to the manufacturer’s instructions. Briefly, the total reaction 
volume was set to 20 µl per well in the PCR 96-well plate. In each reaction well, the following 
volumes were added: 10 µl (2x SYBR Green RT-PCR), 300 nM primer mix, 0.2 µl (QuantiNova 
SYBR Green RT Mix which contains HotStaRT-Script reverse transcriptase), 1-2 µl sample 
volume, and the volume was completed to 20 µl with RNase-free water. Contamination was 
monitored with two controls; (No reverse transcriptase) control to determine DNA contamination 
in the samples and (No template) control to determine other contaminations. The thermal cycler 
(CFX96 Touch™ , Bio-Rad) was set to the following parameters:  reverse transcription reaction 
(50°C for 10 minutes), DNA polymerase activation and initial DNA denaturation (95°C for 3 
minutes) for 1 cycle, denaturation, annealing and extension (95°C for 15 seconds, 55°C for 30 
seconds, 72°C for 30 seconds) for 40 cycles. 
2.15 Clustered regularly interspaced short palindromic repeats (CRISPR) technique 
CRISPR technique was used to generate TOP2B knockout clones used in chapters 5 and 6. The 
workflow of this technique is described in the following steps.  
2.15.1 Genomic editing design  
Genomic editing design step involved guide RNA (gRNA) oligonucleotide design, bioinformatical 
testing of their possible off-target, and designing a PCR primer required for genotyping (TOPKO1 
primer). Guide RNA (gRNA) oligonucleotides that target exon 1 of TOP2B gene were designed 
using the publically available CRISPR design web tools (http://crispr.mit.edu/) and 
(http://zifit.partners.org/ZiFiT/ChoiceMenu.aspx). Eight different gRNA oligonucleotides were 
designed and presented in (Table 2.7) and (Figure 2.1). Off-targets were determined using 
(http://www.rgenome.net/cas-offinder/) and (http://crispr.dbcls.jp/) algorithms. For each gRNA, a 
pair of oligos were designed in such a way that upon annealing, they have (CAAA and CCAC) 
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Figure 2-2 TOP2B targeting gRNAs used in CRISPR 
overhangs and contain gRNA sequence in the middle. In addition G nucleotides was added to 
gRNAs 6, 7, and 8 as it is preferable for U6 promoter. Oligonucleotides were synthesized by 
Integrated DNA Technologies (IDT, Glasgow, UK). 
 
gRNA Sequence 5' to 3' Strand Efficiency score* 
1 GGTGGCTGCGGCGCGGGAGC - 47 
2 GGCGCGGGAGCCGGCGTGGG - 44 
3 GCGGGAGCCGGCGTGGGCGG - 43 
4 GCCGGCGTGGGCGGCGGCAA - 68 
5 GCGGCAACGGGGCACTGACC - 79 
6 CGCGCCGCAGCCACCCGACT + 89 
7 AAGTCGGGTGGCTGCGGCGC - 83 
8 CAAGTCGGGTGGCTGCGGCG - 79 
* From http://crispr.mit.edu/  

















Figure 2-3 PX458 cloning vector 
2.15.2 Cloning 
Guide RNA oligonucleotides cloned into either pSpCas9(BB)-2A-GFP (PX458) or pSpCas9(BB)-
2A-Puro (PX459) V2.0 vector (Figures 2.2 and 2.3 respectively) which were a gift from Feng 
Zhang (Addgene plasmid # 48138 and # 62988) (Ran et al., 2013). 
Guide RNA (gRNA) Oligonucleotides were annealed to form the double-stranded oligos with 
overhangs that match the digested vector. For each (gRNA), 1 µl of each (100 µM) stock of both 
strands was mixed with 8 µl of nuclease free water. Annealing of the oligonucleotides was 
performed using MyiQ Single colour dual time PCR detection system (Bio-Rad) by applying the 
following incubations: 37 ⁰C for 30 minutes followed by 5 minutes at 95 ⁰C then the reaction was 






























Figure 2-4 PX459 cloning vector 
 
The Cloning vector was digested using BbsI restriction enzyme (New England Biolabs, UK, cat. 
R3539S) by mixing the following at 37 ⁰C for 1 hour: 1 µg vector, 1 µl of BbsI, 2 µl of (10X) 
buffer (New England Biolabs, UK, cat. B7202S), and volume was completed with nuclease-free 
water to 20 µl. Digested vector was loaded on a 1% agarose gel electrophoresis and run at 100 volt 
for 1 hour. Vector band was gel purified using the Qiaquick Gel extraction kit (Qiagen, UK, cat. 
28704) according to the manufacturer’s instructions. 
Guide RNA (gRNA) oligonucleotides were cloned into PX458 or PX459 vector by ligation 
reaction for 30 minutes at room temperature. The following were mixed in the ligation reaction: 
50ng of BbsI digested vector, 2 µl of diluted (1:200 in DW) annealed (gRNA), 5 µl of (2X) T7 
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ligase buffer (New England Biolabs, UK, cat. B0318S), and the volume was completed with 
nuclease-free water to 10 µl, then 1 µl of T7 ligase (New England Biolabs, UK, cat. M0318S). 
Vector in which (gRNA) was inserted was transformed into a competent bacterial cell DH5α 
(Invitrogen, UK, cat. 18265-017) as follows: 
Four microliter of ligation reaction was mixed with 40 µl of subcloning cells and left for 30 minutes 
on ice. The mixture was transferred to 42 ⁰C for 20 seconds to apply heat shock. The transformation 
mixture was then transferred onto ice for 2 minutes, then 950 µl of pre-warmed LB media was 
added and sample was incubated at 37 ⁰C for 45 minutes with shaking (180 rpm). Part of the sample 
(300 µl) was spread onto an LB agar plate containing 100 µg/ml Ampicillin and plates were 
incubated overnight at 37 ⁰C for colony selection. On the following day, 2-5 colonies were isolated 
and inoculated in 5 ml LB media containing 100 µg/ml Ampicillin to prepare cultures for plasmid 
miniprep. Plasmid miniprep was performed using QIAprep Spin Miniprep Kit (Qiagen, UK, cat. 
27104) according to manufacturer’s instructions. 
Plasmid samples from the miniprep were test digested to verify successful gRNA insertions. Both 
PX458 and PX459 have a pair of BbsI restriction sites that upon digestion, form overhangs match 
the (CAAA and CCAC) overhangs in the gRNA oligos. Successful insertion should destroy the 
BbsI restriction site which can be determined using digestion test. Therefore, a digestion test was 
performed using two restriction enzymes; BbsI + EcoRV for PX458 and BbsI + StuI for PX459 
(New England Biolabs, UK, cat. R0195S). PX458 and PX459 have only one EcoRV and StuI 
restriction site respectively. Upon digestion, successful insertion should give a single band and 
unsuccessful insertion should give two. 
In addition, for successful insertions, samples were sent for Sanger sequencing from (GATC 
Biotech) according to their sample requirements. Forward primer of Human U6 promoter, LKO.1 
5’ (5’-GACTATCATATGCTTACCGT-3’) was used. Verified plasmid samples were purified 
again with enough quantities by midiprep using Qiagen Plasmid Midi Kit (Qiagen, UK, cat. 12143) 
according to the manufacturer’s instructions. 
2.15.3 Nucleofection 
Plasmid with (gRNA) was introduced into cells by Nucleofection with Nucleofector II system 
(Amaxa, USA) using Amaxa® Cell Line Nucleofector® Kit V (Lonza, UK, cat. VCA-1003) for 
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Figure 2-5 PmaxGFP cloning vector. 
(SH-SY5Y and K562) or Amaxa® Cell Line Nucleofector® Kit T (Lonza, UK, cat. VCA-1002) 
for (Nalm6) cells according to the manufacturer’s instructions. Briefly, 1*106 cells per sample were 
harvested by centrifugation at 1000 rpm for 8 minutes then resuspended in 100 µl of supplemented 
Nucleofector® Solution V or T.  Cloning vector (PX458 or PX459) with or without gRNA was 
then added and mixed. Empty vector was used as a negative control and a GFP-expressing vector 
(PmaxGFP) (Figure 2.5), which was provided with the kit, was used as a positive control for 
transfection. Mixtures were then transferred into the cuvettes and Nucleofection was performed 
using either A-023 (for SH-SY5Y) or T-016 (for K562) or C-005 (for Nalm6) program. Samples 
within cuvettes were then left for about 10 minutes then 500 µl of pre-warmed media was added 










2.15.4 Determining transfection efficiency 
Cells were firstly observed for GFP expression by live cell imaging using TiE fluorescence wide 
field inverted microscope (Nikon) then harvested and prepared for FACS analysis. Gating was 
performed as described in (Figure 2.6). Transfection efficiency represents ratio of GFP expressed 




Figure 2-6 Determining transfection efficiency using FACS analysis. 
This figure shows gating used in FACS for both analysis and cell sorting of transfected cells (A) Cells were 
selected from other debris (B) Cell clumps and doublets were excluded by selection of only singlet cell 
population (C) Dead cells were excluded by selection of only DAPI negative stained cells (D) Cells stained 
positively with GFP were selected (E) FACS quantitative summary table.     
 
2.15.5 Determining gRNA efficiency 
Efficiency of gRNA in generating genome editing was determined by transfection of PX458 
plasmid with cloned gRNA (1-8) followed by selection of transfected cells by FACS then DNA 
extraction using (Wizard® SV Genomic DNA Purification System, Promega, UK) according to 
the manufacturer’s instructions. Efficiency of gRNA in achieving mutation was measured as an 
insertion and/or deletion ratio (Indel %) using (EnGen mutation detection kit, New England 
Biolabs, UK) according to manufacturer’s instructions. The principle of the kit is based on 
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Figure 2-7 Workflow of T7 Endonuclease I digestion test 
amplification of the genomic region which is targeted by CRISPR to produce a 500-1000 bp PCR 
product then performing denaturation followed by annealing to produce heteroduplex DNA 
fragments. These duplexes were then digested with T7 Endonuclease I, a DNA nuclease that targets 
any mismatch of more than one base pair. Digestion products were visualized by gel 














Experimentally the protocol was performed on samples which were either transfected with PX458 
only (Control) or PX458 with cloned gRNAs (1-8). Briefly it was performed as the following: 
The targeted region was amplified using TOPKO19 primer pair (Table 2.5) which produces a 511 
bp amplicon. PCR was performed using reagents provided with the EnGen kit by mixing the 
following (25 µl reaction volume): 12.5 µl Q5 Hot Start High-Fidelity 2X Master Mix, 1.25 µl 
(F+R primer mixture 10 µM stock), 100 ng DNA, 2.5 µl DMSO (as targeted region was high GC, 
the PCR was optimized with 10 % DMSO) and complete volume to 25 µl with nuclease-free water. 
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The thermal cycler (CFX96 Touch™ , Bio-Rad) was set to the following parameters:  Initial DNA 
denaturation (98°C for 30 seconds) for 1 cycle, denaturation, annealing and extension (98°C for 5 
seconds, 58°C for 10 seconds, 72°C for 20 seconds) for 35 cycles, final extension (72°C for 2 
minutes). 
The product of the PCR reaction was then denatured followed by annealing to allow for 
heteroduplex formation. This was performed by mixing the following: 5 µl PCR reaction, 2 µl 10X 
NEBuffer 2, and 12 µl nuclease-free water. The mixture was then incubated in a thermal cycler 
with the following parameters: Initial denaturation (95°C for 5 minutes), then annealing by ramp 
down in 2 steps: from 95 to 85°C at 2°C/second, then from 85 to 25°C at 0.1°C/second. 
Heteroduplex digestion was performed by incubating the above mixure with 1 µl T7 Endonuclease 
I at 37 °C for 15 minutes. Following digestion, 1 µl of Proteinase K was added and incubated at 37 
°C for 5 minutes to denature and hence stop the T7 Endonuclease I. 
Samples were then separated electrophoretically on a 2 % agarose gel and the efficiency were 
determined semiquantitatively by measuring band intensities and analyzing them with (Image lab 
software version 5.2).    
2.15.6 Clonal selection and expansion 
Cells were selected and sorted based on GFP expression of transfected cells using a BD 
FACSAria™ Fusion cell sorter (BD Bioscience, UK) through 488 nm wavelength channel. GFP 
positive cells were sorted into a single cell per well of 96-well plate and incubated at 37 ⁰C for 2-
3 weeks until colonies formed. 
2.15.7 Screening for knockout clones  
2.15.7.1 Genotyping 
Genotyping involved amplification of the targeted region using PCR, high percentage agarose gel 
separation, band extraction, then DNA purification and Sanger sequencing. Clones were harvested 
then centrifuged at 1000 rpm for 5 minutes. Genomic DNA was extracted using (Wizard® SV 
Genomic DNA Purification System, Promega, UK) according to the manufacturer’s instructions. 
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The PCR reaction was performed using the TOPKO1 primer (Table 2.5) which amplified the region 
that is targeted by the gRNA oligonucleotides and produced an amplicon of 193 bp size on an 
agarose gel.  
PCR was performed using reagents provided with the EnGen kit by mixing the following (25 µl 
reaction volume): 12.5 µl Q5 Hot Start High-Fidelity 2X Master Mix, 1.25 µl (F+R primer mixture 
10 µM stock), 100 ng DNA, 2.5 µl DMSO (as targeted region was GC rich (76.7 %) and the PCR 
was optimized with 10 % DMSO) and volume was completed to 25 µl with nuclease-free water. 
The thermal cycler (CFX96 Touch™ , Bio-Rad) was set to the following parameters:  Initial DNA 
denaturation (98°C for 30 seconds) for 1 cycle, denaturation, annealing and extension (98°C for 5 
seconds, 60°C for 10 seconds, 72°C for 20 seconds) for 35 cycles, final extension (72°C for 2 
minutes). 
Screening for Mutant clones was performed by running PCR products on a 3 % agarose gel and 
comparing the samples with the wild type. Clone bands that showed a difference from the wild 
type were purified from the gel using (QIAquick Gel Extraction Kit, Qiagen) according to the 
manufacturer’s instructions and sent for Sanger sequencing (GATC Biotech) according to their 
sample requirements to confirm genome editing. 
2.15.7.2 Determining TOP2B protein expression  
Clones were tested for TOP2B expression by both immunofluorescence and western blotting 
techniques as described previously with some modifications in the immunofluorescence protocol 
applied specifically for clones screening. For immunofluorescence, cells were harvested and 
resuspended in PBS then added to poly-lysine coated multi-well slides (Marienfeld, Germany) to 
adhere for 10-15 minutes. Excess PBS with non-adherent cells were then removed by pipetting and 
samples were fixed with 4 % paraformaldehyde for 10 minutes at room temperature.  
Samples were then washed twice with PBS and permeabilized with KCM with 0.1% (V/V) Triton 
X-100 for 15 minutes. Slides were incubated in blocking solution (KCM -T, 2% bovine serum 
albumin (BSA), 10% dried milk powder) for 1 hour then incubated with primary antibody (Table 
2.1) for 1 hour at room temperature or at 4 °C overnight.  
Slides were then washed with KCM-T for 3 × 10 minutes and incubated with secondary antibody 
(Table 2.1) for 1 hour at room temperature in the dark. Slides were further washed with KCM-T 
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for 3 × 10 minutes in subdued light. Vectashield mounting medium with DAPI (Vector laboratories, 
USA) was added to each slide and the coverslips were fixed by sealing with nail polish. 
Immunofluorescence imaging was performed using Olympus IX-81 microscopic imaging system 
and the integrated FITC fluorescence per nucleus was determined using (Volocity software V6.3, 
PerkinElmer, UK).        
2.16 Chromatin immunoprecipitation (ChIP) 
Chromatin immunoprecipitation is a technique used to test for interactions between DNA and 
proteins in biological systems and mostly in chromatin such as studying sites of interaction of 
transcription factors with DNA. The workflow of the ChIP protocol that was used in this study is 
outlined in (Figure 2.8). 
2.16.1 Reagents 
Preliminary solutions and buffers, which were used in preparing main ChIP buffers, are all detailed 
in (Appendix Table 1).   
2.16.2 Cell harvesting and chromatin cross-linking 
Nalm6 cells were grown to about 106 cells /ml in a large culture flask in a volume of 120 ml.  
Depending on the required number of immunoprecipitations (IPs), cell suspensions that correspond 
to  (2*107 cells per IPs) were harvested by centrifugation at 1600 rpm for 5 minutes at 4°C and 
pellet were resuspended in 18 ml of ice cold PBS. Freshly prepared formaldehyde was added to 1 
% (2 ml of 10 % stock) and the cell suspension was incubated for 10 minutes on ice with gentle 
mixing every 2 minutes. Formaldehyde was quenched by addition of Glycine to 0.125 M and cells 
were incubated for 5 minutes at room temperature. Cell suspension was centrifuged at 1600 rpm 
for 5 minutes at 4°C and the supernatant was removed. Cells were then resuspended in ice cold 
PBS and centrifuged at 1600 rpm for 5 minutes at 4°C. PBS was discarded carefully and pellets 















2.16.3 Chromatin extraction and fragmentation 
Cell pellets were resuspended in (1 ml per 2x107 cells) of ice cold 0.22 µm unit-filtered Farnham 
lysis buffer (5 mM PIPES pH 8.0, 85 mM KCl, 0.5% NP-40) with protease inhibitor cocktail 
(Expedeon, UK) and mixed by pipetting. Lysate was then passed 20 times through a 20 gauge 
needle. This treatment breaks the cells while keeping the nuclei mostly intact. Lysate was 
centrifuged at 2,000 rpm at 4°C for 5 minutes. Pellets were then resuspended with (300 µl per 
2x107 cells equivalent) of ice cold 0.22 µm unit-filtered RIPA buffer (1X PBS, 1% NP-40, 0.5% 
Na deoxycholate, 0.1% SDS) with protease inhibitor cocktail (Expedeon, UK) and mixed by 
pipetting. Lysate was then redistributed into pre-chilled eppendorf tubes depending on required 
number of immunoprecipitations (~2x107 cells equivalent / tube). 
Chromatin fragmentation to 200-600 bp range was performed by probe sonication (Bandelin 
Sonopuls HD2070 sonicator) by applying 10 rounds of 7 pulsed cycle for 15 seconds and 20% 
power. Sonicated samples were centrifuged at 14,000 rpm for 15 minutes at 4°C in a microfuge 
and supernatants which came from the same sample were collected together in a pre-chilled 15 ml 
falcon tube (this step is to reduce sample-to-sample variation between IPs which might arise from 
variation in chromatin shearing level among samples). DNA and protein concentrations of 
chromatin samples were determined by Nanodrop ND-1000 UV-Vis Spectrophotometer (Thermo 
Scientific, UK) and 10 % of chromatin was taken as Input for analysis. To test fragmentation of 
the chromatin on a gel, 20 µl was taken and DNA was purified as described in (section 2.16.5).   
2.16.4 Immunoprecipitation 
ChIP-Grade Protein A/G Magnetic Beads (Thermo Scientific, UK, Cat. 26162) were used in the 
protocol. Beads stock was resuspended by gentle vortexing then 20 µl of resuspended magnetic 
bead slurry was added to a 1.5 ml eppendorf tube on ice containing 0.9 ml of ice cold 0.22 µm unit-
filtered 5 mg/ml BSA (fraction V) in PBS and mixed well by brief vortexing. Eppendorf tubes were 
placed on a magnet and supernatants were removed. This washing step was repeated 3 more times, 
then beads were resuspended in 200 μl of BSA solution and antibodies were added as illustrated in 
(Table 2.1). Tubes were incubated on a rotator platform for 4 hrs at 4°C to allow for antibody-bead 
binding. Beads were washed 3 times with BSA solution and resuspended in 100 µl of BSA solution 
then chromatin was added (amount equivalent to 100 µg DNA per IP) and tubes were incubated on 
a rotator platform for 1 hour at room temperature followed by overnight incubation at 4°C. 
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Tubes were placed on a magnet and supernatants were removed then beads were washed with 0.9 
ml of ice cold 0.22 µm unit-filtered LiCl IP Wash Buffer (100 mM Tris pH 7.5, 500 mM LiCl, 1% 
NP-40, 1% sodium deoxycholate) and tubes were incubated on a rotator platform for 3 minutes at 
room temperature. Tubes were placed on a magnet and supernatants were removed and this 
washing step was repeated 4 more times then beads were washed once with 0.9 ml of ice cold 0.22 
µm unit-filtered TE Wash Buffer (10 mM Tris-HCl pH 7.5, 0.1 mM Na2EDTA) and tubes were 
incubated on a rotator platform for 1 minutes at room temperature. Beads were then resuspended 
in 200 µl of 0.22 µm unit-filtered IP Elution Buffer (1% SDS, 0.1 M NaHCO3) with vortexing at 
room temperature. 
Binding between beads and chromatin-coupled antibodies was firstly destroyed by incubating tubes 
at 65 °C for 1 hour with vortexing every 15 minutes. Tubes were then centrifuged at 14,000 rpm 
for 3 minutes at room temperature and placed on the magnet for 5 minute and supernatant was 
collected in new tubes. 
2.16.5 Reversing Chromatin cross-linking and DNA purification 
For fragmentation testing samples and Input only, volume was brought up to 200 µl with 1X PBS. 
To each sample, 20 µl of 20 mg/ml proteinase K stock (Melford, Cat. MB2005) was added and 
samples were incubated for 5 minutes at room temperature followed by addition of 4 µl of 10 
mg/ml RNase stock (Thermo Scientific, UK) and incubation for 20 minutes at room temperature. 
To purify DNA, QIAquick PCR Purification Kit (Qiagen, UK, Cat. 28104) was used according to 
the manufacturer’s instructions. Briefly, 5 volumes (that’s ~ 1000 µl) of Qiagen buffer PB was 
added to each sample and sample was applied to (QIAquick column in a provided 2 ml collection 
tube) and centrifuged at 17,900 x g (13,000 rpm) in a microfuge for 60 seconds at room temperature 
then flow-through was discarded. Columns were washed with 750 μl Qiagen Buffer PE then 
centrifuged at 17,900 x g (13,000 rpm) in a microfuge for 60 seconds at room temperature and 
flow-through was discarded. Centrifugation was repeated once again to allow removal of residual 
wash buffer.  
Each QIAquick column was placed in a clean 1.5 ml microcentrifuge tube and DNA was eluted by 
adding 30 μl of warmed (~55°C) Qiagen Buffer EB (10 mM Tris·Cl, pH 8.5) to the center of the 
QIAquick membrane and allow for 2-5 minutes then column was centrifuged as before for 1 min 
then this step was repeated (total eluted volume was 60 µl). ChIP DNA was used in qPCR or stored 
at -20 °C until use.  
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2.16.6 PCR reaction and analysis  
PCR reactions were performed using iTaq universal SYBR Green supermix (Bio-Rad) and primers 
described in (Table 2.5) by mixing the following (20 µl reaction volume): 10 µl iTaq universal 
SYBR Green supermix (2X), 1 µl (F+R primer mixture 10 µM stock), 2 µl ChIP DNA, and 
complete volume to 20 µl with nuclease-free water.  
The thermal cycler (CFX96 Touch™ , Bio-Rad) was set to the following parameters: Initial DNA 
denaturation (95°C for 3 minutes) for 1 cycle, denaturation, annealing and extension (95°C for 15 
seconds, 55°C for 20 seconds, 72°C for 30 seconds) for 40 cycles, melting curve analysis 65-95 °C 
at 0.5 °C increment for 5 seconds. 
Signal of enrichment of protein of interest at primer amplification region was presented as % of 
Input and analysis was performed using the following formula: 
      = � 2
(𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼 𝑐𝑐𝐼𝐼 − 𝐼𝐼𝐼𝐼 𝑐𝑐𝐼𝐼)
𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼 𝑑𝑑𝑑𝑑𝑑𝑑𝐼𝐼𝐼𝐼𝑑𝑑𝑑𝑑𝐼𝐼 𝑓𝑓𝑓𝑓𝑓𝑓𝐼𝐼𝑑𝑑𝑓𝑓 
� × 100  
 
2.17 Statistical analysis 
Data were analysed for significant difference with unpaired two-tailed Student's t-test using 
(Graphpad Prism software (v4.0), Graphpad, Inc., USA). Difference was considered to be 
significant when p value < 0.05 and all data represent the mean of 3 independent experiments 






3 Chapter Three: TOP2 as a target for cancer treatment  
3.1 Introduction 
3.1.1 TOP2-targeting drugs 
Drugs that act against Topoisomerases II are divided into two main groups; TOP2 poisons and 
catalytic inhibitors (Larsen et al., 2003; Nitiss, 2009). Clinically, TOP2 poisons are the most 
frequently used class of anti TOP2 agents and used mainly as antineoplastic agents while catalytic 
inhibitors, in addition to their usage as an antitumor agent, have various therapeutic applications 
such as cardio-protectors and modulators of other agents (Larsen et al., 2003). 
Catalytic inhibitors involve a wide range of compounds that inhibit TOP2 activity by different 
mechanisms; for example, aclarubicin which is an anthracycline that inhibits TOP2 by interference 
with TOP2 catalytic action and preventing its binding to DNA because of its potent intercalating 
activity. Thus, it acts against the action of a group of TOP2 poisons such as etoposide, and 
amsacrine (Sørensen et al., 1992; Petersen et al., 1994; Larsen et al., 2003). Similarly, Suramin 
acts as a TOP2 inhibitor by interfering with bounding between TOP2 and DNA and as a 
consequence antagonizes the cytotoxicity of some TOP2 poisons such as etoposide (Bojanowski 
et al., 1992; Lelievre et al., 1995; Larsen et al., 2003). 
Another catalytic inhibitor the coumarin novobiocin, inhibits TOP2 activity either by blocking 
ATP-binding site (Gormley et al., 1996) or by interference with the enzyme capability to bind DNA 
(Sekiguchi et al., 1996; Larsen et al., 2003). On the other hand, it has been shown that merbarone 
has no significant effect on ATP hydrolysis nor TOP2 binding to DNA. Instead, it has a strong 
inhibitory effect on DNA cleavage mediated by TOP2 (Fortune and Osheroff, 1998; Larsen et al., 
2003). Bisdioxopiperazines such as ICRF-154, ICRF-187 and ICRF-193 exert their cytotoxicity 
via TOP2 by formation of noncovalent stabilized form of TOP2 around DNA (Andoh and Ishida, 
1998) leading to the inhibition of ATPase activity of TOP2 (Hu et al., 2002; Larsen et al., 2003). 
However, many of the catalytic inhibitors have no clear mechanism of action but they are generally 
antagonistic with TOP2 poisons (Austin and Marsh, 1998). 
TOP2 poisons act by stabilising TOP2-DNA covalent complexes formed as part of the catalytic 
cycle of the enzyme while the catalytic inhibitors exert their anti-TOP2 activity through at least 
one of the other steps of the catalytic action of TOP2 (Larsen et al., 2003; Nitiss, 2009). TOP2 
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Figure 3-1 Chemical structures of selected TOP2 poisons 
poisons increase levels of DNA-TOP2 cleavage complexes by two mechanisms; either by 
preventing the ligation step of the catalytic cycle of TOP2 which leads to an increase in both the 
level of complexes formed and their lifetime, or by increasing the rate of complex formation with 
limited effect on ligation efficacy of the enzyme (McClendon and Osheroff, 2007). 
TOP2 poisons are classified into several groups including epipodophyllotoxins (e.g. etoposide and 
teniposide), anthracyclines (e.g. doxorubicin, epirubicin, daunorubicin, and idarubicin), acridines 
(e.g. amsacrine), the anthracenediones (e.g. mitoxantrone), and the benzo [c] phenanthridine 
alkaloid (e.g. NK314) (Cowell and Austin, 2012). Chemical structures of selected TOP2 poisons 
are depicted in (Figure 3.1). 
 
 














(A) Anthracycline (B) epipodophyllotoxins (C) Acridines (D) Anthracenediones. Structures are adapted from 





Epipodophyllotoxins are natural toxins extracted from the Indian Podophyllum plant and have been 
used for hundreds of years (Slevin, 1991). One of the most common epipodophyllotoxins is 
etoposide, an antitumor agent that was first synthesized in 1966 as a synthetic analogue for the 
natural epipodophyllotoxins 4′-demethylepipodophyllin benzylidene glucoside (DEPBG). Since 
this time, etoposide has been used as an antineoplastic agent but the anti TOP2 activity was not 
described until 1984 (Hande, 1998). Etoposide is one of the most frequently used drugs in the 
treatment of small-cell lung cancer and a wide range of haematological and germ-line tumours 
(Belani et al., 1994; Hirabayashi et al., 1994; Burden and Osheroff, 1998). Studies have shown 
that etoposide does not have potent intercalative activity and has little interaction with DNA in the 
absence of TOP2. It acts by binding non-covalently to TOP2 and inhibits religation of DSBs 
catalysed by the enzyme (McClendon and Osheroff, 2007).  
A high resolution (2.16 Å) crystal structure of TOP2B (residues from 445 to 1201)-DNA complex 
stabilised by etoposide has been determined (Wu et al., 2011). This model has shown an 
oligonucleotide DNA segment bound symmetrically by homodimeric TOP2B in a process that 
involves two etoposide molecules and six catalytic Mg2+, three Mg2+ per monomer were clearly 
visible in the electron density maps. The cleavage complex was confirmed by the detection of the 
linkage between the scissile phosphates and the active tyrosine residues with the rupturing of 
phosphodiester bonds (Wu et al., 2011). The crystal structure has shown that etoposide inhibits 
religation of the G-segment by physically keeping apart broken ends of the G-segment in a process 
involving insertion of two etoposide molecules in the DNA cleavage sites. In addition, this crystal 
structure shows relatively more opened DNA gate than those in the DNA-bound models of bacterial 
and yeast TOP2s and the catalytic Mg2+ is dissociated from the phosphotyrosyl moiety (Wu et al., 
2011).  
Anthracyclines are a group of compounds that have been used in the treatment of haematological 
and solid tumours for decades (Johnson and Richardson, 1998). The anti-cancer activity of 
anthracyclines was first noted in the 1960s when an antibiotic Daunomycin isolated from 
Streptomyces peucetius cultures showed an anti-tumour activity against a number of cancer cell 
lines. Another structurally identical antibiotic rubidomycin was isolated at the same time from 
Streptomyces coeruleorubidus by another group and the compound subsequently named 
daunorubicin (Johnson and Richardson, 1998).  
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Shortly after that, doxorubicin was isolated from a mutant culture of the original strain (Johnson 
and Richardson, 1998). The chemical structure of doxorubicin is very similar to that of 
Daunomycin and it differs only by the substitution of a hydrogen atom with a hydroxyl group on 
the acetyl radical (Figure 2.3A). Doxorubicin showed a greater variety of activities than 
daunorubicin (Tan et al., 1967; Bonadonna et al., 1969; Johnson and Richardson, 1998).  
The anti-TOP2 properties of anthracyclines were described in the mid-1980s and it is assumed that 
the antineoplastic properties of anthracyclines is due to their anti-TOP2 activity (Hande, 1998). 
Furthermore, in addition to their poisoning effect on TOP2, anthracyclines are highly intercalative 
compounds and have the ability to bind DNA with high affinity (Gewirtz, 1999). The intercalation 
properties of anthracyclines is due to the ability of their planar aglycone moiety to insert between 
DNA bases (Hande, 1998). Moreover, formaldehyde production upon ROS stimulation by 
anthracyclines leads to the formation of anthracycline DNA adducts and crosslinks which might 
increase their cytotoxicity (Zeman et al., 1998; Parker et al., 2004).  
The chemical structure of anthracyclines also allows them to act as electron acceptors and produce 
reactive products which damage lipid membranes and macromolecules which might contribute to 
the cytotoxicity of anthracyclines (Gewirtz, 1999). In addition, anthracyclines interfere with DNA 
helicases and modify their ability to separate double-stranded DNA and obstruct separation of 
strands (Bachur et al., 1992; Hande, 1998). However, one of the major side effects of 
anthracyclines is the development of cardiotoxicity (Kizek et al., 2012). Several mechanisms have 
been suggested for anthracyclines-induced cardiotoxicity although the most common hypothesis is 
the oxidative stress results from free radical intermediates that primarily affect cardiac cells 
because of their lack of free radical scavenging system (Hande, 1998). Recently, evidence has 
shown that anthracyclines exert their cardiotoxicity via TOP2β (Zhang et al., 2012).  
Doxorubicin is one of the most common anthracyclines in clinical use. It has been prescribed 
widely for treatment of acute leukaemias, lymphoma, and solid tumours (Johnson and Richardson, 
1998). Doxorubicin exerts its cytotoxicity by intercalation with DNA and binding to multiple 
nuclear targets such as TOP1 and TOP2 causing DNA damage which leads to apoptosis. In 
addition, doxorubicin is a known intercalative agent with the ability to inhibit both DNA and RNA 
polymerases and subsequently preventing DNA replication and transcription (Tacar et al., 2013). 
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Daunorubicin is an antibiotic that acts effectively as an anti-cancer drug by inhibiting DNA 
synthesis and stabilizing TOP2-DNA complexes. Other mechanisms such as DNA adducts 
formation, free radicals generation, interference with strand separation and DNA helicase also have 
been reported (Gewirtz, 1999; Bertuzzi et al., 2014). Daunorubicin has a narrower range of clinical 
use than doxorubicin (Hande, 1998), but it is the most common agent that has been used for the 
treatment of acute myeloid leukemia (AML) in combination with cytosine arabinoside (Ara-C) for 
decades (Feldman, 2011; Miyawaki et al., 2011).  
Idarubicin is a synthetic derivative of daunorubicin with a more lipophilic structure (Bertuzzi et 
al., 2014). Idarubicin structure differs from daunorubicin only in the absence of the methoxy group 
from position 4 of the chromophore ring. Lipophilic properties of idarubicin over daunorubicin 
result in a higher cellular uptake and stronger DNA binding (Johnson and Richardson, 1998). 
Idarubicin has been introduced as an alternative for daunorubicin only for AML treatment (Hande, 
1998). Several studies and clinical trials have been conducted to compare treatment outcomes of 
idarubicin with daunorubicin (Ohtake et al., 2011). Some studies suggest more therapeutic benefits 
upon use of idarubicin instead of daunorubicin but these are not clinically significant and did not 
show an  improvement in the general survival (Hande, 1998; Bertuzzi et al., 2014). 
Mitoxantrone is an anthracenedione that was introduced in the 1980s as an alternative for 
doxorubicin with less toxicity. Mitoxantrone has the same structure as doxorubicin with the 
exception of lacking of an amino-sugar moiety at C9 (Johnson and Richardson, 1998). 
Mitoxantrone has been proved to be less cardiotoxic than doxorubicin and other anthracyclines as 
it has a remarkably decreased potential for free radical formation (Hande, 1998). However, many 
studies has shown that in spite of lower cardiotoxicity of mitoxantrone, it has generally less anti 
tumour activity than doxorubicin (Hande, 1998). Mitoxantrone has been prescribed for the 
treatment of acute myeloid leukaemia, non-Hodgkin lymphoma, breast and prostate cancer 
(Johnson and Richardson, 1998). 
Acridines are a group of compounds that have intercalation activity with DNA as a result of their 
planar structure. In addition, the majority of acridines have the ability to interfere with 
topoisomerase action. However, few agents of this group have been validated for cancer treatment 
in the clinic (Demeunynck, 2004). Amsacrine (m-AMSA) was introduced in the 1970s and was 
one of the early developed TOP2 poisons.  
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Amsacrine (m-AMSA) is one of the most famous antineoplastic acridines and it is prescribed for 
acute myeloid leukaemia (AML) treatment. It has been proposed that the anti tumour activity of 
(m-AMSA) is due to stabilization of TOP2 cleavage complex and prevention of the ligation 
process. Studies have shown that (m-AMSA) interacts with TOP2 through the 
methanesulfonamido side chain located on the anilino ring (Demeunynck, 2004). In vitro studies 
has been shown that (m-AMSA) targets both TOP2 isoforms and both enzymes form similar 
ternary complexes with DNA and m-AMSA. TOP2B deletion from murine cell lines resulted in 
increasing resistance to amsacrine, etoposide, and mitoxantrone suggesting that TOP2β might be a 
target for them in vivo (Marsh et al., 1996; Errington et al., 1999). 
3.1.2 Relative contribution of TOP2 isoforms to the effect of TOP2 targeting drugs 
Type II DNA topoisomerases are important targets in the treatment of human malignancies 
(Deweese and Osheroff, 2009). TOP2 targeting drugs are involved in about half of the 
chemotherapeutic treatments for cancer in the clinic (McClendon and Osheroff, 2007). The relative 
contribution of TOP2α and TOP2β isoforms in the effect of chemotherapeutic treatments of cancer 
is not clear (McClendon and Osheroff, 2007). Isoform-specific cellular roles and regulation 
patterns might reflect the contribution of TOP2 isoforms in the efficacy of TOP2 targeting drugs. 
As described previously in chapter one, TOP2α isoform is essential for proliferation-related 
activities and is highly expressed in proliferating but not in quiescent cells, whereas TOP2β isoform 
is expressed in all tissues even the fully differentiated cells such as cardiac cells. This suggests that 
TOP2α could be the isoform that primarily is responsible for anti-tumour activity of TOP2 targeting 
drugs while the TOP2β is associated with toxic side effects of these drugs.  
Studies have been conducted to investigate the relative role of TOP2α and TOP2β in the 
cytotoxicity of TOP2 targeting drugs. While there is some evidence that both isoforms contribute 
to the cytotoxicity of etoposide, mitoxantrone, and amsacrine (mAMSA) in vivo (Willmore et al., 
1998; Errington et al., 1999), other findings suggested that the cytotoxicity of etoposide follows 
TOP2α more than TOP2β (Errington et al., 1999; Azarova et al., 2007). 
Attempts to develop TOP2 isoform specific agents are in progress. For example, NK314, a 
synthetic alkaloid that has been shown to specifically target TOP2α in vivo (Toyoda et al., 2008). 
Moreover, pixantrone; a novel anthracycline and anthracenedione derivative agent which is 
currently under clinical trials is reported to show TOP2α selectivity (Hasinoff et al., 2016). So far 
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there are no isoform specific drugs successfully employed in the clinic (Deweese and Osheroff, 
2009). 
Another important aspect is the development of therapy-related leukaemia (t-AL) typically acute 
myeloid leukaemia (t-AML) in patients treated with TOP2 targeting drugs which might be due to 
the genetic damage caused by these agents (Mauritzson et al., 2002; Kayser et al., 2011). The 
prevalence of (t-AL) is increasing due to the higher survival rates in patients with primary 
malignancy and the use of more intensive chemotherapeutic protocols. The development of (t-AL) 
is thought to be a result of non-lethal DNA damage induced in bone marrow progenitor cells by 
anti-cancer agents (Cowell and Austin, 2012). 
It has been suggested that TOP2β is the isoform that is involved in chromosomal rearrangements 
that are associated with the development of (t-AL) (Azarova et al., 2007; Azarova et al., 2010; 
Haffner et al., 2010; Cowell and Austin, 2012; Cowell et al., 2012; Smith et al., 2014).          
3.1.3 Cytosine Arabinoside (Ara-C) 
Cytosine arabinose (Ara-C) or its synonyms; arabinosylcytosine or cytarabine (Reiter et al., 2001) 
is an effective anti-cancer drug that has been employed in the treatment of various types of adult 
and paediatric leukaemias (Hiddemann, 1991; Cline and Osheroff, 1999; Reiter et al., 2001). The 
anticancer activity of Ara-C was determined for the first time in culture and animal models in the 
1960s. This led to the first clinical trials against lymphoma and solid tumours in 1963. After 
beneficial outcomes of Ara-C incorporation in the treatment of acute leukaemias in 1986, it has 
been established that Ara-C is one of the most effective anticancer agents whether used as a single 
agent or in combination (Hiddemann, 1991).  
It has been demonstrated that Ara-C is the most effective agent in the induction phase of AML 
treatment and become incorporated in all standard treatments for acute myeloid leukaemia (Kanno 
et al., 2007). Furthermore, clinical trials have shown that Ara-C is an active drug against non-
Hodgkin’s lymphoma and acute lymphoblastic leukaemia (ALL) (Kanno et al., 2007).  
Ara-C is an antimetabolite derived synthetically from the nucleoside deoxycytidine (Hiddemann, 
1991; Reiter et al., 2001). It differs from the parent molecule by the addition of a β-hydroxyl group 
to the sugar moiety in the 2′ position (Hiddemann, 1991) (Figure 3.2). Despite successful clinical 
outcomes of treatment with Ara-C, the precise mechanism of action remains controversial (Han et 
al., 2000; Wills et al., 2000).  
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Figure 3-2 Structure of nucleoside and its derivative 
The overall evidence has shown that the cytotoxic effect of Ara-C is due to the combination of two 
mechanisms; inhibition of DNA polymerase(s), and incorporation into DNA structure and causing 
chain termination which stops DNA synthesis (Cline and Osheroff, 1999; Cros et al., 2004; Krogh-
Madsen et al., 2012). Furthermore, accumulated evidence suggests that Ara-C acts in a cell cycle-
specific pattern and selectively targets S phase cells leading to cell arrest at G1-S boundary 
(Gorczyca et al., 1993; Horber et al., 2000). In vitro studies have shown that the cell cycle 









Deoxycytidine (A) and its analogue cytosine arabinoside (Ara-C) (B). Adapted from (Garcia-Diaz et al., 
2010). 
Because of the hydrophilic properties of Ara-C, it requires to be actively transported into the cell 
by a specific membrane transport protein; human equilibrative nucleoside transporter-1 (hENT-1) 
which permeates the cell membrane (Kanno et al., 2007). Ara-C becomes toxic when activated by 
phosphorylation to its 5′-triphosphate form (Ara-CTP) by cell kinases (Cline and Osheroff, 1999; 
Kanno et al., 2007). The (Ara-CTP) represents the key behind the cytotoxicity of Ara-C (Yamauchi 
et al., 1996). Much evidence has shown a clear relationship between the intracellular level of Ara-
CTP and the treatment outcome with Ara-C and in vitro and in vivo resistance to Ara-C (Cros et 
al., 2004).   
Phosphorylation of Ara-C to its active form (Ara-CTP) inside the cell is a process of three steps, it 
begins when Ara-C is converted to Ara-C monophosphate (Ara-CMP) by deoxycytidine kinase, 
then the latter is further phosphorylated to Ara-C diphosphate (Ara-CDP) by (deoxy)cytidylate 
kinase. Subsequently, Ara-CDP is phosphorylated into Ara-CTP by nucleoside diphosphate kinase 
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(Zhang and Kiechle, 2004). The first step of phosphorylation of Ara-C to Ara-CMP which is 
mediated by deoxycytidine kinase represents the rate limiting step of Ara-C activation (Gandhi and 
Plunkett, 1992; Zhang and Kiechle, 2004).  
The activity of deoxycytidine kinase is effected by the intracellular level of deoxynucleotides and 
cell cycle phase (Gandhi and Plunkett, 1992), and is maximal during middle and late S phase 
(Hiddemann, 1991). Furthermore, this process is also controlled by the counter activity of 
deoxycytidine kinases and cytidine/deoxycytidine deaminase which is produced predominantly in 
the liver. These enzymes convert Ara-C to the nontoxic form uracil arabinoside (araU) 
(Hiddemann, 1991). 
The (Ara-CTP) competes with deoxycytidine triphosphate (dCTP) for incorporation in the DNA 
by DNA polymerase during the DNA synthesis process (Zhang and Kiechle, 2004). Incorporation 
of the activated form (Ara-CTP) into the DNA causes chain termination and subsequent inhibition 
of DNA synthesis (Sarkar et al., 2005). It has been determined that there is a tight relationship 
between the cytotoxicity of Ara-C and the level of Ara-CTP incorporation into DNA (Lacombe et 
al., 1996). Studies have determined that Ara-CTP incorporation into DNA correlates with several 
events including; localized alteration in a DNA duplex, DNA polymerase and TOP 1 inhibition, 
and corruption of DNA elongation (Zhang and Kiechle, 2004). 
Furthermore, it is believed that the cytotoxicity of Ara-C is associated with its inhibitory effect on 
DNA polymerases; α, δ, and ε (Han et al., 2000; Sekizawa et al., 2007). Nevertheless, studies have 
shown that DNA polymerase α is the most sensitive polymerase isoform to Ara-CTP (Han et al., 
2000; Cros et al., 2004). However, the mechanism by which Ara-CTP exerts its cytotoxicity might 
not be simply explained by the competition with deoxycytidine triphosphate (dCTP) for binding 
with DNA polymerase as kinetic studies have shown that Ara-CTP is a weak competitive with 
(dCTP) for DNA polymerase binding (Han et al., 2000; Wills et al., 2000).    
Another studies have suggested that incorporation of Ara-CMP at the 3′ end of a replicating  DNA 
leading to chain termination and blocking DNA synthesis (Han et al., 2000). However, this again 
has been opposed by findings of other groups that the incorporation of Ara-C does not lead to 
complete chain termination and high percentage of incorporated Ara-C was located in 
internucleotide positions throughout the daughter DNA (Han et al., 2000).                   
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The (Ara-CTP) form also might exert toxicity on the cells which are not synthesizing DNA due to 
its involvement as a nucleoside alternative in glycoprotein and phospholipid metabolism 
(Hiddemann, 1991). 
3.1.4 Combinations of TOP2 targeting drugs and Ara-C 
The combination of nucleoside analogue Cytosine Arabinoside (Ara-C) and Anthracyclines such 
as daunorubicin or idarubicin have been commonly investigated in a wide range of studies 
including Acute Myelogenous Leukaemia (Hiddemann, 1991; Feldman, 2011; DiNardo and 
Cortes, 2015), Acute Lymphocytic Leukaemia (Bassan, 1996; Rowe, 2009), non-Hodgkin’s 
lymphoma (Dufour et al., 1996), and Acute Promyelocytic Leukaemia (Fenaux et al., 2001). 
Despite the broad use of this combination, it has been mostly applied in the treatment of Acute 
Myelogenous Leukaemia (AML) over the last decades (Tardi et al., 2009; Feldman et al., 2012) 
and has proved to be an effective regimen (Krogh-Madsen et al., 2012; DiNardo and Cortes, 2015).  
Anthracyclines exert their anticancer activity by targeting the cellular enzyme topoisomerase II 
(TOP2) and prevent the ligation step of its catalytic cycle leading to a cytotoxic Double-Stranded 
Breaks (DSBs) that trigger cell death (Cowell and Austin, 2012). on the other hand, the effect of 
Ara-C is more controversial but it might be mainly due to a combination of  two mechanisms (1) 
inhibition of DNA polymerase, and (2) incorporation into the DNA structure and causing chain 
termination which stops DNA synthesis (Hiddemann, 1991; Cline and Osheroff, 1999; Cros et al., 
2004).  
The combination between an anthracycline (especially daunorubicin) and Ara-C represents the 
backbone treatment of AML in the majority of clinical trials over the world (Ohtake et al., 2011; 
Bertuzzi et al., 2014). Since the successful introduction of daunorubicin in the treatment of patients 
with AML, numerous studies and clinical trials tested the combination between daunorubicin and 
Ara-C that finally lead to the establishment of the (7+3) Ara-C plus daunorubicin induction regimen 
by Cancer and Leukaemia group B (CALGB) in 1982 (Rai et al., 1981; Yates et al., 1982). This 
combination has become the standard induction treatment of AML (Bertuzzi et al., 2014).  
Clinically, the first course of induction therapy for AML involves continuous infusion of  100-200 
mg/m2 of cytarabine for 7 days simultaneously with bolus injection of 45-90 mg/m2 of daunorubicin 
daily for 3 days (Ohtake et al., 2011; Burnett et al., 2015; Lynch and Medeiros, 2015). For example, 
the AML17 clinical trial which is performed over 136 centres in the UK, Denmark, and New 
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Zealand from September 2011 to October 2013. This clinical trial involved 1206 patients who were 
randomized to be given 100 mg/m2 of cytarabine every 12 hours for 10 days and either 60 or 90 
mg/m2 daunorubicin on days 1, 3, and 5 (Burnett et al., 2015).  
Numerous attempts for increasing the clinical outcome of (daunorubicin+Ara-C) combination have 
successfully increased the efficiency of this regime. These attempts involved changing doses and/or 
timing or both (Goldstone et al., 2001; Tardi et al., 2009; Miyawaki et al., 2011). On the other 
hand, it has been suggested that the combination of Ara-C with TOP2 targeting drugs has an 
enhanced outcome upon scheduling over concurrent treatment (Rao et al., 1975; Ritch et al., 1981; 
Minford et al., 1984; Loughlin et al., 1996).  
3.2 Aims 
Literature reviewed above involved two aspects in cancer treatment with TOP2 targeting drugs. 
First, the relative contribution of TOP2α and TOP2β isoforms in anti-tumour (cytotoxicity) and 
therapy-related leukaemia (genotoxicity) of TOP2 targeting drugs, with the suggestion that TOP2β 
isoform is implicated in therapy-related leukaemia. Second, the role of dose ratio/order or both in 
enhancing outcome of cancer treatment with TOP2 targeting drugs in combination with Ara-C. 
This study was conducted to investigate these two aspects. The aims were to: 
• Investigate the relative contribution of TOP2 isoforms in cytotoxicity and genotoxicity of 
two TOP2 poisons used interchangeably: daunorubicin and idarubicin. 
• Test whether using different dose ratio, scheduling, or both might enhance the efficiency 
of (daunorubicin+Ara-C) combination in terms of cytotoxicity and genotoxicity. 
To address the aims above, the following experimental objectives were followed: 
• The dose response curves were determined for each single drug; daunorubicin, idarubicin, 
Ara-C in Nalm6WT, Nalm6B-/-, and Nalm6A+/- cells lines. 
• Determine genotoxicity of drugs using the in vitro micronucleus (MN) test by FACS. 
• Determine the cytotoxicity and genotoxicity of different Ara-C and daunorubicin 
combinations. 
• The cytotoxicity and genotoxicity of scheduled (daunorubicin+Ara-C) combination was 
compared with the concurrent treatment. 
• Determine the effect of all treatments on cell cycle phase distribution in Nalm6 cell lines. 
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3.3 Results  
3.3.1 TOP2 expression in Nalm6 cell lines 
The wild type Nalm6 cell line was originally derived from a patient with acute lymphoblastic 
leukaemia (ALL) in relapse and it has shown that their genes can be knocked out with high 
efficiency by homologues recombination (So et al., 2006; Adachi et al., 2008a). Two TOP2 genetic 
variants were generated using this method by (Toyoda et al., 2008); Nalm6B-/- and Nalm6A+/- and 
they have been shown to express different levels of the TOP2 isoforms. The expression of TOP2 
in Nalm6 cell lines in this study was evaluated by both western blotting and immunofluorescence 
and consistently shown that the expression of TOP2B is absent in Nalm6B-/- and the expression of 








































Expression of both TOP2 isoforms was determined in Nalm6 cell lines; Nalm6WT, Nalm6B-/-, and Nalm6A+/- 
by western blotting (A) and immunofluorescence (B) as described in the materials and methods. For western 
blotting, the whole cell extracts (WCEs) were prepared for SDS-page then transferred onto nitrocellulose 
membranes and probed with the following antibodies: anti-TOP2A (4566), anti-TOP2B (30400), and anti-
actin (ab3280). For immunofluorescence, cells were prepared for staining then probed with anti-TOP2A 
(4566) and anti-TOP2B (4555) antibodies. Imaging was performed using an Olympus IX-81 microscopic 
imaging system and the integrated FITC fluorescence per nucleus was determined using (Volocity software 
V6.3, PerkinElmer, UK) and analysed using (Graphpad Prism software (v4.0), Graphpad, Inc., USA) as 
described by (IG et al., 2011). Scatter plot represents the raw integrated fluorescence for nuclei and the 





Figure 3-4 Growth curve of Nalm6 cell lines 
3.3.2 Nalm6 cell lines have comparable Growth curves and doubling times 
Growth curve of Nalm6 cell lines used in this study is shown in (Figure 3.4).  
 
 





   
Nalm6 cell lines were seeded at 1×105 cells/ml then grown for up to 4 days. Cell counting was performed 
every 24 hrs. Growth curves were generated from at least 3 independent experiments, error bars representing 
the SEM. 
The doubling time of the Nalm6 cell lines was determined and the mean of 48-96 hour time points 
where the cells are in their exponential growth was calculated. The doubling time means were 22 
hours 1 minute, 22 hours 56 minutes, and 21 hours 57 minutes for Nalm6WT, Nalm6B-/-, and 
Nalm6A+/- respectively as detailed in (Table 3.1). Statistical analysis showed no significant 
difference between Nalm6 cell lines in terms of doubling times. The determination of doubling 
times for cell lines in our study is important because in the micronuclei assay, it is crucial that the 
micronuclei which are formed during mitosis are scored when the cells undergo at least one cell 
cycle but no more than two (OECD, 2010). This time allows cells to be exposed to the agents and 
undergo mitosis without undergoing further cell cycles as the fate of the micronuclei formed is 
unknown in the additional cycles (Fenech, 2000).  
Cell line Doubling time (hrs.) SEM (±) 
Nalm6 WT 22.01 0.22 
Nalm6 B-/- 21.94 0.29 
Nalm6 A+/- 21.95 0.46 
Table 3-1 Doubling times of Nalm6 cell lines 




3.3.3 Cytotoxicity of TOP2 poisons in Nalm6 cell lines 
The dose response curves were determined for Nalm6 cell lines treated with two TOP2 poisons 
daunorubicin and idarubicin (Figure 3.5). The IC50 of drugs as well as the contribution of TOP2 
isoforms to the cytotoxicity of drugs was determined by comparing the dose response curve of the 
wild type cells with the TOP2 null knockout for TOP2B (Nalm6B-/-) and the TOP2 heterozygote 
(one allele) knockout for TOP2A (Nalm6A+/-).  
It has been well established that the TOP2 enzyme is Targeted by daunorubicin (Gewirtz, 1999). 
In support of this, the IC50 for daunorubicin in the Nalm6 wild type cell line was 7.77 nM which 
was significantly less than the IC50 in the Nalm6B-/- and Nalm6A+/- of 14.03 and 12.13 nM 
(p=0.0001 and p=0.0004) respectively. Similarly, there was a significant increase (p=0.0003) in 
the IC50 of idarubicin in the wild type cell line from 4.327 nM to 7.55 nM in Nalm6B-/- and to 
6.213 nM Nalm6A+/- (p=0.0247).  
In addition, it has been widely suggested that the cytotoxicity of TOP2 poisons is mainly TOP2α 
dependent (Azarova et al., 2007). However, this might not be confirmed in our results by direct 
comparison between the IC50s for two reasons: firstly, both Nalm6B-/- and Nalm6A+/- showed 
significant increase in IC50 over the wild type cells. Secondly, both Nalm6B-/- and Nalm6A+/- cell 
lines showed no significant difference in terms of the IC50 of idarubicin (p=0.0827) (Figure 3.5).      
In addition, Nalm6A-/- is not viable and the knockout in Nalm6A+/- cell line is heterozygous unlike 
Nalm6B-/- which are TOP2B-null cells and this makes it difficult to compare the role of both 
isoforms by direct comparison of IC50 values. Unlike idarubicin, however, the IC50 of 
daunorubicin in Nalm6B-/- was significantly lower than that of Nalm6A+/- (p=0.0040). Moreover, 
the IC50 of idarubicin was significantly less than that of daunorubicin in all cell lines (Figure 3.5). 
These results suggest that both TOP2 isoforms contribute to the cytotoxicity of TOP2 poisons 
































Cells were incubated with drugs for 48 hours continuously and the cytotoxicity was determined as the 
relative increase in cell count (RICC) using cell counting protocol. Data presented here is the mean of at 






P values (unpaired t test) 
 WT B-/- A+/- 
WT 7.77 0.292 WT    
B-/- 14.03 0.167 B-/- <0.0001   






P values (unpaired t test) 
 WT B-/- A+/- 
WT 4.327 0.11 WT    
B-/- 7.55 0.245 B-/- 0.0003   
A+/- 6.213 0.526 A+/- 0.0247 0.0827  
Figure 3-5 Both TOP2 isoforms comparably contribute to the cytotoxicity induced 
by daunorubicin and idarubicin 
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3.3.4 Cytotoxicity of Ara-C in Nalm6 cell lines  
The antimetabolite Ara-C is a nucleoside analogue that interferes with DNA synthesis processes 
and inhibits DNA polymerase (Hiddemann, 1991; Cros et al., 2004). The dose response curves of 
Nalm6 cell lines treated with Ara-C were determined and are presented in (Figure 3.6). The IC50 
of Ara-C in Nalm6 cell lines were 6.33, 7.617, and 6.573 nM for Nalm6WT, Nalm6B-/-, and 
Nalm6A+/- respectively. As expected from the mechanism of action of Ara-C, there was no 










Cells were incubated with Ara-C for 48 hours continuously and the cytotoxicity was determined as the 
relative increase in cell count (RICC) using cell counting protocol. Data presented here is the mean of at 
least three independent experiments with error bars representing the SEM. 
 
3.3.5 Cytotoxicity of Ara-C and daunorubicin in combination 
The relationship between drugs when combined with each other is either synergistic, antagonistic, 
or additive (Chou and Talalay, 1984; Mayer et al., 2006). The cytotoxicity profile for daunorubicin 
and idarubicin in Nalm6 cell lines suggests that both TOP2 isoforms contribute to the cytotoxicity 
of these drugs. For better understanding of the combination between daunorubicin and Ara-C, 
selected combinations were tested in the wild type cells. Daunorubicin was selected for two 
reasons; firstly, it is more commonly used in the treatment of AML than idarubicin, secondly, 
despite the cytotoxicity of idarubicin being higher than daunorubicin, both drugs generally have 
the same mechanism of action.  
  IC50 (nM) 
Cell line Mean SEM 
Nalm6WT 6.33 0.196 
Nalm6 B-/- 7.617 1.089 
Nalm6 A+/- 6.573 0.427 
P values (unpaired t test)  
 WT B-/- A+/- 
WT    
B-/- 0.2574   
A+/- 0.4356 0.7548  
Figure 3-6 Ara-C induces cytotoxicity in a TOP2-independent manner 
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Many studies have shown that the relationship between drugs in combination can be synergistic, 
antagonistic, or additive according to the ratio of the drugs when combined (Mayer et al., 2006). 
Based on the cytotoxicity profile of drugs as a single agent, three different combinations of Ara-C 
and daunorubicin were used to evaluate whether the relationship between Ara-C and daunorubicin 
is synergistic, antagonistic, or additive using the combination Index (CI) which was calculated as 
described in (Materials and methods, section 2.8). The first combination involved a range of Ara-
C and daunorubicin doses in a constant ratio (1:1) that covered the total cytotoxicity profile (Figure 
3.7). The combination index (CI) of each combination was determined and presented in (Figure 
3.7). In spite of the significant decrease in the IC50 of the combination (3.87 nM) when compared 
with Ara-C (6.703 nM) or daunorubicin (7.733 nM) alone, the combination index (CI) of all 
treatment points suggested that the inhibitory effect is additive (Figure 3.7). 
  
                                    
 
 
   
   
 





Cells were incubated with Ara-C, daunorubicin, or both for 48 hours continuously and the cytotoxicity was 
determined as the relative increase in cell count (RICC). Data presented here is the mean of at least three 
independent experiments with error bars representing the SEM. (CI) the combination Index. Note: CI < 0.9 






P values (unpaired t test) 
 Ara-C Daun Ara-C + Daun 
Ara-C 6.703 0.283 Ara-C    














2+2 1.04 ± 0.14 
4+4 1.10 ± 0.09 
5+5 1.06 ± 0.11 
6+6 1.28 ± 0.11 
8+8 1.08 ± 0.12 
10+10 1.02 ± 0.10 




The second combination involved a non-constant (Ara-C+daunorubicin) molar ratio. Cells were 
treated with a low cytotoxic dose (IC20) of daunorubicin (4 nM) combined with a range of Ara-C 
doses as described in (Figure 3.8). The IC50 of Ara-C was significantly reduced (p=0.0050) from 
6.713 nM to 3.973 nM when combined with daunorubicin. The combination index data for this 
combination showed that the relationship is synergistic at the highest Ara-C doses of 10 nM 
(CI=0.85 ± 0.05) and 14 nM (CI=0.89 ± 0.050) and this might be due to the enhanced effect of 
daunorubicin: Ara-C (1:3) molar ratio. Studies have shown the effect of molar ratio of drugs in 
combination regardless of the total dose (Tardi et al., 2009).  












Cells were incubated with Ara-C, daunorubicin, or the combinations for 48 hours continuously and the 
cytotoxicity was determined as the relative increase in cell count (RICC). Data presented here is the mean 
of at least three independent experiments with error bars representing the SEM. (CI) the combination Index. 
Note: CI <0.9 (synergistic), CI>1.1 (antagonistic), CI =0.9-1.1 (additive). 
 
The third combination involved non-constant Ara-C:daunorubicin molar ratios where cells were 
treated with a fixed low cytotoxic dose (IC20) of Ara-C (2 nM) in combination with different doses 
of daunorubicin that spanned the IC10 to IC80 of the cytotoxicity profile (Figure 3.9). There was 
no significant change (p=0.5518) in the IC50 of daunorubicin upon the addition of low cytotoxic 
dose of Ara-C and the combination index values indicated an additive to slightly antagonistic 
  IC50 (nM) 
Drug Mean SEM 
Ara-C 6.713 0.278 








2+4 1.2 ± 0.04 
4+4 1.1 ± 0.09 
5+4 1.18 ± 0.19 
6+4 1.16 ± 0.07 
8+4 1.26 ± 0.15 
10+4 0.85 ± 0.05 
14+4 0.89 ± 0.05 
Figure 3-8 Dose response curve of (Ara-C+daunorubicin) combination 
at non-constant ratio 
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relationship. The advantage of using the combination index (CI) in evaluating the relationship 
between drugs when combined is that it allows for a quantitative determination of synergy, 
antagonism, or additive relationships and provides a useful method to compare the efficiency of 
different combinations (Mayer et al., 2006). Moreover, it allows for determining whether the 
enhancement of the effect of one drug by the other is due to a real synergistic relationship or simply 
because of the additive effect of both drugs (Chou, 2010). 
 










Cells were incubated with Ara-C, daunorubicin, or the combination for 48 hours continuously and the 
cytotoxicity was determined as the relative increase in cell count (RICC). Data presented here is the mean 
of at least three independent experiments with error bars representing the SEM. (CI) the combination Index. 
Note: CI <0.9 (synergistic), CI>1.1 (antagonistic), CI =0.9-1.1 (additive). 
 
Although Ara-C and daunorubicin combination is well established in the treatment of acute 
myeloid leukaemia, the mechanism by which both of the Ara-C and daunorubicin contribute to the 
therapeutic effect of this common combination in the clinic is not fully understood. Some evidence 
has suggested that Ara-C potentiates the cytotoxicity of a number of TOP2 poisons in a scheduling-
dependent manner (Edelstein et al., 1974; Ritch et al., 1981; Minford et al., 1984; Fountzilas et al., 
1990; Chresta et al., 1992). These studies have shown that the cytotoxicity of TOP2 poisons was 
dramatically increased when the cells were pre-treated with Ara-C first and the potentiation was 
time-dependent. Therefore, the following step was to determine the effect of Ara-C pre-treatment 
  IC50 (nM) 
Drug Mean SEM 
Daun 7.54 0.231 
2nM Ara-C + 







2/2 1.04 ± 0.14 
2/4 1.20 ± 0.04 
2/6 1.25 ± 0.03 
2/8 1.19 ± 0.13 
2/10 1.05 ± 0.02 
2/12 1.20 ± 0.15 
Figure 3-9 Dose response curve of (Ara-C+daunorubicin) combination at 
a non-constant ratio 
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Figure 3-10 Comparison between growth inhibition effect of scheduled and 
concurrent (Ara-C+daunorubicin) combinations. 
on the cytotoxicity of daunorubicin and in comparison with the concurrent treatment of the 













Cells were incubated with either Ara-C and daunorubicin at the same time for 48 hours continuously (Ara-
C+Daun), or treated with Ara-C for 24 hrs then daunorubicin was added for further 24 hours (Ara-
C→Daun). The cytotoxicity was determined as the relative increase in cell count (RICC). Data presented 
here is the mean of at least three independent experiments with error bars representing the SEM, (*P≤0.05, 
**P≤0.01, ***P≤0.005, NS: No significance). RICC values are also presented in Appendix table 2.  
 
Generally, pretreatment of cells with Ara-C did not increase growth inhibition of combinations. At 
lower doses (2+2) and (4+4) nM, there was no significant difference between concurrent and 
scheduled treatment (P values: 0.6256 and 0.0808) respectively. At higher dose (8+8) nM, the 
difference was significant (P= 0.0247). On the other hand, statistical analysis showed that the p 
values for (10+4), (12+6), and (4+10) nM combinations were (0.1640, 0.2834, and 0.0017) 
respectively. These results were consistent with the above findings that the growth inhibition effect 
of Ara-C and daunorubicin in combination is additive in Nalm6 cell lines.  
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3.3.6 FACS analysis 
The flow cytometry in vitro micronucleus assay (Litron Laboratories) was used in this study. It is 
a high content assay that provides a high throughput quantitative measurement of different 
parameters involving the determination of relative survival (%), micronuclei formation (MN), and 
cell cycle analysis. This analysis was performed in all three Nalm6 cell lines treated with 
daunorubicin, idarubicin, or Ara-C as a single agents as well as in the Ara-C+daunorubicin 
combinations.  
3.3.6.1 Effect of drugs on relative survival of Nalm6 cell lines measured by FACS  
Relative survival of the Nalm6 cell lines was determined during the micronuclei assay procedure 
by the addition of microsphere beads that could be stained with a nucleic acid dye (CYTOX green). 
These beads can be scored and counted in the flow cytometer. The ratio of healthy nuclei (which 
are negatively stained with EMA) per bead can be determined. Nuclei-to-bead ratio for the control 
and the treated samples can be used to determine the relative survival. Therefore, the relative 
number of healthy cells can be efficiently determined by this method which might be 
underestimated by other counting methods such as coulter counts. In addition, it is more rapid and 
allows for counting of a large number of cells (around 30000 nuclei per sample). Determining the 
cytotoxicity levels in the micronuclei assay is important because samples that show high levels of 
cytotoxicity are more likely to show false positive micronuclei results as a result of chromosomal 
damage as a secondary consequence of cytotoxicity (OECD, 2010) and this must be considered 
during the analysis of the results. 
The relative increase in cell count (RICC) was determined for controls and treated samples at the 
time of harvesting to compare the outcome of both relative survival (%) measured by FACS and 
the RICC results. This was also advantageous to confirm the appropriate levels of cytotoxicity in 
the cell lines. The RICC was determined for all samples that underwent FACS analysis. A 
comparison between the relative survival measured by FACS and the RICC is shown in (Figure 
3.11). Generally, both methods showed a clear similarity in the determination of cytotoxicity of 
agents with slightly elevated values of relative survival over the RICC which might be due the 
differences between methods, but statistical analysis showed that the majority of samples showed 



















Cells were incubated with agents for 48 hours continuously and the cytotoxicity was determined by two methods; the relative increase in cell count (RICC) 
using cell counting protocol and the relative survival using flow cytometer. Data presented here is the mean of at least three independent experiments with 
error bars representing the SEM. Relative survival was determined as described in section 2.8 of materials and methods. RICC and relative survival values 
are also presented in Appendix table 3.  
Figure 3-11 Comparison between relative survival measured with FACS and RICC. 
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3.3.6.2 Micronuclei (MN) and apoptosis induction by TOP2 poisons and Ara-C 
Determining the genotoxicity of many drugs and especially TOP2 poisons is an important issue in 
the development of an effective anti-cancer treatment (Cowell and Austin, 2012). Therefore, it is 
important to use a sensitive method that can efficiently determine the level of genotoxicity (Pfuhler 
et al., 2011). There are different methods to determine the genotoxicity of agents and there is a 
growing tendency to use micronuclei as a parameter for genotoxicity for several reasons; firstly, 
micronuclei scoring provides an indicator for both structural and numerical chromosomal 
aberrations (OECD, 2010). Secondly, this assay can be automated using immunofluorescence 
staining and a large number of micronuclei can be detected with a flow cytometer (Bryce et al., 
2007).  
In our procedure, several criteria for micronuclei scoring by flow cytometer were followed to insure 
minimum false positive results. Firstly, very high cytotoxic doses were avoided as this might result 
in increased false positive MN counting. Secondly, precautions were taken into account that the 
MN events must exhibit 1/100th to 1/10th of the CYTOX Green fluorescent intensity of 2n nuclei. 
Thirdly, events of MN must fall within both forward and side light scatter against CYTOX Green 
area. Fourthly, the micronuclei events must be EMA-negative. 
Samples that showed two-fold micronuclei increase over control was considered to be positive for 
genotoxicity. The results of micronuclei formation suggested that both daunorubicin and idarubicin 
induce micronuclei formation in a dose-dependent manner and the genotoxicity is linked to the 




















The figure shows the relative survival against micronuclei (MN) fold increase over control for Nalm6 cell lines exposed to daunorubicin, idarubicin, and 
Ara-C. Cells were incubated with agents for 48 hours continuously. Data represents the mean of at least three independent experiments with error bars 
representing the SEM. Micronuclei (MN) fold increase was determined as described in section 2.8 of materials and methods. Average Micronuclei (%) is 
presented in Appendix figure 1. Micronuclei (%) and fold change values are also presented in Appendix table 4. 




Figure 3-13 Comparison of MN induction by comparable cytotoxic doses 
of Drugs in Nalm6 cell lines. 
The results from (Figure 3.12) suggested that both TOP2 isoforms are contributing to the 
genotoxicity induced by treatment with daunorubicin or idarubicin because the genotoxicity was 
induced at comparable levels in all Nalm6 cell lines. This might be clearer by presenting the 
genotoxicity level at a comparable cytotoxic level in Nalm6 cell lines as in (Figure 3.13 A). 
Interestingly, Ara-C was less genotoxic than daunorubicin or idarubicin at the same cytotoxicity 















This figure is derived from figure 3.12. This figure shows comparison of micronuclei induction by 
comparable cytotoxic doses of drugs in Nalm6 cell lines for 48 hrs (A) Comparison of Micronuclei induction 
in Nalm6 lines. For daunorubicin, doses were 8.5 nM (Nalm6WT), 12 nM (Nalm6B-/-), and 12 nM (Nalm6A+/-
). For idarubicin, doses were 4 nM (Nalm6WT), 7 nM (Nalm6B-/-), and 6 nM (Nalm6A+/-). (B) Comparison of 
Micronuclei induction in Nalm6WT by 6 nM (Ara-C), 8.5 nM (daunorubicin), and 4 nM (idarubicin). Data 




Figure 3-14 Apoptotic cells fold increase over control induced by TOP2 
poisons and Ara-C in Nalm6 cell lines 
In addition, Apoptotic cells fold increase over control was also determined by FACS and it is 
presented in (Figure 3.14). Results showed dose-dependent induction of apoptotic cells by all drugs 





















This figure shows Apoptotic cells fold increase over control in Nalm6 cell lines exposed to daunorubicin, 
idarubicin, and Ara-C. Cells were incubated with agents for 48 hours continuously. Data represents the 
mean of at least three independent experiments with error bars representing the SEM. Apoptotic cells fold 
increase was determined as described in section 2.8 of materials and methods. Values of average apoptotic 
cells (%) and apoptotic cells fold increase are also presented in Appendix Table 5.   
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3.3.6.3 Micronuclei (MN) and apoptosis induction by daunorubicin and Ara-C combinations 
In order to determine the effect of the treatment with Ara-C and daunorubicin in combination on 
genotoxicity, FACS analysis was conducted to compare micronuclei induction between different 
combinations and their respective single agents. Four different (Ara-C+daunorubicin) 
combinations were selected to achieve moderate cytotoxicity hence avoiding overestimation of 
micronuclei due to false positive as mentioned previously. Cytotoxicity and MN of these 
combinations are presented in (Figure 3.15). Each combination was then compared with its 
respective single agents of comparable level of cytotoxicity as presented in (Figure 3.16).   













Nalm6 wild type cells were incubated with combinations for 48 hours continuously and the cytotoxicity was 
determined as the relative survival (%) using a flow cytometer. Data represents the mean of at least three 
independent experiments with error bars representing the SEM. The average micronuclei (%) and RICC are 
depicted in Appendix figures 2 and 3 respectively. All data values for RICC, relative survival, Average (%) 
micronuclei, MN fold increase, Average apoptotic (%) cells, and apoptotic cells fold change are presented 
in Appendix table 6. 
 
 
Figure 3-15 Micronuclei (MN) induction by selected (Ara-C+daunorubicin) 
concurrent combinations in Nalm6WT cell line. 
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Comparable level of cytotoxicity in (Figure 3.16) was confirmed by showing no statistical 
difference between each combination and the chosen doses of its members. This comparison again 
confirm the interesting observation that Ara-C on its own achieved less genotoxicity compared 



















Nalm6 wild type cells were incubated with drugs for 48 hours continuously and the cytotoxicity was 
determined using flow cytometer and presented as relative survival (%). Data represents the mean of at least 
three independent experiments with error bars representing the SEM. (*P ≤ 0.05). 
 
 
Figure 3-16 Comparison of MN induction between single agents and 
comparable cytotoxic doses of combinations.  
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Overall, results revealed that the Ara-C on its own induced significantly less micronuclei than 
daunorubicin at the same level of growth inhibition. For example, the micronuclei formation 
induced by 7 nM of Ara-C was significantly less than that induced by 6 nM daunorubicin 
(p=0.0109). Moreover, the genotoxicity of the combinations generally followed daunorubicin ratio 
within each combination, as there was no significant difference in micronuclei level between 
combinations and their comparable cytotoxic dose of single daunorubicin. For example, there was 
no statistical difference between micronuclei induction by 6 nM daunorubicin and by (4+4 nM) 
Ara-C+daunorubicin combination (p=0.2517) (Figure 3.16).   
In addition, micronuclei induced by Ara-C showed no significant difference with that induced by 
combinations that involved low and mild daunorubicin doses; 2 and 4 nM (p=0.3055 and p=0.0522 
respectively), while the difference was significant (p=0.0422) when compared with combinations 
involved higher daunorubicin dose (7 nM) although the Ara-C dose was low (2 nM) (Figure 3.16).  
Apoptotic cells fold increase over control for the combination was also determined by FACS and 
it is presented in (Figure 3.17). (2+7) nM Ara-C+daunorubicin combination showed about 4 fold 














Figure 3-17 Apoptotic cells fold increase over control induced by selected 











Nalm6 wild type cells were incubated with different combinations for 48 hours and the number of apoptotic 
cells were determined by flow cytometry. Data represents the mean of at least three independent experiments 
with error bars representing the SEM. All data values for RICC, relative survival, Average (%) micronuclei, 
MN fold increase, Average apoptotic (%) cells, and apoptotic cells fold change are presented in Appendix 
table 6. 
 
On the other hand, this study also involved the effect of Ara-C pre-treatment on the outcome of 
Ara-C+daunorubicin combination in terms of micronuclei (MN) induction as a parameter of 
genotoxicity. As mentioned above, the doses for micronuclei assay by FACS should not produce 
more than 50% growth inhibition, as this could give false positives. The (4+4 nM) combination 
was chosen to assess the effect of scheduling of combination on MN induction. Results showed 
that when cells were treated with Ara-C first, the MN induction was significantly less than that in 







Figure 3-18 Micronuclei (MN) induction by different (Ara-C+daunorubicin) 













Nalm6WT cell were divided into three groups: (Ara-C+Daun) was incubated with concurrent (Ara-
C+daunorubicin) combination for 48 hrs, (Daun→Ara-C) was incubated with daunorubicin for 48 hrs and 
Ara-C was added over the last 24 hrs, (Ara-C→Daun) was incubated with Ara-C for 48 hrs and 
daunorubicin was added over the last 24 hrs. The cytotoxicity was determined as relative survival (%) using 
flow cytometer. Data represents the mean of at least three independent experiments with error bars 
representing the SEM. The average micronuclei (%) and RICC are depicted in Appendix figures 4 and 5 
respectively. All data values for RICC, relative survival, Average (%) micronuclei, MN fold increase, 
Average apoptotic (%) cells, and apoptotic cells fold change are presented in Appendix Table 7. (*P ≤ 0.05). 
 
Apoptotic cells fold increase over control for the combination was also determined by FACS and 
it is presented in (Figure 3.19). Cells exposed to Ara-C first (Ara-C→Daun) showed significantly 
less apoptotic cells induction than both simultaneous (Ara-C+Daun) and scheduled (Daun→Ara-
C) combinations although all these combinations showed comparable growth inhibition level as in 







Figure 3-19 Comparison of apoptotic cells fold increase induced by selected 














Nalm6WT cells were treated with different combinations as explained in (Figure 3.18) and the number of 
apoptotic cells were determined using flow cytometry. Data represents the mean of at least three independent 
experiments with error bars representing the SEM. All data values for RICC, relative survival, Average (%) 
micronuclei, MN fold increase, Average apoptotic (%) cells, and apoptotic cells fold change are presented 
in Appendix table 7. (*P ≤ 0.05, **P ≤ 0.01). 
 
3.3.6.4 Effect of treatments on Cell cycle phase distribution 
Cell cycle analysis for controls and treated samples was performed along with the micronuclei 
assay by FACS. Nucleic acid dye (CYTOX Green) fluorescence can be determined by flow 
cytometer and provide a histogram of DNA content of analysed samples. These histograms were 
analysed by (Flowjo software (v7.6), FlowJo, LLC, USA) to quantitatively determine the relative 
cell population in each cell cycle phase. The advantage of using this software is that it allows for 
quantitative comparisons and performs statistical analysis between samples which is not be 
possible by direct visual comparisons of DNA content histograms. Effect of single drug treatment 
in all cell lines are depicted in (Figure 3.20). 




















Figure shows the relative cell cycle population (%) in Nalm6 cell lines incubated with TOP2 poisons. Data 
was collected from FACS and analysed with (Flowjo 7.6) software and bar graphs were drawn by (Prism 4) 
software. Data represents the mean of at least three independent experiments with error bars representing 
the SEM. All data values are presented in Appendix table 8. 
 
Both daunorubicin and idarubicin caused a decrease in the S phase cell population and G1 phase 
arrest in a dose dependent manner in all Nalm6 cell lines (Figure 3.20). For instance, in the wild 
type cells the relative S phase cell population (%) was significantly reduced from (47.49±1.41) % 
for the control to (32.58±2.99) % and (25.08±3.47) % for samples treated with 8.5 and 12 nM 
daunorubicin respectively. On the other hand, the relative G1 phase cell population (%) was 
significantly increased from (35.70±1.68) (%) for the control to (46.46±1.99) % and (50.61±1.49) 
% for samples treated with 8.5 and 12 nM daunorubicin respectively (Figure 3.20). Likewise, 
Figure 3-20 Relative cell cycle phase distribution in Nalm6 cell lines treated 
with daunorubicin, idarubicin, and Ara-C 
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Nalm6WT cells treated with idarubicin followed the same pattern and showed elevated G1 and G2 
phase populations with decreased levels in the S phase populations. Furthermore, both Nalm6B-/- 
and Nalm6A+/- cell lines showed similar patterns of cell cycle phase distribution upon treatment 
with daunorubicin and idarubicin (Figure 3.20).    
Conversely, Nalm6WT cell line treated with Ara-C showed slight increase in the S phase population 
(%) and slight decrease in G1 phase population at the high doses (Figure 3.21). For example, 
relative S phase population (%) showed significant increase (p=0.0184) from (45.14±1.67) % for 
control to (52.27±0.8) % for cells treated with 10 nM. At this dose, there was a significant decrease 
(p=0.0417) in G1 phase population from (37.31±2.16) % to (30.29±0.96) %. These findings agreed 
with a previous data in which CCRF-CEM cell line treated with Ara-C showed an increase in S 
phase population (Chresta et al., 1992). In addition, similar effects of Ara-C on the cell cycle phase 
distribution in K562 cell lines has been shown (Loughlin et al., 1996). Furthermore, flow cytometry 
analysis of patients samples have shown S phase cell cycle arrest upon treatment with Ara-C 
(Caldwell et al., 2014).  
These results suggest that efficiency of (Ara-C + daunorubicin) combination is due to the combined 
effect of both drugs where Ara-C induce S phase cell accumulation which is more prone to be 
targeted by TOP2 poisons which target S phase cells more than other phases as (Figure 3.20) 
suggested. No major change was observed in the G2 phase population in all treatments. 
Overall, cell cycle analysis results showed three major trends: first, both daunorubicin and 
idarubicin target S phase population and hence induced G1 cells accumulation. Second, in contrast 
to TOP2 poisons, Ara-C induced accumulation of S phase population and reduced G1 phase 
population. Third, dose effect of Ara-C was very similar in all cell lines suggesting completely 
TOP2-independent mechanism and it is presented in (Figure 3.21) which is derived from (Figure 
3.20) to show a cell line based comparison. This figure also shows the cell cycle patterns behind 




























This figure is derived from (Figure 3.20) to highlight differences between Nalm6 cell lines in terms of effect 
of drugs on S and G1 population (%). Data represents the mean of at least three independent experiments 
with error bars representing the SEM. All data values are presented in Appendix table 8. (NS= no 
significance, *P ≤ 0.05, **P ≤ 0.01, ****P ≤ 0.0001). 
 
Figure 3-21 Comparison of effect of drugs on S and G1 phase cell population in 
Nalm6 cell lines. 
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For (Ara-C+daunorubicin) combinations, cell cycle analysis showed no significant difference in 
cell cycle phase distribution between control cells and all combinations with the exception of (2+7) 
Ara-C+daunorubicin combination which showed significant reduction (p=0.0009) and elevation 
(p=0.0404) in the S and G1 phase populations respectively (Figure 3.22). In addition, no significant 
change was observed between combinations with the exception of the (2+7) Ara-C+daunorubicin 
combination which showed significant difference with all other combinations in terms of relative 
G1 and S phase cell populations. On the other hand, no significant change in G2 phase cell 
population was observed between combinations. 
 
   
 
 







This figure shows the relative cell cycle population (%) in Nalm6WT incubated with different Ara-
C+daunorubicin combinations. Data was collected from FACS and analysed with (Flowjo 7.6 software) and 
bar graphs were drawn by (Prism 4) software. Data represents the mean of at least three independent 
experiments with error bars representing the SEM. Stars (*P ≤ 0.05, **P ≤ 0.01) represent p values of 
difference between (2 nM Ara-C+ 7 nM Daun) combination and other combinations. Neither significant 
difference was seen in combinations other than (2 nM Ara-C+ 7 nM Daun) nor in G2/M population between 
all combinations. All data values are presented in Appendix table 9. 
 
The cell cycle phase distribution (%) for Nalm6WT exposed to three different scheduled treatments 
is presented in (Figure 3.23). Results showed similar cell cycle distribution between (Ara-
C→Daun) and (Ara-C+Daun) combinations. This is consistent with the comparable growth 
inhibition level of these two combinations shown in (Figure 3.18). Notably, (Daun→Ara-C) 
Figure 3-22 Relative cell cycle phase distribution in Nalm6WT cells treated 
with different (Ara-C+daunorubicin) concurrent combinations. 
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Figure 3-23 Relative cell cycle phase distribution in Nalm6WT cells treated 
with scheduled (Ara-C+daunorubicin) combinations. 
combination showed significant difference with the other two combinations in terms of G1 and 












Nalm6WT cells were treated with different combinations as explained in (Figure 3.18). This figure shows the 
relative cell cycle population (%) in Nalm6WT incubated with different Ara-C+daunorubicin combinations. 
Data was collected from FACS and analysed with (Flowjo 7.6 software) and bar graphs were drawn by 
(Prism 4) software.  Data represents the mean of at least three independent experiments with error bars 
representing the SEM. All data values are presented in Appendix table 10. 
 
3.4 Discussion  
This chapter involved studying TOP2 as a target for two anti-tumour drugs daunorubicin and 
idarubicin as well as testing efficiency of daunorubicin combined with Ara-C in different ratios 
and treatment orders. Contribution of TOP2 isoforms in the cytotoxicity of daunorubicin and 
idarubicin was determined using two genetic derivatives of Nalm6 cell line with isoform specific 
deletion of either both TOP2B alleles (Nalm6B-/-) or one TOP2A allele (Nalm6A+/-). Ideally, 
comparison of the precise contribution of both isoforms would be by deleting the same number of 
alleles of both isoforms. However, cells cannot survive with deletion of both TOP2A alleles while 
they survive and grow in culture without TOP2β. Growth inhibition curves of daunorubicin and 
idarubicin in the wild type and genetically modified Nalm6 lines showed that both TOP2α and 
TOP2β contribute in the cytotoxicity of both drugs. This agreed with previous studies showed that 
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both isoforms are targeted by TOP2 poisons in murine (Errington et al., 1999) and human (Toyoda 
et al., 2008; Lee et al., 2016) cells. On the other hand, as expected, no isoform-specific contribution 
of TOP2 was seen in the effect of Ara-C alone.  
Overall, both daunorubicin and idarubicin showed the same pattern with idarubicin being more 
cytotoxic. Daunorubicin is widely used in combination with Ara-C as a standard treatment for 
leukaemia. For this reason, daunorubicin was chosen in the rest of experiments to test the efficiency 
of using different combination ratio or treatment order. It has been shown that the effect of Ara-
C:daunorubicin ratio in the efficiency of this combination (Tardi et al., 2009). Different Ara-
C:daunorubicin ratios were tested and the efficiency of combinations was evaluated for synergistic, 
additive, or antagonistic relationships using combination Index (CI), a parameter which was 
calculated as described in (Materials and methods, section 2.8). Generally, all combination ratios 
used showed additive relationships, while the combinations in which daunorubicin was about one-
third of the Ara-C molarity (Figure 3.8), the effect was synergistic. This agreed with studies that 
showed synergistic effects in combinations involved more Ara-C than daunorubicin (Mayer et al., 
2006; Tardi et al., 2009). 
The genotoxicity of drugs in this study as single agents and in combination was also determined. 
Drug-induced genotoxicity is an important issue in cancer treatment (Cowell and Austin, 2012). In 
this study, the genotoxicity of drugs was measured by micronuclei (MN) assay by FACS for two 
reasons. First, it is easy to conduct and requires less technical experience in comparison with 
conventional chromosomal aberration analyses which is labour intensive and requires relatively 
high experience. Second, this assay can be automated using immunofluorescence staining and a 
large number of micronuclei can be detected with a flow cytometer (Bryce et al., 2007). 
Furthermore, micronuclei assays by FACS are sensitive to both numerical and structural 
abnormalities (OECD, 2010). 
Doses with high cytotoxicity were avoided during (MN) assay to avoid false positives that arise 
from chromosomal damage due to cytotoxicity as recommended by (OECD, 2010). For comparison 
between drugs as single agents, results showed that both TOP2 isoforms contribute in the 
genotoxicity of daunorubicin and idarubicin while no isoform specific effect was seen with Ara-C 
as single agent. Interestingly, genotoxicity induced by Ara-C was significantly less than that 
induced by daunorubicin at the same level of cytotoxicity (Figure 3.13). The same observation was 
seen with idarubicin but the difference did not reach significance. This would have an important 
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impact on modulation of this combination in clinical use to reduce genotoxicity of combinations 
by increasing Ara-C/daunorubicin ratio.                      
Consistent with the above genotoxicity profile of single agents, concurrent drug combinations 
showed that genotoxicity generally followed the daunorubicin ratio within the combination (Figure 
3.15) and comparisons between comparable cytotoxic levels for MN induction again showed that 
Ara-C clearly induced less genotoxicity than TOP2 poisons at the same growth inhibition levels 
(Figure 3.16). 
Furthermore, the effect of order of drug treatment on outcome of the combination was evaluated 
for both cytotoxicity and genotoxicity. Results showed that treatment with Ara-C first did not have 
an effect on the overall growth inhibition of combination (Figure 3.18). However, Ara-C pre-
treatment significantly reduced genotoxicity as compared with simultaneous treatment of both Ara-
C and daunorubicin in combination (Figure 3.18). Overall, our results suggest that genotoxicity of 
this common drug combination can be reduced by modulating Ara-C ratio within the combination 
and/or treatment with Ara-C first. 
The effect of drug treatment as single agents or in combination on cell cycle distribution was also 
analysed using FACS. Cell cycle histograms were generated by determining DNA content of 
analysed samples using nuclei acid dye (CYTOX Green) fluorescence which was captured by flow 
cytometry. These histograms were analysed using (Flowjo software (v7.6), FlowJo, LLC, USA) to 
quantitatively determine the relative cell population in each cell cycle phase. The advantage of 
using this software is that it allows for quantitative comparisons and performs statistical analysis 
between samples which is not be possible by direct visual comparisons of DNA content histograms.             
Generally, both daunorubicin and idarubicin treatment reduced the S phase population and 
increased G1 population in a dose-dependent manner and this effect was seen in all Nalm6 cell 
lines suggesting a non TOP2 isoform-dependent mechanism (Figure 3.20). Conversely, Ara-C 
treatment caused a reduction in G1 and an increase in S phase population in all cell lines (Figure 
3.20). Accumulation of S phase upon Ara-C treatment was reported in the literature in an in vitro 
studies using CCRF-CEM and K562 cell lines (Chresta et al., 1992; Loughlin et al., 1996) as well 
as in an acute myeloid leukaemia patient samples (Caldwell et al., 2014).     
The cell cycle distribution in response to drugs was compared between cell lines in (Figure 3.21). 
This figure was derived from (Figure 3.20) to show a direct comparison between cell lines. The 
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cell-cycle distribution difference between cell lines in (Figure 3.21) reflects the dose-response 
difference between cell lines in (Figure 3.11).      
Cell cycle analysis of concurrent combinations (Figure 3.22) showed that the combination with the 
high daunorubicin ratio (2nM Ara-C+ 7nM Daun) caused a significant reduction in the S phase 
population which was consistent with the previous results seen in (Figure 3.20) suggesting that 
daunorubicin mainly targets S phase population which require TOP2 activity to resolve topological 
problems accompanied by DNA synthesis that peaked at this phase. 
The cell cycle phase distribution analysis of different treatment orders (Figure 3.23) showed similar 
cell cycle distribution between (Ara-C→Daun) and (Ara-C+Daun) combinations. This is consistent 
with the comparable growth inhibition level of these two combinations shown in (Figure 3.18). 
These results showed a consistent relationship between cytotoxicity, genotoxicity, and cell cycle 
distribution which collectively represent a useful strategy to study the mechanism of action, cell 
cycle related activity, and genotoxicity of anti-tumour agents. 
Overall, these results led to the following conclusions: firstly, the cytotoxicity and genotoxicity 
induced by anti-tumour drugs can be rapidly and efficiently measured using in vitro micronucleus 
(MN) test automated with FACS, suggesting use of this method for rapid investigation of a wide 
range of drugs for differential targeting of TOP2 isoforms. Secondly, both TOP2 isoforms 
comparably contribute to the cytotoxicity and genotoxicity of daunorubicin and idarubicin in 
Nalm6 cell line and more drugs need to be investigated using this method. Thirdly, Ara-C is 
significantly less genotoxic than daunorubicin at the same level of cytotoxicity, suggesting that 
increasing the Ara-C ratio within the (daunorubicin+Ara-C) combination would enhance the 
therapeutic outcome of this combination in the treatment of leukaemia patients. Fourth, scheduled 
treatment of (daunorubicin+Ara-C) combination where Ara-C is administered first might be less 
genotoxic than simultaneous treatment (Figure 3.18). However, further experiments need to be 








4 Chapter Four: TOP2 role in whole genome transcription of Nalm6 cell. 
4.1 Introduction 
Human type II topoisomerases are divided into two isoforms; TOP2α and TOP2β. These isoforms 
are encoded by separate genes located on 17q21-22 and 3p34 for TOP2A and TOP2B respectively 
(Chung et al., 1989; Austin and Fisher, 1990; Jenkins et al., 1992; Tan et al., 1992). Although both 
enzymes have very similar structure (Drake et al., 1989; Austin et al., 1993a; Austin et al., 1995), 
and catalytic properties in vitro (Austin et al., 1995), their physiological function and expression 
pattern are different (Wang, 1996; Nitiss, 1998; Wang, 2002; Austin et al., 2018). TOP2α is mainly 
expressed in proliferating cells and its level peaked at G2/M phase whereas TOP2β is expressed in 
proliferating and non-proliferating cells (Giovanni Capranico and Zunino, 1992; Watanabe et al., 
1994; Zandvliet et al., 1996; Turley et al., 1997; Austin and Marsh, 1998) and in terminally 
differentiated cells like neurons and cardiomyocytes (Tsutsui et al., 1993; Zhang et al., 2012).  
TOP2α is essential and cannot be substituted by TOP2β for proliferation-related processes (Grue 
et al., 1998) while TOP2β cellular function is less clear. TOP2β is not essential for cell growth and 
TOP2B null cells grow in culture normally (Dereuddre et al., 1997; Errington et al., 1999; Tiwari 
et al., 2012). For the past two decades, evidence has been accumulating about the role of TOP2B 
in the transcription and regulation of a number of genes especially neuronal genes. 
In one study on murine tissues, the two isoforms were expressed differentially with TOP2α 
expressed predominantly in proliferating tissues while TOP2β is expressed in a wider range of 
tissues (Giovanni Capranico and Zunino, 1992). In this study, both enzymes were expressed at high 
levels during the early but not the late stage of embryogenesis. However, one day after birth there 
was an interesting shifting in the pattern of expression of both enzymes in the brain and liver 
tissues. There was a remarkable increase in TOP2β expression in the brain but not in liver. 
Conversely, there was an increase in TOP2α in the liver but not in the brain indicating that the 
regulation of both genes is a tissue specific and developmental stage-dependent (Giovanni 
Capranico and Zunino, 1992). 
Later on, the distribution of expression of both enzymes was studied in different developmental 
stages of rat brain. TOP2α expression was mainly expressed in the growing regions while TOP2β 
expression at the early developmental stages was higher than that at the mature stages in different 
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brain regions indicating that TOP2β is involved in the differentiation and maturation of neurons 
(Watanabe et al., 1994). 
Closely related findings were determined in a study on human foetal tissues. Generally, the 
intensity of expression of TOP2α was higher than that of TOP2β and especially elevated in the 
proliferation regions despite that the latter being expressed in a wider range of tissues which is 
further evidence that both enzymes are differentially regulated in human tissues (Zandvliet et al., 
1996). Similarly, this pattern of TOP2α and TOP2β expression was determined in another study 
on human adult tissues (Turley et al., 1997). Recently, analysis of human foetal brain tissues 
showed that TOP2α is expressed in the proliferating layers while TOP2β is expressed in both 
proliferating and non-proliferating sections (Harkin et al., 2016). 
The role of Top2β in neural development in mice was confirmed by (Yang, 2000). This study 
showed that TOP2β has a crucial role in neural development. In TOP2B mutant mice, despite 
normal neurogenesis, the motor axons failed to connect to the skeletal muscle and the sensory 
axons did not innervate the spinal cord. The failing of motor axon to grow properly led to breathing 
defects and postnatal death (Yang, 2000). This phenotype was investigated by (Nur et al., 2007) 
who suggested that the defect in the formation of neuromuscular junction in the Top2b mutant mice 
was due to blocking the neurite outgrowth in the absence of TOP2β. In this study, neurons isolated 
from Top2b mutant mice formed shorter neurites than those isolated from wild type mice. In 
addition, the TOP2 inhibitor ICRF-193 blocked the neurite outgrowth in cultured neurons. 
Furthermore, neurons from TOP2B mutant mice did not form junctions with muscle cells in co-
culture (Nur et al., 2007). 
Consistent with (Yang, 2000), the role of TOP2β in neuronal differentiation was determined in a 
study on rat cerebellum. It showed a remarkable transition from TOP2α to TOP2β expression signal 
when cells reached their final stage of division and started to differentiate into granule or Purkinje 
cells, then the TOP2β level reduced sharply at the final differentiation stage (Tsutsui et al., 2001a; 
Tsutsui et al., 2001b).  
The effect of TOP2β on corticogenesis in various tissues was further studied in mouse embryos. 
Again the Top2b mutant embryos showed an aberrant lamination in the cerebral cortex 
characterized by a defect in cerebral stratification, in addition, the neurons at late stages of 
corticogenesis did not migrate to the superficial layers indicating a role for TOP2β in neuronal 
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development (Lyu and Wang, 2003). In addition, this study suggested that TOP2β might be 
important not only for regulation of neuronal development genes but also for genes of other post 
mitotic cells. 
Another study has revealed that the activity of TOP2β is especially involved in the regulation of 
expression of genes which are in the late stage of development (Lyu et al., 2006). This study 
analysed the transcription profile of brains of wild type and Top2b null mouse embryos. 
Interestingly, in Top2b null mice, only (1-4 %) of genes were affected and all other genes 
responsible for general cellular function and early differentiation markers were not. However, the 
expression of about one-third of developmentally-regulated genes at late stage of differentiation 
were changed (down-regulation for most of them) in the Top2b null mouse embryos in comparison 
with the wild type group.  
Furthermore, immunohistochemical staining of brain sections showed that TOP2β expression was 
induced at the late differentiation stage of neurons. In addition, chromatin immunoprecipitation 
(ChIP) analysis showed that TOP2β bound 5′ regions of a number of genes which were affected by 
the absence of TOP2β but not those which were TOP2β -insensitive, and the binding was especially 
near the promoter region (kb -0.5 to +2.5) as the study of one of those genes (Kcnd2) showed (Lyu 
et al., 2006). In support of this, other studies have demonstrated that TOP2β is involved in the 
activation of a number of genes related to the maturation of neurons (Sano et al., 2009; King et al., 
2013). 
Because of the perinatal death phenotype in the above murine models, the effect of TOP2B deletion 
was confirmed using a non-fatal mutation model. This was studied by (Li et al., 2014) using a 
mouse model with a retinal progenitor specific-Top2b deletion mutation. Top2b deletion led to 
defects in retina development characterized by; remarkable decrease in cell number, degenerative 
plexiform layers and outer part of photoreceptors, and delay in neuronal differentiation. In addition, 
RNA-seq analysis showed that genes which involve in neuronal survival and maintenance were 
affected in the TOP2B-truncated retinas. Later on, the same lab group revealed Top2b role in 
differentiation and maturation of mouse photoreceptor through regulation of expression of a 
network of key genes in photoreceptor function (Li et al., 2017). Similarly, Top2b was shown to 
be one of the genes whose mutation disrupted the visual system in zebrafish as determined by both 
genetic screening along with immunohistochemical labelling (Nevin et al., 2011)     
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Studies have demonstrated that TOP2β interacts with several proteins involved in transcription-
regulation processes such as P53 (Cowell et al., 2000), HDAC1 and HDAC2 (Tsai et al., 2000; 
Johnson et al., 2001), SNF2H (LeRoy et al., 2000), UBC9 (Mao et al., 2000), CD3ε (Nakano et 
al., 1996). Histone deacetylase inhibition by agents like trichostatin A (TSA) caused a shift in 
TOP2β from heterochromatin to euchromatin regions in murine cells (Cowell et al., 2011). In 
addition, interaction between topoisomerase II beta (TOP2β) and nucleophosmin (NPM) in APL 
cells has been reported (Nichol et al., 2016). 
The role of TOP2β in transcriptional regulation has been shown in Michigan Cancer Foundation 
(MCF)-7 cell line. This study suggested that activation of gene transcription mediated by nuclear 
receptors and DNA-binding transcription factors requires site-specific, intermediate double-
stranded DNA break (dsDNA) mediated by TOP2β (Ju et al., 2006). 
Studies have shown the recruitment of TOP2β to the 5′ region of a number of genes as a result of 
signalling pathways induced by nuclear hormones such as androgen (Haffner et al., 2010), estradiol 
(Ju et al., 2006), retinoic acid (McNamara et al., 2008). These studies involved a double stranded 
DNA break induced by TOP2β. In addition, it has been shown that TOP2β is involved in the 
expression of fatty acid synthase in liver cells in response to insulin (Wong et al., 2009). 
It has been confirmed that TOP2β associates with the Retinoic Acid Receptor α (RARα) and 
negatively modulates its transcriptional activity in acute Promyelocytic Leukaemia (APL) cell lines 
leading to Retinoic Acid (RA) resistance. TOP2B knockdown in RA-resistant clones released a 
transcription block and allowed RA-induced differentiation. TOP2B overexpression in RA-
sensitive clones was able to induce RA resistance by reducing expression of RA target genes. In 
addition, Chromatin Immunoprecipitation (ChIP) analysis showed that TOP2β is specifically 
bound to the Retinoic Acid Response Element (RARE) region of the promoter of RARβ gene which 
is one of the RA target genes (McNamara et al., 2008). 
It has been shown a shifting from Top2a to Top2b upon differentiation of murine embryonic stem 
cells (ESCs) into neuronal cells (Tiwari et al., 2012). Genome-scale location analysis of these 
neurons revealed interaction of Top2b at H3K4me sites indicating a regulatory role of Top2b and 
these sites were enriched preferentially at promoter regions. Top2b deletion followed by neuronal 
differentiation of (ESCs) did not affect the early differentiation steps, while caused losing of 
97 
 
survival of postmitotic neurons, an observation accompanied with the up regulation of ngfr p75 
which is bound and down regulated by Top2b (Tiwari et al., 2012).         
Furthermore, it has been shown by ChIP-qPCR that, as a response to neuronal activity, Top2b 
mediates a double stranded DNA break in the promoter of a number of early response genes such 
as Fos, Egr1, and Npas4 necessary for their expression leading to changes related to memory and 
learning (Madabhushi et al., 2015a). Further studies added more information about TOP2β binding 
sites over the genome as well as interaction with other transcription factors. TOP2β occupancy 
testing in MCF-7 cell line using ChIP-seq showed that approximately half of TOP2β binding sites 
locate within genes or about 5 kb long from a transcription start sites (Manville et al., 2015). 
Moreover, transcription factor motif enrichment analysis of TOP2β binding sites highlighted group 
of transcription factors involved SP1, KLF4, TFAP2A, MYF, REST, CTCF, ESR1 and ESR2. 
Gene ontology analysis of genes coincided with TOP2β peaks showed significant enrichment of 
neuronal function terms such as axon guidance and axonogenesis (Manville et al., 2015). Using 
ChIP-seq, it has been shown that TOP2β associates with about half of CTCF and cohesin-bound 
sites on mouse genome (Uusküla-Reimand et al., 2016). Interaction of TOP2β binding sites with 
DNase I hypersensitivity and allele-specific transcription factor binding sites was also shown in 
this study. Interestingly, these interactions were shown to be evolutionarily conserved in a cross-
species comparison involved CTCF ChIP-seq peaks mapped in human, macaque, rat, and dog 
(Uusküla-Reimand et al., 2016).  
In addition, a study showed an overlapping between CTCF/cohesin occupying sites and TOP2β 
binding sites at the evolutionarily conserved chromatin loop anchors and these anchors are more 










The aim of this study was to determine the role of the TOP2β isoform in gene expression. Nalm6 
(wild type) cell line and two genetic modified lines; TOP2B knockout cell line (Nalm6B-/-) and 
heterozygous knockout of TOP2A (Nalm6A+/-) were used in this study. To answer this question, I 
needed to confirm the genes that were differentially expressed in Nalm6B-/- which were highlighted 
in an RNA-seq data previously generated in our lab (cited as AROS data in this thesis). The full 
list of the differentially expressed genes from the AROS data are detailed in the appendix (figures 
7-8 and tables 11-14). In addition, because cancer cell lines are not as genetically stable as normal 
cells and have higher mutation frequency (Geraghty et al., 2014), taking into account that Nalm6B-
/- cells have been cultured for long time, it is possible that the differential expression might arise 
from reasons other than the lack of TOP2β. Therefore, I needed to determine the differential gene 
expression directly after downregulation of TOP2β. I performed RNA-seq analysis using Nalm6 
cells in which both TOP2 isoforms were knocked down by siRNA for 48 hrs.         
To achieve the aims mentioned above, the following experimental objectives were followed: 
• Optimizing electroporation conditions for Nalm6 cell line and generating cells in which 
TOP2A has been knocked down by siRNA (TOP2A-siRNA), and cells in which TOP2B 
has been knocked down by siRNA (TOP2B-siRNA). 
• Determining the effect of TOP2β isoform on gene expression in Nalm6 cell line by 
comparing whole transcriptome data of Nalm6WT with that of Nalm6B-/- as well as with that 
of (TOP2B-siRNA). 
• Determining genes that show a high fold change difference between Nalm6WT and Nalm6B-
/- and confirming up or downregulation trends by RT-qPCR. 
• In addition to TOP2β, the effect of TOP2α isoform on whole genome expression in Nalm6 
cell line was determined by comparing whole transcriptome data of Nalm6WT with that of 








Figure 4-1 siRNA knockdown of TOP2A and TOP2B in Nalm6 cells. 
4.3 Results 
4.3.1 Optimizing electroporation conditions and generating TOP2α- and β-knockdown cells. 
Firstly, knockdown efficiency for our siRNA stocks (Table 2.4) was tested in K562WT cells as the 
electroporation condition for this cell line had already been optimized in our lab. Western blotting 
showed efficient signal reduction of TOP2B (see Appendix figure 6). Knockdown conditions in 
Nalm6 were optimized by performing electroporation with a range of voltages and siRNA 
concentrations then visualising TOP2 reduction by western blotting. Results showed that 600 nM 
siRNA concentration and 300-350 V was the most efficient condition in achieving reduction in 













                  
 
 
Cells were transfected with 600 nM of either control or TOP2 siRNA. Electroporation conditions were (10 
mSec and 300-350 V). Samples were loaded (2.5-10 μg/lane) and probed with (A) TOP2A (4566) or (B) 
TOP2B (30400) antibodies. Actin (ab3280) antibody was used as loading control.  
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Figure 4-2 Western blotting of samples used for RNA-Seq analysis 
4.3.2 Gene expression analysis 
The role of TOP2B in gene expression in Nalm6 cell line was determined by whole transcriptome 
analysis using RNA sequencing. The analysis was performed on six different Nalm6 cell samples; 
wild type (Nalm6WT), TOP2B knockout (Nalm6B-/-), wild type transfected with non-targeting 
siRNA (Con-siRNA), wild type transfected with TOP2B siRNA (TOP2B-siRNA), wild type 
transfected with TOP2A siRNA (TOP2A-siRNA), and TOP2A knockout (Nalm6A+/-). The study 
was performed on four replicates of each sample. Transfection with siRNA was performed by 
electroporation as described in the Materials and Methods (Section 2.11). TOP2 expression was 
verified in these six samples by western blotting as shown in (Figure 4.2). Total RNA samples for 
sequencing were extracted and evaluated as described in the Materials and Methods (Sections 
2.14.1 and 2.14.2) and detailed information about the quantity and quality of RNA samples is 








   
 
   
 
 
Western blotting of Samples used for RNA-Seq analysis. Samples were loaded (10 μg/lane) on SDS-












WT 139 9.8 
Con-siRNA 208 9.9 
TOP2B-siRNA 219 9.9 
Nalm6B-/- 316 9.9 
TOP2A-siRNA 213 9.9 







WT 340 9.9 
Con-siRNA 337 10 
TOP2B-siRNA 389 10 
Nalm6B-/- 402 10 
TOP2A-siRNA 357 9.6 







WT 395 9.8 
Con-siRNA 318 9.9 
TOP2B-siRNA 302 10 
Nalm6B-/- 309 10 
TOP2A-siRNA 319 9.9 







WT 354 10 
Con-siRNA 328 10 
TOP2B-siRNA 491 10 
Nalm6B-/- 365 10 
TOP2A-siRNA 402 9.9 
Nalm6A+/- 455 10 
 
Table 4-1 Nalm6 RNA samples used in RNA-Seq study. 
(Nalm6WT) untreated wild type, (Con-siRNA) wild type transfected with non-targeting siRNA, (TOP2B-
siRNA) wild type transfected with TOP2B siRNA, (Nalm6B-/-) TOP2B knockout cells, (TOP2A-siRNA) 
wild type transfected with TOP2A siRNA, (Nalm6A+/-) TOP2A knockout cells.  
 
All RNA samples were tested for quantity and quality before sequencing using Bioanalyzer system 





































Figure 4-4 Differential gene expression in Nalm6WT vs. Nalm6B-/- 
4.3.3 Gene expression in TOP2B-knockout and -knockdown cells  
The comparison between the whole transcriptome of the Nalm6WT and the Nalm6B-/- was performed 
using RNA sequencing (RNA-Seq) technology which is described in Materials and methods 
(section 2.14.2). The analysis highlighted 16 genes that were down regulated in the Nalm6B-/- cells 
by more than 1 log2 fold change (Figure 4.4 and Table 4.2). All of these genes (except TMIGD2) 
also showed high fold reduction in previous data from our lab generated by another sequencing 
service provider (AROS Applied Biotechnology, Denmark) (Appendix figure 7 and Appendix 













Volcano plot shows log2 fold change in gene expression. Genes that showed more than 1 log2 fold change 
are labelled. Y axis shows adjusted P values (padj) which represent p-value adjusted for multiple testing 
correction using Benjamini-Hochberg method to control the False Discovery Rate (FDR). Genes showed < 












YOD1 YOD1 deubiquitinase 3.38 9.62 9.58E-176 
ZNF43 zinc finger protein 43 3.37 9.69 4.2E-186 
TOP2B Topoisomerase (DNA) II beta 2.92 13.19 2.64E-205 
CBR1 Carbonyl Reductase 1 2.87 13.71 1.28E-114 
PRKACB protein kinase cAMP-activated catalytic subunit beta 2.65 15.91 
2.11E-99 
ZSCAN18 zinc finger and SCAN domain containing 18 2.17 22.19 2.47E-63 
MTMR1 Myotubularin related protein 1 2.02 24.72 5.64E-143 
ZNF573 zinc finger protein 573 1.81 28.52 1.33E-43 
ARMCX5 Armadillo repeat containing, X-linked 5 1.68 31.14 1.36E-57 
ZNF626 zinc finger protein 626 1.56 34.01 7.07E-33 
BTBD6 BTB domain containing 6 1.36 38.96 1.05E-26 
NBPF15 neuroblastoma breakpoint family member 15 1.32 40.18 5.33E-23 
ARMCX5-
GPRASP2 ARMCX5-GPRASP2 readthrough 1.24 42.33 2.88E-20 
TMIGD2 Transmembrane and immunoglobulin domain containing 2 1.07 47.78 2.55E-14 
RIBC2 RIB43A domain with coiled-coils 2 1.04 48.56 8.09E-14 
PYCARD PYD and CARD domain containing 1.03 49.10 8.09E-14 
* The control (Nalm6WT) corresponds to 100% 
 
Table 4-2 Down regulated genes in Nalm6B-/- compared to Nalm6WT 
Genes are listed from the highest to the lowest log2 fold change value. 
 
On the other hand, there were several genes that up regulated in the Nalm6B-/- cells although the 
fold change did not exceed 1.0 log2 for all of them (Figure 4.4 and Table 4.3). All of these genes 
(except ZNF518B, LINC00665, and MT1H) also showed high fold increase in previous data of our 
lab generated by another sequencing service provider (AROS Applied Biotechnology, Denmark) 
(Appendix figure 7 and Appendix table and 12). 
The genes that showed high fold change difference between the Nalm6WT and the Nalm6B-/- were 






Figure 4-5 RT-qPCR analysis of genes which were down regulated in Nalm6B-/- 





FLT1 fms related tyrosine kinase 1 1.10 214.17 1.6E-28 
EMP2 epithelial membrane protein 2 1.09 213.58 1.4E-18 
ZNF518B zinc finger protein 518B 1.08 211.37 3.33E-40 
LINC00665 long intergenic non-protein coding RNA 665 0.91 187.61 2.95E-10 
MT1H metallothionein 1H 0.91 187.26 3.5E-10 
GZMA granzyme A 0.83 177.75 3.54E-12 
TUB tubby bipartite transcription factor 0.81 175.29 0.000000043 
ME3 malic enzyme 3 0.79 172.71 5.76E-13 
* The control (Nalm6WT) corresponds to 100% 
 
Table 4-3 Up regulated genes in Nalm6B-/- compared to Nalm6WT 












Relative gene expression were determined by RT-qPCR analysis as described in section 2.14.3. PP1A gene 
was used as a reference gene for normalizing data. Data presented here is the mean of at least three 




Figure 4-6 RT-qPCR analysis of genes which were Up regulated in Nalm6B-/- 
In addition, a number of genes that showed up regulation in both (NCL) and (AROS) data 
(Appendix figure 9 and Appendix Table 12) were selected for RT-qPCR analysis. Results showed 
the same gene expression patterns but none of the RT-qPCR differences between Nalm6WT and the 











Relative gene expression were determined by RT-qPCR analysis as described in section 2.14.3. PP1A gene 
was used as a reference gene for normalizing data. Data presented here is the mean of at least three 
independent experiments with error bars representing the SEM, (*P≤0.05, **P≤0.01, NS: No significance). 
 
Furthermore, whole transcriptome analysis was performed in Nalm6WT transfected with anti 
TOP2B small interfering RNA (siRNA) for 48 hrs. Firstly, a comparison between Nalm6WT and 
wild type transfected with non-targeting siRNA (Con-siRNA) was performed to determine if 
transfection condition affecting whole gene expression. Results showed that there was no 
difference between Nalm6WT and (Con-siRNA) cells (figure 4.7A). RNA-Seq analysis showed that 
transfection of Nalm6WT with anti TOP2B siRNA for 48 hrs affected only TOP2B gene as depicted 
in (figure 4.7B and Table 4.4). This might be because knockdown of TOP2B for 48 hours was not 
sufficient to induce change in gene expression shown in Nalm6B-/- which has grown for many 
passages in the absence of TOP2β or due to other reasons that need to be further addressed. 
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                              (A)             (B) 
 
 
Volcano plot shows log2 fold change difference in gene expression. (A) Comparison of Nalm6WT with 
Nalm6 transfected with non-target siRNA (B) Comparison of Nalm6 transfected with non-target siRNA 
with Nalm6 transfected with TOP2B siRNA. Y axis shows adjusted P values (padj) which represent p-value 
adjusted for multiple correction testing using Benjamini-Hochberg method to control the False Discovery 
Rate (FDR). Genes showed < 0.05 padj were considered as significantly changed. 
 
* The control (Con-siRNA) corresponds to 100% 






Genes Description Log2 Fold change 
% of 
control* padj 
TOP2B topoisomerase (DNA) II beta 0.78 58.11 1.11E-13 
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Figure 4-8 Differential gene expression in Nalm6WT vs. Nalm6A+/- 
4.3.4 Gene expression in TOP2A heterozygote-knockout and -knockdown cells 
The comparison between whole transcriptome of the Nalm6WT and the Nalm6A+/- was performed 
using RNA sequencing (RNA-seq) as described in the Materials and methods (section 2.14.2). The 
analysis highlighted 12 genes that were down regulated in the Nalm6A+/- cells by more than 1 log2 
fold change (Figure 4.8 and Table 4.5). All of these genes (except PRKACB, GVINP1, and 
OCIAD2) also showed high fold reduction in previous data from our lab generated by another 
sequencing service provider (AROS) (Appendix figure 8 and Appendix table 13). On the other 
hand, there were several genes that up regulated in the Nalm6A+/- cells by more than 1 log2 (Figure 
4.8 and Table 4.6). These genes (except ZNF518B) also showed high fold increase in previous data 
from our lab generated by another sequencing service provider (AROS) (Appendix figure 8 and 












Volcano plot shows log2 fold change in gene expression. Genes that showed more than 1 log2 fold change 
are labelled. Y axis shows adjusted P values (padj) which represent p-value adjusted for multiple testing 
correction using Benjamini-Hochberg method to control the False Discovery Rate (FDR). Genes showed < 









ME3 malic enzyme 3 2.85 13.85 1.64E-97 
S100A16 S100 calcium binding protein A16 1.62 32.43 4.12E-30 
GSTK1 glutathione S-transferase kappa 1 1.54 34.27 1.47E-41 
MID1 midline 1 1.54 34.33 4.45E-38 
XAF1 XIAP associated factor 1 1.18 44.13 4.85E-18 
PRKACB protein kinase cAMP-activated catalytic subunit beta 1.15 44.93 4.77E-19 
SIKE1 suppressor of IKBKE 1 1.15 45.07 3.82E-31 
PADI4 peptidyl arginine deiminase 4 1.14 45.32 2.1E-14 
GVINP1 GTPase, very large interferon inducible pseudogene 1 1.13 45.58 2.1E-14 
MMADHC methylmalonic aciduria and homocystinuria, cblD type 1.12 46.06 1.79E-28 
PPM1E protein phosphatase, Mg2+/Mn2+ dependent 1E 1.02 49.16 1.48E-12 
OCIAD2 OCIA domain containing 2 1.01 49.69 2.46E-12 
TOP2A topoisomerase (DNA) II alpha 0.64 64.06 3.66E-09 
* The control (Nalm6WT) corresponds to 100% 
 
Table 4-5 Down regulated genes in Nalm6A+/- compared to Nalm6WT 
Genes are listed from the highest to the lowest log2 fold change value. 
 





ADAMTS9 ADAM metallopeptidase with thrombospondin type 1 motif 9 1.32 249.02 5.06E-27 
SPP1 secreted phosphoprotein 1 1.23 234.21 2.47E-38 
ZNF518B zinc finger protein 518B 1.04 205.78 2.73E-33 
* The control (Nalm6WT) corresponds to 100% 
Table 4-6 Up regulated genes in Nalm6A+/- compared to Nalm6WT 
Genes are listed from the highest to the lowest log2 fold change value. 
 
Furthermore, whole transcriptome analysis was performed in Nalm6WT transfected with anti 
TOP2A small interfering RNA (siRNA) for 48 hrs. RNA-seq analysis showed that transfection of 
Nalm6WT with anti TOP2A siRNA for 48 hrs affected TOP2A gene only as depicted in (Figure 4.9 
and Table 4.7). This might be because knockdown of TOP2A for 48 hours was not sufficient to 
induce a change in gene expression shown in Nalm6A+/- which has grown for many passages with 
only one copy TOP2A or due to other reasons that need to be further addressed. 
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Figure 4-9 Differential gene expression in TOP2A-siRNA compared 














Volcano plot shows comparison of gene expression between Nalm6 transfected with non-target siRNA and 
Nalm6 transfected with TOP2A siRNA. Y axis shows adjusted P values (padj) which represent p-value 
adjusted for multiple testing correction testing using Benjamini-Hochberg method to control the False 
Discovery Rate (FDR). Genes showed < 0.05 padj were considered as significantly changed. 
 
Genes Description Log2 Fold change 
% of 
control* padj 
TOP2A topoisomerase (DNA) II alpha 0.67 62.823 5.63658E-12 
* The control (Con-siRNA) corresponds to 100% 





4.4 Discussion  
TOP2 enzymes are required to resolve topological problems such as positive and negative 
supercoiling during transcription (Liu and Wang, 1987). In this chapter, the role of TOP2α and 
TOP2β in gene expression was tested using Nalm6A+/- and Nalm6B-/- mutated lines (provided by 
Noritaka Adachi). RNA-seq analysis was performed and differential gene expression was 
determined in both mutated lines against the parent cell (Nalm6WT). Protein expression of TOP2α 
and TOP2β in all cell lines used in the RNA-seq analysis was confirmed by western blotting (Figure 
4.2). RNA-seq results confirmed the magnitude of reduction of TOP2A and TOP2B in Nalm6A+/- 
and Nalm6B-/- (by 64.06 and 13.19 % of control) (Tables 4.5 and 4.2 respectively) which reflects 
the number of mutated alleles.  
Results showed that TOP2A knock down and TOP2B knock out did affect the expression of a 
number of genes in Nalm6 cells. This agreed with studies that showed the effect of both isoforms 
in gene expression although there is more published data about TOP2β. For TOP2α, it has been 
shown that gene regulation and priming in embryonic stem cells requires TOP2α (Tiwari et al., 
2012; Thakurela et al., 2013). For TOP2β, it has been reported that transcription induced by ligand 
involved TOP2β-mediated DSBs (Ju et al., 2006; McNamara et al., 2008; Haffner et al., 2010). 
Studies have shown that TOP2β role in transcription of targeted genes involved bounding at or near 
promoter regions (Lyu et al., 2006; Madabhushi et al., 2015b; Manville et al., 2015; Uusküla-
Reimand et al., 2016; Canela et al., 2017). Further details of mechanistic of TOP2β role in gene 
expression will be described in discussion of chapters 5 and 6.  
In Nalm6B-/- cells, differential gene analysis showed that 16 genes were significantly downregulated 
by more than one log fold change (Figure 4.4 and Table 4.2). Some of these genes are involved in 
DNA-binding transcription factor activity (ZNF43, ZSCAN18, ZNF573, and ZNF626). On the other 
hand, fewer genes were significantly upregulated as compared with Nalm6WT (Figure 4.4 and Table 
4.3). RT-qPCR analysis confirmed RNA-seq results although some of them did not reach 
significance (Figure 4.5 and 4.6). In Nalm6A+/- cells, 13 and 3 genes were significantly down and 
up regulated respectively (Figure 4.8 and Tables 4.5 and 4.6). 
These genes were also differentially regulated in these cells in another RNA-seq experiment that 
was performed by another sequencing service provider (AROS Applied Biotechnology, Denmark). 
RNA-seq results from (AROS) showed more genes that differentially expressed in Nalm6B-/- and 
Nalm6A+/-. For example, 67 or 148 genes were down or up regulated respectively in Nalm6B-/- 
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(Appendix tables 11 and 12), and 27 or 48 were down or up regulated respectively in Nalm6A+/- 
(Appendix tables 13 and 14). This could be due to the more depth of sequencing applied in AROS 
than that the current experiment within Newcastle (NCL) (40 million (AROS) versus 30 million 
(NCL) paired-end (PE) reads).  
Both (NCL) and (AROS) Nalm6 datasets were analysed for Gene ontology as described in section 
(2.14.2.3). Analysis showed no significant enrichment of GO terms or KEGG pathways in (NCL) 
dataset, while (AROS) dataset showed enrichment of few terms as follows: in (Nalm6WT vs. 
Nalm6B-/-) comparison, one molecular function (MF) term (serine-type endopeptidase activity, GO: 
0004252) was highlighted. This term involves CTSG, C1RL, GZMA, GZMK, KLK1, and TMPRSS3 
genes. No biological process (BP) terms were significantly enriched, while five cellular component 
(CC) terms were significantly enriched (extracellular region [GO: 0005576], integral component 
of plasma membrane [GO: 0005887], proteinaceous extracellular matrix [GO: 0005578], vesicle 
[GO: 0031982], plasma membrane part (GO: 0044459)). In (Nalm6WT vs. Nalm6A+/-) comparison, 
only two (CC) terms were significantly enriched (external side of plasma membrane [GO: 
0009897], tertiary granule lumen [GO: 1904724]). 
Analysis also involved testing of over-representation of pathways linked to differentially expressed 
genes using (KEGG). Analysis of RNA-seq data from AROS data showed over-representation of 
two pathways (Hematopoietic cell lineage [hsa04640] and Amoebiasis [hsa05146]) in (Nalm6WT 
vs. Nalm6B-/-) comparison. On the other hand, no significant enrichment of KEGG pathways were 
seen in (Nalm6WT vs. Nalm6A+/-) comparison.       
In addition, analysis was performed using samples in which both TOP2A and TOP2B were targeted 
by siRNA. Knockdown of TOP2A and TOP2B was performed for 48 hrs before RNA-seq analysis. 
The knockdown reduced expression of TOP2A and TOP2B genes by 62.8 and 58.1 % of control 
(Tables 4.7 and 4.4 respectively). Protein level of all samples was checked using western blotting 
before RNA-seq analysis as in (Figure 4.2).   
However, siRNA knockdown did not show similar effect to knockout, and only the targeted genes 
were affected (Figures 4.9 and 4.7). The reasons might be the knockdown of TOP2 for 48 hours 
was not sufficient to induce a change in gene expression similar to that seen TOP2B knockout cells, 
which has grown for longer time with downregulated TOP2. Another possibility is that some of 
the difference in gene expression between Nalm6WT and the two other modified lines might be due 
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to genetic instability of cells rather than TOP2 deletion. It has been reported that chromosomal 
content of continuous cells lines has increased mutation frequency (Geraghty et al., 2014).     
Over the last decade, TOP2β predominates over TOP2α in studies involved the role of TOP2 
enzymes in gene expression. For this reason, we are more interested in TOP2β role in gene 
expression in more than one model. In this chapter, we showed how Nalm6B-/- cells is different 
from the parent Nalm6WT but we still need to confirm our observations because of the reasons 
mentioned above as well as to further extend our understanding on genes regulated by TOP2β and 
the mechanism of action. 
The current model (Nalm6 cell) was used as a model to study the effect of TOP2β absence on 
transcription. However, in many situations transcription is induced in response to triggers such as 
ligands. Nalm6 might undergo partial differentiation or change in expression of cell surface 
markers (CD10, CD19, and CD38) in response to ligands (Martin-Kleiner et al., 2006; Ardekani 
et al., 2011; Soleymani Fard et al., 2012). We compared response of Nalm6WT and Nalm6B-/- to 
all-trans retinoic acid (ATRA) (Appendix figure 16 and 17) or vitamin D3 (Appendix figure 14 
and 15). Results showed that both Nalm6WT and Nalm6B-/- did not show response to either D3 or 
ATRA and there was no difference between the two cell lines. 
To generate further TOP2B knockout models, I used CRISPR to generate a TOP2B knockout in 
Nalm6 (Chapter 5) as well as TOP2B knockout model of SH-SY5Y, a neuronal cell line that can 











5 Chapter Five: TOP2β regulates expression of CBR1, a gene implicated in 
doxorubicin-induced cardiotoxicity 
5.1 Introduction 
Anthracyclines are a group of antibiotics that are widely used in clinic. Adriamycin (doxorubicin), 
daunorubicin, and epirubicin represent the most commonly used anthracyclines in cancer treatment 
(Mordente et al., 2001). Doxorubicin is one of the most effective antineoplastic agents used for the 
treatment of solid and haematological tumours such as lymphoblastic and myeloblastic leukaemias, 
sarcoma, neuroblastoma, breast and bladder cancer (Wallace, 2003). However, efficiency of this 
agent is widely hampered by the development of acute or chronic cardiotoxicity following drug 
exposure (Ferrans et al., 1997; Singal et al., 1997; Singal et al., 2000). This cardiotoxicity includes 
ventricular contractile dysfunction, pericarditis, hypertension, arrhythmias, and thromboembolism 
(Higgins et al., 2015).  
There is an extensive literature about the cause, mechanism, and management of doxorubicin-
induced cardiotoxicity. Several hypotheses have been suggested to explain the molecular 
mechanism of doxorubicin-induced cardiotoxicity. The most common are oxidative stress (Singal 
and Iliskovic, 1998), disruption of intracellular Ca2+ homeostasis, iron complex formation, 
mitochondrial dysfunction and oxidative stress-independent apoptotic mechanisms (Mordente et 
al., 2001; Octavia et al., 2012). Each suggested mechanism has a limitation and, to date, the 
oxidative oxygen species (ROS) hypothesis is the most prevalent mechanism underlying 
doxorubicin-induced cardiac injury and myocardiopathy. This is supported by the fact that cardiac 
tissue has lower levels of catalase and superoxide dismutase activities in comparison with other 
tissues (Pai and Nahata, 2000). However, studies utilising treatment with (ROS) scavengers did not 
show protection from doxorubicin-induced cardiotoxicity (Myers et al., 1983; Hasinoff et al., 2003; 
Martin et al., 2009). Therefore, alternative molecular mechanisms has been hypothesized and tested 
as an attempt to understand events underlying doxorubicin-induced cardiotoxicity. 
TOP2β has been suggested as a possible key factor in the mechanism of doxorubicin-induced 
cardiotoxicity for several reasons; firstly, the well established fact that TOP2 is one of the main 
targets of doxorubicin (Tewey et al., 1984; Cowell and Austin, 2012), together with the evidence 
that TOP2β but not TOP2α, is the main TOP2 isoform expressed in adult mammalian 
cardiomyocytes (Giovanni Capranico and Zunino, 1992) and postmitotic cells in general (Austin 
and Marsh, 1998; Austin et al., 2018). In support of this, it has been shown that apoptosis induced 
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by doxorubicin in peripheral blood cells was associated with TOP2B level (Kersting et al., 2006). 
Secondly, Top2b deletion in primary mouse embryonic fibroblasts (MEF) is reported to protect 
these cells from doxorubicin-induced DNA damage as shown by the reduction of γH2AX signal in 
MEFTop2b-/- compared with MEFTop2b+/+ (Lyu et al., 2007).  
In addition, (Lyu et al., 2007) showed that H9C2 cardiomyocytes were protected from DNA 
damage induced by doxorubicin, but not hydrogen peroxide or camptothecin, when treated with 
ICRF-187 (clinically known as dexrazoxane) which both reduced TOP2β-doxorubicin cleavage 
complex level and induced TOP2B degradation. ICRF-187 is a well-known catalytic inhibitor of 
TOP2 and has been used commonly with doxorubicin as a cardioprotective agent (Speyer et al., 
1988; Speyer et al., 1992; Hensley et al., 2009). Furthermore, (Lyu et al., 2007) showed that 
γH2AX signal was reduced by ICRF-193, another catalytic inhibitor derived from the same family 
as ICRF-187 that has been shown to be more specific against TOP2β isoform (Xiao et al., 2003). 
The role of TOP2β in doxorubicin-induced cardiotoxicity at the molecular level has been 
investigated by (Zhang et al., 2012). In this study, the authors generated a mouse model with 
targeted deletion of Top2b in cardiomyocytes. They showed that the mice lacking Top2b in cardiac 
tissue were protected from doxorubicin-induced cardiotoxicity. Interestingly, Top2b-deleted  
cardiomyocytes showed about 60 % decrease in doxorubicin-induced DNA double stranded breaks 
(DSBs) as measured by γH2AX immunostaining of heart sections as well as around 70 % reduction 
in the ratio of apoptotic cells as measured by TUNEL assay (Zhang et al., 2012).  
In addition, they showed that doxorubicin treatment induced transcriptional changes related to 
mitochondrial dysfunction and oxidative stress in Top2b+/+ but not Top2b∆/∆ cardiomyocytes. 
Ingenuity Pathways Analysis (IPA) of microarray data of genes that are altered by more than 1.5 
fold showed that doxorubicin treatment for 16 hrs activates Trp53inp1, Apaf1, Bax and Fas in 
Top2b+/+ but not Top2b∆/∆ cardiomyocytes. These genes are involved in the p53 apoptosis pathway. 
Analysis 72 hrs post doxorubicin treatment showed downregulation of both Ppargc1a and 
Ppargc1b by 50% in Top2b+/+ but not Top2b∆/∆. These genes encode PGC-1α and PGC-1β, 
transcription coactivators that are involved in the function and the biogenesis of mitochondria. 
PGC-1α has been shown to be a hallmark of heart failure in another study (Sihag et al., 2009). 
Treatment of mice with doxorubicin for 5 days followed by measuring of ejection fraction by 
magnetic resonance imaging (MRI) scan showed decreases in Top2b+/+ and Top2b+/∆  by 53 % and 
116 
 
Figure 5-1 Doxorubicin and doxorubicinol chemical structures 
43% respectively, while no change seen in Top2b∆/∆. Reduction of ejection fraction is a clinical 
feature of cardiotoxicity (Zhang et al., 2012).     
The role of TOP2β in doxorubicin-induced cardiotoxicity in human cells was investigated in human 
pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) by (Maillet et al., 2016). This involved 
TOP2B knockout in a human pluripotent stem cell (hPSC) by CRISPR followed by induction of 
differentiation into cardiomyocytes. The TOP2B knockout hPSC-CMs showed significant 
reduction in cytotoxicity and DNA damage (γH2AX signal) induced by doxorubicin as compared 
with wild type cells. 
Collectively, studies above showed a role for TOP2β in doxorubicin-induced cardiotoxicity 
regardless of the mechanism or pathway involved. This suggests that TOP2β could be used as a 
useful biomarker for early prediction of susceptibility to doxorubicin-induced cardiotoxicity. 
Indeed, in a study involving comparison of TOP2β levels in peripheral blood cells between two 
groups: anthracycline-resistant and anthracycline-sensitive patients, results showed that 
anthracycline-sensitive patients who had overall Left Ventricular Ejection Fraction (LVEF) <50% 
showed markedly higher TOP2β level (Vejpongsa et al., 2013). 
Another aspect of doxorubicin-induced cardiotoxicity is the potential role of the doxorubicin 
metabolite doxorubicinol (Figure 5.1). It has been shown that about half of the administered 
doxorubicin is eliminated from the body without change while the other half is metabolized mainly 
to the doxorubicin alcohol metabolite doxorubicinol (Joerger et al., 2005). This is mainly achieved 
by the Carbonyl Reductase 1 (CBR1) enzyme through a two-electron reduction of the carbonyl 
group in the side chain of doxorubicin to generate the C13-alcohol metabolite doxorubicinol 






Figure was reproduced from (Mordente et al., 2003) with permission. 
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There is a variability in the literature as to whether the doxorubicin or doxorubicinol is the most 
toxic. A systematic review of the various reports suggests that doxorubicinol is more cardiotoxic 
but has less anti-tumour effect than doxorubicin (Edwardson et al., 2015). Generally, in vivo 
studies suggest doxorubicinol as more cardiotoxic than doxorubicin while in vitro studies using 
cell lines in culture showed remarkable lower anti-tumour effect of doxorubicinol compared with 
doxorubicin. It has been shown that cardiac tissue has enhanced accumulation of doxorubicinol 
over other tissues in rats receiving multiple doses of doxorubicin (Peters et al., 1981). 
There is a wide range of evidence suggesting that doxorubicinol is responsible for doxorubicin-
induced cardiotoxicity and is more cardiotoxic than the parent compound (Boucek et al., 1987; 
Olson et al., 1988; Mushlin et al., 1993; Minotti et al., 1995). The early and preclinical evidence 
includes different types of findings; first, it has been shown that anthracyclines with reduced 
cardiotoxicity form less alcohol metabolite (Menna et al., 2007). Second, a correlation was shown 
between cardiotoxicity and the level of doxorubicinol accumulation in the heart (Olson and 
Mushlin, 1990; Cusack et al., 1993; Stewart et al., 1993; Sacco et al., 2003). Third, overexpression 
of doxorubicin reducing enzyme CBR1 in mice heart increases cardiotoxicity (Forrest et al., 2000). 
Fourth, deletion of one copy of Cbr1 gene in mice significantly protects from cardiotoxicity (Olson 
et al., 2003). Furthermore, reducing doxorubicinol formation by the inhibition of doxorubicin 
metabolism with phenobarbital results in less cardiotoxicity in rats (Behnia and Boroujerdi, 1999).  
For these reasons, many carbonyl reductase inhibitors have been evaluated and a line of research 
involving the cardioprotection effect of CBR1 inhibition has emerged (Huang et al., 2010; Arai et 
al., 2015; Piska et al., 2017). Some of these inhibitors were tested in clinical trials (Bruynzeel et 
al., 2007). In a murine study, carbonyl inhibitor 23-hydroxybetulinic acid (23-HBA) reduced 
doxorubicin-induced cardiotoxicity and this was manifested as a selective reduction of 
doxorubicinol in the heart. Similar effects were seen in the cardiomyocyte H9c2 cell line (Zhou et 
al., 2015).  
In support of a role of CBR1, it has been shown that interindividual variability in susceptibility to 
doxorubicin-induced cardiomyopathy is correlated to single nucleotide polymorphism (SNP) in the 
CBR1 gene (Blanco et al., 2012). The effect of SNPs of human CBR1 on the metabolism of 
doxorubicin has been indicated in an in vitro study (Bains et al., 2009). Moreover, studies have 
shown that cancer patients with Down Syndrome (Trisomy 21) are at increased risk of 
anthracycline-induced cardiotoxicity over those without Down Syndrome (Krischer et al., 1997; 
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O'Brien et al., 2008; Quinones-Lombrana et al., 2014), which might be due to higher CBR1 
expression (CBR1 gene is located at chromosome 21) and hence may contribute to the 
pharmacology of doxorubicin-induced cardiotoxicity in this group. 
Another strategy to reduce doxorubicin toxicity induced by its metabolites involved testing 
doxorubicin analogues with reduced metabolite formation.  A novel doxorubicin (DOX) analogue, 
13-deoxy, 5-iminodoxorubicin (DIDOX) has shown a comparable cytotoxicity profile with 
doxorubicin with reduced cardiotoxicity in a chronic rabbit model as measured by left ventricular 
fractional shortening and contractility as well as by histological examination (Frank et al., 2016). 
Interestingly, in this study inhibition of TOP2β decatenation activity by DOX and DIDOX was 
compared. DOX inhibited TOP2β decatenation while DIDOX did not interact with TOP2β in a 
decatenation assay, consistent with other evidence that suggests TOP2β has a role in a 
cardiotoxicity. This drug was also tested in a clinical trial phase I to treat in patients with advanced 
solid tumours and no cardiotoxicity was observed (Holstein et al., 2015).        
On the other hand, studies have suggested that doxorubicinol has much less antitumour activity 
than doxorubicin (Heibein et al., 2012; Bains et al., 2013). These studies involved in vitro 
comparison of the cytotoxicity profile of doxorubicin with doxorubicinol in cell lines such as the 
V79/AP4 fibroblast (Bernardini et al., 1991) and MCF-7 (Veitch et al., 2009). Therefore, it has 
been suggested that doxorubicinol and reductase enzymes such as CBR1 are important factors in 
tumour resistance (Tak et al., 2011; Heibein et al., 2012). Accordingly, studies have shown 
increased expression of reductase enzymes in resistant tumour samples (Zhong et al., 2015).  
In agreement with this, inhibition of doxorubicin metabolism using aldose-reductase inhibitor 
(fidarestat) significantly increased doxorubicin-sensitivity of resistant colorectal cancer cells and 
significantly reduced cardiotoxicity in mice (Sonowal et al., 2017). In this study, fidarestat 
treatment significantly increased sensitivity of human colon cancer cell lines HT-29 and SW480 
as well as nude mice xenografts to doxorubicin. In addition, fidarestat treatment protected mice 
from doxorubicin-induced cardiotoxicity as determined by serum cardiotoxic biomarker troponin-
I as well as heart function by echocardiography. Furthermore, fidarestat treatment of H9c2 
cardiomyocyte cell line reduced cytotoxicity of doxorubicin (Sonowal et al., 2017). So far, there is 
no reported clinical trial of fidarestat for cardioprotection against doxorubicin although it has been 
shown not to cause any toxicity in human in a phase III clinical trials for treatment of diabetic 




The literature reviewed above confirms the role of two factors in doxorubicin-induced 
cardiotoxicity: TOP2β and CBR1. Interestingly, both TOP2β and CBR1 play their role in the same 
direction, i.e. downregulation of either TOP2B or CBR1 reduce doxorubicin-cardiotoxicity. 
However, all existing studies have involved studying TOP2B or CBR1 independently of each other 
and so far, there is no published data suggesting that TOP2β mediates doxorubicin-induced 
cardiotoxicity through the regulation of CBR1 gene. 
In the previous chapter, RNA-seq and RT-qPCR results showed a significant regulation of a 
number of genes including CBR1 upon TOP2B knockout (Figure 4.3, Table 4.2, Appendix Figure 
9, Appendix Table 11, and Figure 4.5). However, the downregulation of TOP2B using siRNA did 
not cause similar effects as was mentioned in the discussion of previous chapter.  
In this chapter, the aim was to further verify the observations seen in the previous chapter regarding 
the differentially expressed genes including the CBR1. For this reason, new TOP2B knockout 
clones in the Nalm6 cell line were generated using CRISPR. The aims of this chapter were to: 
• Confirm regulation of genes seen in Nalm6B-/- in the new TOP2B knockout clones. 
• Study the mechanism of CBR1 regulation by TOP2β. 
 
To address the aims above, the following experimental objectives were followed: 
• Optimize the CRISPR technique to generate a TOP2B knockout model in a Nalm6 cell line. 
• Use of freshly generated TOP2B knockout model to investigate the expression of genes 
which were previously either up or down regulated in Nalm6B-/- using RT-qPCR technique.  
• Investigate the mechanism by which TOP2β regulates CBR1 using Chromatin 
Immunoprecipitation (ChIP) and RT-qPCR techniques. 





5.3.1 Generation of a TOP2B knockout model in Nalm6 cells using CRISPR 
Details for gRNA design, cloning, and verification of their cloning by sequencing are in (Sections 
2.15 and 6.3.1). Briefly, eight different gRNAs were designed to target exon number 1 of the 
TOP2B gene. The sequence of these gRNAs and their predicted off-target effects are detailed in 
the materials and methods (figure 2.2 and table 2.7). The efficiency of these gRNAs was tested 
using T7 endonuclease I as described in the materials and methods (section 2.15.5). As the initial 
DNA samples used in the T7 endonuclease I test were from SH-SY5Y cells, the result of this test 
was presented in the next chapter (section 6.3.1.3). The gRNA number 6 showed the highest 
efficiency (figure 6.7) and the lowest off-target record as well (figure 2.7). For this reason, gRNA 
number 6 was chosen to generate TOP2B knockout clones in Nalm6 in this chapter. The gRNA 
number 6 was cloned into PX458 vector, a plasmid expressing both CRISPR cas9 system as well 
as GFP as a selective marker. Nucleofection was used to transfect Nalm6WT as described in the 
materials and methods (section 2.15.3). Briefly, Nucleofector II system (Amaxa, USA) was used 
to transfect the cells using Amaxa® Cell Line Nucleofector® Kit T (Lonza, UK, cat. VCA-1002) 
according to the manufacturer’s instructions. The optimized protocol from (Lonza, UK) for Nalm6 
was followed. The following sections show the transfection and clones screening steps.  
5.3.1.1 Determining the transfection efficiency in Nalm6 cells 
Nalm6WT cells were transfected with PmaxGFP (as a control) or PX458 cloning vectors then the 
transfection efficiency was determined as described in (Section 2.15.4) and presented in (Figure 
5.2 A and B). 
5.3.1.2 Screening for TOP2B knockout clones  
Many clones were isolated and expanded for screening as described in (Section 2.15). Among 
these, six clones showed a different genotype pattern from wild type (Figure 5.3). PCR products of 
four clones (4, 6, 14, and 18) were extracted and sent for sequencing (Figure 5.3 and Table 5.1). 
Sanger sequencing showed that two of them had an insertion and clone number 4 had a deletion 
while the mutation of clone number 18 could not be sequenced although sequencing attempts were 
repeated several times. These four clones were further tested for TOP2B protein expression and 
they were all negative for TOP2B except clone 14 (in which a 3 base insertion was introduced) 
(Figures 5.4 and 5.5). 
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Figure 5-2 Transfection efficiency in Nalm6 cells 










(A) Live cell imaging of Nalm6 cells transfected with the positive control (PmaxGFP) or the (PX458) vector 
by Nucleofection. Images were captured using TiE fluorescence wide field inverted microscope (Nikon) 












Samples were amplified by PCR as described in the Materials and methods section then loaded on a (3 %) 




Figure 5-4 Screening for TOP2B knockout clones in Nalm6 cells by western 
blotting  
Clone gRNA Mutation 
4 6 Wild:     GGCCAAGTCGGGTGGCTGCGGCGCGGGAGCCGGCGTG  Mutant:  GGCCAAGT…………GCTGCGGCGCGGGAGCCGGCGTG 
6 6 Wild:    CCATGGCCAAGT…..CGGGTGGCTGCGGCGCGGGAGCC Mutant: CCATGGCCAAGTGCCGGGTGGCTGCGGCGCGGGAGCC 
14 6 Wild:    ATGGCCAAGTC…….GGGTGGCTGCGGCGCGGGAGCCG Mutant: ATGGCCAAGTCCCCGGGTGGCTGCGGCGCGGGAGCCG 
18 6 Mutation sequence could not be confirmed. 
 











   
 
Clone protein samples (5 µg / lane) were prepared for western blotting as described in (Section 2.3) and 


































Cells were prepared for immunofluorescence as described in (Section 2.15.7.2) then probed with anti 
TOP2B antibodies (4555) followed by Alexa fluor®488 secondary antibodies then immunofluorescence 
signal was captured via FITC channel. 
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5.3.2 RT-qPCR analysis of selected genes 
The knockout clone number 4 (Nalm6BKO4) was selected to check expression level of genes which 
showed up or down regulation in Nalm6B-/- (Adachi) cells to confirm the expression trends in the 
absence of TOP2β. In addition, expression levels of the same genes were tested in a TOP2B 
knockout model of K562 cells (K562BKO33) which were generated at the same time by me using 
CRISPR (details are in Appendix figures 9, 10, 11, and 12 as well as Appendix table 15). The aim 
was to answer the question of whether any of these genes are regulated by TOP2β in a non-cell line 
specific mechanism. However, none of these genes showed statistically significant changes in 
K562BKO33 (Appendix Figures 13).  
In Nalm6BKO4, of 16 genes tested, 2 genes (CBR1 and PRKACB-1) showed significant change in 
comparison with Nalm6WT. The CBR1 gene was the only gene that showed significant decrease 
consistent with the previous results (Figure 5.6). The CBR1 gene expression level showed tight 
dependency on TOP2β. Significant reduction of this gene upon TOP2B knockout was determined 
in 4 different experiments in this study: 2 independent RNA-seq experiments (Figure 4.4, Table 
4.2, Appendix figure 7 and Appendix table 11) and 2 independent RT-qPCR experiments with two 


































RT-qPCR analysis of genes which were either downregulated (A) or upregulated (B) in knockout Nalm6 
from Adachi (Nam6B-/-). RT-qPCR analysis as described in (section 2.13.4). The PP1A gene was used as a 
reference gene for normalizing data. Data presented here is the mean of at least three independent 





These results were consistent and it is interesting to further study how TOP2β regulates CBR1 gene 
expression because both TOP2β and CBR1 have clinical importance in cardiotoxicity associated 
with cancer treatment (See section 5.1).  
Studies have shown the role of both TOP2β and CBR1 in doxorubicin-induced cardiotoxicity. So 
far, no published data suggest a model in which the cardioprotection effect seen upon TOP2β 
inhibition is due to decreased CBR1 activity and hence decrease in doxorubicin reduction into the 
cardiotoxic metabolite doxorubicinol.  
5.3.3 Chromatin Immunoprecipitation analysis of CBR1 gene 
To determine whether TOP2β regulates CBR1 directly, Chromatin Immunoprecipitation (ChIP) 
technique was used to study the molecular events associated with CBR1 gene landscape especially 
the promoter (Figure 5.7). The ChIP protocol was performed as described in (Materials and 
Methods, Section 2. 16). This technique was used to study TOP2β enzyme recruitment at selected 
regions of the CBR1 gene in both Nalm6WT and Nalm6BKO4 cells. In addition, ChIP was used to 
determine the effect of TOP2β absence on the recruitment of four transcription factors that have 
been shown to be recruited to regions at CBR1 genomic locus (ENCODE database): Upstream 
Stimulatory Factor 1 (USF1), Upstream Stimulatory Factor 2 (USF2), C-Myc (also known as 




Figure 5-7 IGV viewer snapshot shows CBR1 gene landscape. 
This figure shows Acetylated Histone 3 peak signals and transcription factors ChIP data reported from (ENCODE database). PCR primers used in ChIP 
(CBR1-C1, CBR1-P2, CBR1-P3, and CBR1-P2) were added below RefSeq Genes track.
128 
 
Figure 5-8 Testing ChIP primers for CBR1 gene. 
5.3.3.1 Testing the ChIP primers on the CBR1 gene  
Based on data from (ENCODE database) which describe sites of active chromatin manifested by 
H3K9ac and H3K4me3 as well as regions of ChIP signal peaks of transcription factors under study, 
multiple primers at different regions of CBR1 gene were designed by myself as detailed in (Table 
2.5) and tested for unique PCR products as described in (Figure 5.8 A and B). Four primers were 
selected to test ChIP signal: CBR1-C1, CBR1-P2,  CBR1-P3, and CBR1-P4 as depicted in 



















(A) Melting curve plot to test specificity of primers (B) Agarose gel of PCR reaction samples in A.   
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5.3.3.2 Optimization of Chromatin fragmentation for ChIP  
Cell harvesting and chromatin fixation with 1% formaldehyde was performed as described in detail 
in (Materials and Methods, Section 2.16). The optimal fragmentation range of chromatin DNA 
depends on the purpose of experiment and ChIP resolution required to be achieved. The aim here 
was to achieve chromatin DNA fragments of 200-600 bp. Six chromatin samples were sonicated 
with a range of cycles using a Bandelin Sonopuls HD2070 probe sonicator by applying (5-10 
rounds of 7 pulsed cycle for 15 seconds at 20% power) as described in (Materials and Methods, 
Section 2.16) and the DNA was purified as descirbed in (Materials and Methods, Section 2.16.5). 
DNA samples were then run on an agarose gel and visualized as in (Figure 5.9). The condition 
which was chosen for further ChIP experiments was (7 rounds of 7 pulsed cycle for 15 seconds at 
20% power).    
 
 






Figure 5-10 ChIP signal of negative and positive controls at two genomic loci of 
Nalm6 cells. 
5.3.3.3 ChIP results 
To validate any ChIP protocol, it is important to have an antibody that is known to give a signal at 
a given genomic locus. For this purpose, Anti-acetylated Histone 3 (Ac-H3) antibody was used as 
a positive control in ChIP (Table 2.1) along side a primer which amplifies a 166 bp region of the 
GAPDH gene promoter (Table 2.5). In addition, all ChIP PCR primers were tested using an 
immunopreceipitate (IP) with an anti-GFP antibody which was used as a negative control. 
Furthermore, for the CBR1 gene locus, CBR1-P4 primer was used as a negative genomic control 
to amplify a region where no signal is expected with the antibodies used in the experiment 
according to various online ChIP databases especially (ENCODE) (Figure 5.7). All antibodies and 
primers are detailed in (Tables 2.1 and 2.5).  
ChIP was performed on both Nalm6WT and Nalm6BKO4 and validated by showing high positive-to-
negative ratio at GAPDH locus as well as a reasonable ratio at CBR1-C1 locus (which 












ChIP signal at (A) GAPDH and (B) CBR1-C1 primer loci. Data presented here is the mean of at least three 




Figure 5-11 ChIP signal of TOP2β at different regions of CBR1 gene in Nalm6 
cells.  
TOP2β signal at the four genomic loci was tested in Nalm6WT and Nalm6BKO4 as presented in 
(Figure 5.11). Notably, and as expected TOP2β ChIP signal was much lower at all sites tested in 
the TOP2B knockout clone (Nalm6BKO4) demonstrating another validation of our ChIP and the 
specificity of TOP2B antibodies used in this experiment. Results showed comparable TOP2β ChIP 
signal at each of the four primer locations tested in (Nalm6WT) and was not concentrated 
specifically at the promoter site (CBR1-C1). This might suggest that TOP2β is not recruited at a 
specific site around the CBR1 gene or the primers tested were not close enough to the TOP2β 
binding site. Another possibility that TOP2β might indirectly regulate CBR1 expression through 
its topology-related activity via generating DNA double-stranded breaks (DSBs) which modulates 
chromatin architecture and hence either change promoter-enhancer proximity or the recruitment 














ChIP signal of TOP2B at four different regions of theCBR1 gene in Nalm6WT and Nalm6BKO4 cells. Anti-
GFP was used as a negative control. Data presented here is the mean of at least three independent 





Figure 5-12  USF1 and USF2 ChIP signal on two regions of the CBR1 gene in 
Nalm6 cells. 
The regulation of CBR1 expression by TOP2β might be indirect through regulation of the level or 
recruitment of other transcription factors required to induce or activate CBR1 gene expression. To 
test this, four different transcription factors (USF1, USF2, MAX, and C-Myc) were tested for both 
ChIP signal at CBR1-C1 primer locus (Figure 5.7) and basal mRNA level in the presence or 
absence of TOP2β (Nalm6WT compared to Nalm6BKO4). ChIP signal was determined for USF1 and 
USF2 transcription factors at two regions of the CBR1 gene landscape: promoter region (CBR1-
C1) and a region where no signal was expected (from ENCODE DATABASE), the negative 

















USF1 and USF2 ChIP signal at two regions of CBR1 gene in Nalm6WT and Nalm6BKO4 cells was tested using 
two primers: CBR1-C1 (promoter) and CBR1-P4 (amplify a negative genomic control where no signal is 
expected). Data presented here is the mean of at least three independent experiments with error bars 




Figure 5-13 RT-qPCR analysis of USF1 and USF2 mRNA level in Nalm6 cells 
Overall, USF2 signal (Figure 5.12) was higher than USF1. USF2 ChIP signal at CBR1 promoter 
(CBR1-C1 primer) was significantly higher than the control region (CBR1-P4) in both Nalm6WT 
and Nalm6BKO4 cells, consistent with ENCODE USF2 ChIP data (presented in Figure 5.7) which 
added further validation to our ChIP results. Interestingly, USF2 signal was significantly (10X) 
reduced at the promoter region (CBR1-C1 primer) in the knockout cells (Nalm6BKO4) compared to 
wild type (Nam6WT) (Figure 5.12) without changing USF2 basal mRNA level (Figure 5.13). This 
suggests a molecular mechanism where TOP2β mediates recruitment of USF2 transcription factor 
to CBR1 promoter thereby regulates transcription level. 
USF1, on the other hand, did not show a significant difference between Nalm6WT and Nalm6BKO4 













Relative gene expression was determined by RT-qPCR analysis as described in (Materials and Methods, 
Section 2.14.3. The PP1A gene was used as a reference gene for normalizing data. Data presented here is 










In addition, both C-Myc and MAX transcription factors were tested for ChIP signal at the same 
two regions of the CBR1 gene (CBR1-C1 and CBR1-P4). As for USF2, TOP2B knockout cells 
(Nalm6BKO4) showed a significant reduction in ChIP signal of both C-Myc (1X) and MAX (3.5X) 
at the CBR1 promoter (CBR1-C1 primer) with more effect on MAX than C-Myc as shown in 
















ChIP signal of C-Myc and MAX at two regions of CBR1 gene in Nalm6WT and Nalm6BKO4 cells. CBR1-P4 
primer was used as a negative genomic control where no signal expected. Data presented here is the mean 


















Relative gene expression was determined by RT-qPCR analysis as described in (Materials and Methods, 
Section 2.14.3). PP1A gene was used as a reference gene for normalizing data. Data presented here is the 
mean of at least three independent experiments with error bars representing the SEM, (NS: No significance). 
 
These results showed that TOP2B knockout significantly reduced the ChIP signal of C-Myc, MAX, 
and USF2 at CBR1 promoter without affecting their mRNA level. This suggests that TOP2β 
regulates CBR1 expression by a molecular mechanism where TOP2β through its topology-related 
activity creates a suitable chromatin environment (see discussion) for recruitment of transcription 
factors (mainly USF2 and MAX and, to less extent, C-Myc) to the CBR1 promoter which leads to 
the regulation of transcription of the CBR1 gene.        
5.3.4 Effect of CBR1 inhibition on doxorubicin toxicity  
Results above showed that TOP2β is required for the induction of CBR1 expression possibly by 
enhancing the recruitment of USF2, MAX, and C-Myc transcription factors to the promoter. As 
mentioned in the introduction, in vivo studies showed that doxorubicinol is more cardiotoxic than 
doxorubicin while in vitro studies on tumour cell lines showed significantly less anti-tumour 
activity of doxorubicinol than doxorubicin. In theory, CBR1 inhibition should reduce 
doxorubicinol production and result in less cytotoxicity and more cardiotoxicity. Unfortunately, 
we could not test the latter effect as the generation of TOP2B knockout cardiomyocyte clones is 
beyond the scope of this study. However, the Nalm6 cell line was used to test the effect of CBR1 
inhibition on doxorubicin cytotoxicity.  
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Figure 5-16  Growth inhibition of Nalm6 by doxorubicin. 
It is well established that TOP2β downregulation reduces doxorubicin cytotoxicity (Lee et al., 
2016). Firstly, doxorubicin cytotoxicity profile was confirmed in knockout clone (Nalm6BKO4) as 










Nalm6WT and Nalm6BKO4 cells were treated with range of doxorubicin doses and growth inhibition was 
measured using the XTT method as described in (Materials and Methods, Section 2.8). Data presented here 
is the mean of at least three independent experiments with error bars representing the SEM. 
 
The fact that TOP2 itself is a target of doxorubicin is reflected in the substantial reduction in 
doxorubicin cytotoxicity in Nalm6BKO4 (Figure 5.16), and this is likely to mask other secondary 
effects of TOP2β downregulation such as CBR1 inhibition. Therefore, a robust method of 
inhibition of CBR1 enzyme activity either chemically or by gene downregulation is required to test 
the effect of CBR1 on doxorubicin cytotoxicity.  
In the meantime, no chemical agent that acts specifically against CBR1 is available in the literature 
even though a number of agents have been proposed (Abou El Hassan et al., 2003; Tanaka et al., 
2005; Willems et al., 2006; Bruynzeel et al., 2007; Carlquist et al., 2008; Gonzalez-Covarrubias et 
al., 2008; Arai et al., 2015; Zemanova et al., 2015). Rutin, a flavonoid that has been shown to 
inhibit CBR1 enzyme activity in vitro (Gonzalez-Covarrubias et al., 2007) was used in this study.  
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Figure 5-17 Growth inhibition of Nalm6 by doxorubicin +/- Rutin. 
Results of doxorubicin treatment with or without rutin showed that rutin significantly reduced 
doxorubicin cytotoxicity in both Nalm6WT and Nalm6BKO4 (Figure 5.17). This protection effect of 
rutin suggests either that rutin inhibits CBR1 enzyme and hence doxorubicinol formation 
suggesting that doxorubicinol is more cytotoxic to Nalm6 than doxorubicin or the protection effect 
of rutin was due to another mechanism that does not involve CBR1.  
The latter would be more convincing for reasons. First, as mentioned before, no chemical agent 
that acts specifically against CBR1 enzyme is available and the obvious reduction in growth 
inhibition shown in (Figure 5.17) might reflect a protection mechanism that does not involve 
CBR1. Second, most published data shows that doxorubicinol has much lower anti-tumour effect 
than doxorubicin. Third, CBR1 inhibition by siRNA slightly increased cytotoxicity of doxorubicin 
as compared with control siRNA, even the difference was insignificant, suggesting that 












Nalm6WT cells were treated with a range of doxorubicin doses with and without 100 µM Rutin. Growth 
inhibition was measured using XTT method as described in (Materials and Methods, Section 2.8). Data 





Figure 5-18 Effect of CBR1 siRNA on doxorubicin cytotoxicity 
Currently, the best available option to inhibit CBR1 activity is to either knockout the gene or 
downregulate by siRNA knockdown. CBR1 downregulation was performed using anit-CBR1 
siRNA (Table 2.4) followed by doxorubicin treatment. Nalm6WT Cells were transfected with a 
control or CBR1 siRNA for 48 hours. CBR1 downregulation was determine by RT-qPCR (Figure 
5.18 A). Cells were then treated with doxorubicin for 5 days and growth inhibition was measured 










                     (A)                                                                (B)  
 
Nalm6WT cells were transfected with non-targeting or CBR1 siRNA for 48 hrs then treated with a range of 
doxorubicin doses for 5 days (A) CBR1 level determined by RT-qPCR (B) Growth curve was measured by 
XTT method as described in (Materials and Methods, Section 2.8). Data presented here is the mean of at 
least three independent experiments with error bars representing the SEM. 
 
CBR1 mRNA level was reduced by approximately 50 % after 48 hrs of siRNA transfection. This 
might result in slight reduction in doxorubicin cytotoxicity which is more consistent with CBR1 
role in doxorubicin activity on cancer cells. However, further optimization is needed for this 
experiment as CBR1 was downregulated for a short time. In summary, a robust and specific method 
for inhibition of CBR1 is required to further extend the observations above and this beyond the 





In this chapter, CRISPR was used to generate a TOP2B knockout model in the Nalm6 cell line. 
The transfection efficiency was determined using both live cell imaging and FACS analysis as in 
(Figure 5.2). Efficiency of transfection with the positive control PmaxGFP vector was 10.5 fold 
higher than the transfection efficiency with the PX458 vector. This might be due to two reasons; 
firstly, PX458 is ~ 3 times larger than PmaxGFP which might reduce cellular uptake. Secondly, 
the two vectors use different promoters (PmaxGFP uses a CMV promoter while PX458 uses a U6 
promoter).  
The advantage of using a GFP selective marker in a vector based CRISPR method is that selection 
for positively transfected cells is very efficient even with low transfection efficiency. In addition, 
single cell cloning can be performed using the cell sorter to efficiently allocate single cells in each 
collecting well (96-well plates were used). Single cell cloning by cell sorter was also verified by 
microscope before clone expansion. Out of total clones that were tested, screening of 4 clones are 
presented in the results section. Genotyping analysis at the targeted region of exon 1 of the TOP2B 
gene confirmed a mutation in 3 of 4 clones screened. Two clones have an insertion and one has a 
deletion (Table 5.1). All clones were confirmed for abrogation of TOP2β protein expression except 
clone 14 which was positive for TOP2B although it has 3 bases insertion mutation which might 
add one amino acid without disrupting protein expression. Clone number 4 (Nalm6BKO4) was used 
for experiments in this chapter.  
RT-qPCR analysis of genes which were either down or up regulated in Nalm6B-/- in the previous 
chapter showed insignificant change in all of the genes tested except for CBR1 (Figures 5.6). In 
agreement with the previous RNA-seq and RT-qPCR results, the CBR1 gene showed a 68 fold 
reduction in Nalm6BKO4 which indicates that TOP2β positively regulates CBR1 gene expression. 
The consistency in the downregulation of CBR1 expression upon TOP2β inactivation in different 
independent analysis and knockout models of Nalm6 cells confirms that CBR1 is regulated by 
TOP2β in this cell line. Whether CBR1 is directly or indirectly regulated by TOP2β, so far there is 
no published data about the role of TOP2β in the expression of this gene.  
A publically available RNA-seq data set might support our finding of a role of TOP2β on CBR1 
gene expression. In this data (GEO accession: GSE106297), a human pluripotent stem cell-derived 
cardiomyocytes (hPSC-CMs) showed downregulation of CBR1 upon treatment of doxorubicin 
(Maillet et al., 2016). In this data, downregulation of CBR1 might be due to TOP2β downregulation 
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by doxorubicin which has been shown to downregulate TOP2β in human primary cardiomyocytes 
(Jiang et al., 2018). This RNA-seq data was analysed by Dr. Simon Cockell (Bioinformatics 
Support Unit, Newcastle University) for differential gene expression analysis of CBR1 gene. CBR1 
gene was downregulated by 2.48 (padj 0.0002931585) and 2.64 (padj 0.0002036932) fold at 1 and 
2.5 μM doxorubicin respectively against control. This might be a secondary effect of TOP2β 
downregulation by doxorubicin, as the same data showed TOP2β downregulation by 2.24 (padj 
9.448 E-08) and 2.29 (6.82292 E-08) fold at 1 and 2.5 μM doxorubicin respectively against control. 
Many studies have suggested that TOP2β regulates targeted genes by binding to or near their 
promoter regions (Lyu et al., 2006; McNamara et al., 2008; Tiwari et al., 2012; Madabhushi et al., 
2015b; Manville et al., 2015; Uusküla-Reimand et al., 2016; Canela et al., 2017; Feng et al., 
2017a). Based on this, it has been proposed that TOP2β might bind a region at the CBR1 gene. We 
designed four different primers at CBR1 genomic locus (Figure 5.7). ChIP-qPCR results showed 
that TOP2β binds at the four regions tested with no specific preference amongst them (Figure 5.11). 
This assumption is aided by the fact that CBR1 is a small gene (3,254 bases). 
On the other hand, the recruitment of four transcription factors at the promoter region of CBR1 was 
tested in both Nalm6WT and Nalm6BKO4. Results showed a significant decrease in ChIP signal for 
USF2 (10 fold), C-Myc (1 fold), and MAX (3.5 fold) transcription factors in the TOP2B knockout 
clone with USF2 most markedly reduced (Figures 5.12, 5.14). Next, we asked the question of 
whether this reduction in ChIP signal of these transcription factors in Nalm6BKO4 was due to lower 
expression or reduced recruitment by a TOP2β-mediated molecular mechanism. For this purpose, 
mRNA levels of USF1, USF2, C-Myc, and MAX transcription factors was determined by RT-qPCR 
in both Nalm6WT and Nalm6BKO4. RT-qPCR results indicated that TOP2B knockout did not affect 
the expression of these transcription factors (Figures 5.13 and 5.15). This suggests that TOP2β is 
required for CBR1 transcriptional regulation by mediating the recruitment of transcription factors 
into the promoter which in turn activate gene expression.        
Different mechanisms have been suggested to elucidate how TOP2β regulates the expression of 
genes that it acts on. One possible mechanism could be that TOP2β supports transcriptional 
elongation through its topological-related activity to alleviate transcription-induced supercoiling 
that suppress progression of transcriptional machinery. In support of this mechanism, it has been 
shown that TOP2 is more required for active promoters (Kouzine et al., 2013; Naughton et al., 
2013; Bunch et al., 2015). It has been shown that the catalytic activity of TOP2β in particular is 
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required for rendering chromatin architecture more permissive for initiation of transcription 
(LeRoy et al., 2000; Racki et al., 2009). These two mechanisms are more relevant for 
developmentally regulated genes.  
Another mechanism is suggested for genes induced by stimuli such as ligands. This mechanism 
involved TOP2β-mediated DNA double stranded break (DSB) at the promoter of stimulus-induced 
genes leading to generate a chromatin environment that is preferable for initiation of transcription. 
Studies that suggest this mechanism involved the requirement of TOP2β to the promoter upon 
stimulation by ligands such as estradiol (Ju et al., 2006), androgen (Haffner et al., 2010), retinoic 
acid (McNamara et al., 2008), glucocorticoid (Trotter et al., 2015), or insulin (Wong et al., 2009). 
However, in our study, results showed differential gene expression without induction with ligand. 
In addition, our model (Nalm6) did not show a response to either ATRA (Appendix figure 16 and 
17) or vitamin D3 (Appendix figure 15).  
Exploring the publically available ChIP data over and around CBR1 locus showed that CBR1 gene 
is flanked by two CCCTC-binding factor (CTCF) sites which are also corresponding to etoposide-
induced END-seq peaks and that presumably correspond to CTCF/TOP2β binding sites (Figure 
5.19). It has been shown that TOP2β interacts with CTCF at topological domains and has a role in 
controlling supercoiling within chromatin loops by generating DNA double-stranded breaks at 
these sites (Uusküla-Reimand et al., 2016; Canela et al., 2017). Therefore, it is possible that CBR1 
gene resides in a chromatin loop bounded by these two CTCF/TOP2β sites and thus in the absence 
of TOP2β, lack of supercoiling control could lead to altered expression of genes such as CBR1 




















IGV snapshot of human CBR1 gene landscape shows from top to bottom: END-seq DSBs profiles of Nalm6 cells treated with or without 
etoposide. CTCF ChIP signals in non-treated Nalm6. H3K4me3 ChIP signal in GM12878 cell line from ENCODE database. DnaseSeq signal 






Figure 5-20 Our data links two factors implicated in doxorubicin-induced 
cardiotoxicity. 
Studies have shown the role of each of TOP2β and CBR1 in doxorubicin-induced cardiotoxicity 
independently of each other. On one hand, TOP2B deletion from mouse cardiomyocyte protects 
from doxorubicin-induced cardiotoxicity (Zhang et al., 2012). The fact that TOP2 catalytic 
inhibitor (ICRF-187) is clinically used as a cardioprotectant supports this role of TOP2β in 
cardiotoxicity (Hensley et al., 2009). On the other hand, lines of evidence have shown the role of 
CBR1 in doxorubicin-induced cardiotoxicity. Most importantly, human CBR1 overexpression in 
mouse heart increases cardiotoxicity induced by doxorubicin (Forrest et al., 2000), and Cbr1 
downregulation protects mouse from doxorubicin-induced cardiotoxicity (Olson et al., 2003). So 
far, no data links these two independent factors in cardiotoxicity induced by doxorubicin. Here, we 
showed a molecular mechanism whereby the cardioprotection effect seen upon TOP2β inhibition 
might be due to decreased CBR1 enzyme activity and hence decrease in doxorubicin reduction into 










Unfortunately, I could not test the effect of TOP2B knockout on CBR1 expression in 
cardiomyocytes and this would be one of the most interesting plans of future work. These results 
have a clinical implication as it suggests that the factors implicated in the cardiotoxicity are 
interconnected, highlighting a question of whether the priority would be to inhibit TOP2β (by 
catalytic inhibitors such as ICRF-187 or other agents) or to inhibit the CBR1 enzyme in order to 
achieve an effective doxorubicin antitumor activity with the least cardiotoxicity. Consideration 
would take into account that TOP2β itself is a target for doxorubicin for antitumour activity, while 
CBR1 enzyme is involved in the production of doxorubicinol, which has less antitumour but higher 
cardiotoxic effect than the parent compound as reviewed in the introduction of this chapter. 
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6 Chapter Six: TOP2β role in gene expression and ATRA-induced 
differentiation of SH-SY5Y cells.    
6.1 Introduction 
As described in chapter four introduction, TOP2β has an important role in transcription and 
regulation of genes in various systems with particular importance in neuronal development. The 
earliest evidence of TOP2β’s role in neuronal development was shown by (Giovanni Capranico 
and Zunino, 1992). This study showed an interesting shifting in expression pattern of Top2 
isoforms over development of normal murine tissue where Top2b was specifically induced in brain 
but not in liver at the post-natal stage. Similar findings were shown in a rat study (Tsutsui et al., 
1993).  
This was followed by studying Top2 isoform distribution in rat brain during development 
(Watanabe et al., 1994). This study showed that Top2a was expressed in the ventricular region at 
the ante-natal stage, and exclusively expressed at the mitotic regions at the first two weeks of post-
natal stage. Top2a expression then rapidly decreased and completely disappeared by 21 days post-
natal. On the other hand, Top2b was shown to be expressed ubiquitously in the brain at all stages 
(Watanabe et al., 1994). Subsequently, closely related findings were shown in studies with human 
tissues (Zandvliet et al., 1996; Turley et al., 1997). 
The essential role of Top2b in neuronal development was determined for the first time using Top2b 
murine knockout model reported by (Yang, 2000). Since then, various studies focusing on role of 
TOP2β in neuronal development have been conducted (Tsutsui et al., 2001b; Lyu and Wang, 2003; 
Lyu et al., 2006; Nur et al., 2007; Sano et al., 2009; Nevin et al., 2011; Tiwari et al., 2012; Li et 
al., 2014; Madabhushi et al., 2015b) as reviewed in chapter four introduction. 
TOP2β has been shown to be necessary for neurite outgrowth in rat cerebellar and cortical neurons 
in culture, differentiating PC12 cells by neurotrophic growth factor (NGF), embryonic murine 
cortical neurons (Nur et al., 2007), mouse dopaminergic neurons, ventral mesencephalic mouse 
primary culture (Heng et al., 2012), and human mesenchymal stem cell-derived neurons (Isik et 




In support of TOP2β’s role in neuronal development, a de novo TOP2B mutation was shown to be 
linked to global developmental delay, intellectual disability, and autism disorder in a case study 
(Lam et al., 2017). Indeed, a study showed that TOP2β regulates expression of long genes 
associated with autism in human and mouse neurons (King et al., 2013). In addition to the role in 
neurogenesis, TOP2β has been shown to play a role in maintaining genome stability of neurons 
and its level of expression is reported to reduce with age in rat (Kondapi et al., 2004; Mandraju et 
al., 2011; Gupta et al., 2012; Bollimpelli et al., 2017)   
In the context of transcription, various studies revealed TOP2β’s role in the expression of genes 
involved in neuronal development and maintenance. For instance, Top2b inhibition in cultured rat 
neurons reduced expression of amphiphysin I, an essential gene for neuronal function (Tsutsui et 
al., 2001b). Top2b deletion reduced reelin expression in mouse embryos (Lyu and Wang, 2003). 
Microarray analysis of mouse brains lacking Top2b revealed regulation of genes involved in 
neuronal activities such as axon guidance and synaptic transmission (Lyu et al., 2006). 
Top2b was shown to bind and regulate neuronal genes in mouse embryonic stem cell-derived 
postmitotic neurons (Tiwari et al., 2012). Top2b deletion led to degeneration of postmitotic neurons 
and was accompanied by downregulation of genes highly enriched for GO terms associated with 
neurogenesis. Contrasting transcriptionally regulated genes in Top2b knockout neurons with 
Top2b chromatin occupation sites measured by ChIP followed by array highlighted 99 genes. The 
downregulated genes within this gene set were enriched for neuronal GO terms such as nervous 
system development, generation of neurons, and transmission of nerve impulse. Moreover, 
neuronal degeneration due to lack of Top2b was caused by up regulation of Ngfr p75 which was 
shown to be a direct target for Top2b through binding to its promoter and negatively regulating its 
transcription (Tiwari et al., 2012). Another study showed that Top2b participates with chromatin  
remodeler CHD7 to regulate a set of long genes involved in neuronal function in mouse cerebellar 
granule neurons and Top2b inhibition led to downregulation of 203 of these genes (Feng et al., 
2017a). 
Moreover, another study showed Top2b has a role in motor neurons (MNs) connectivity and 
migration in mice where terminal branching of MNs was remarkably defective in Top2b knockout 
mice. This was probably due to improper Hox/Pbx-dependent transcriptional activation because of 
downregulation of both Pbx and Hox genes upon Top2b knockout (Edmond et al., 2017)     
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Another aspect of TOP2β’s role in regulation of gene expression is mediation of transcription 
activation by responses such as heat shock, serum induction (Bunch et al., 2015), neuronal activity 
induced by external stimuli (Madabhushi et al., 2015b), and ligands via nuclear receptors (Ju et al., 
2006; Haffner et al., 2010). Various studies showed that activation of expression of genes by 
ligands is associated with TOP2β-mediated DNA double-stranded breaks (DSBs) at the promoter 
of target genes as reviewed in chapter four introduction. Of those studies, (Ju et al., 2006) showed 
that retinoic acid (RA)-induced transcription activation of RARB gene in MCF-7 cells involved 
TOP2β activity. Indeed, another study showed TOP2β recruitment and binding to the promoter of 
this gene in NB4 cells upon RA treatment (McNamara et al., 2008). This suggests that TOP2β 
might be involved in transcriptional activities induced by RA in another cells as well.  
SH-SY5Y is a neuroblastoma cell line that can be induced by RA to differentiate into neuronal-
like cells (Brown et al., 2005; Riddoch et al., 2007; Bell et al., 2013), making these cells a good 
candidate to study the role of TOP2β in both RA-induced transcription and differentiation of 
neuronal cells. Other advantages of using SH-SY5Y cells are their relative ease to culture in 
comparison with primary neurons, their human origin enables study of human specific proteins 
with no ethical issues unlike use of primary neurons (Kovalevich and Langford, 2013)   
The SH-SY5Y cell line is a heterogeneous cell population, a characteristic feature of neuroblastoma 
cells (Biedler et al., 1973; Biedler et al., 1978; Ross et al., 1983). SH-SY5Y cells involve three 
subpopulations: neuroblastic cells (N-type), substrate-adherent (S-type), and intermediate (I-type) 
cells (Ross et al., 1983; Walton et al., 2004). Although these subpopulations show different   
biochemical and phenotypic characteristics, they are not genetically distinct, as one subpopulation 
can be switch into another (Ciccarone et al., 1989; Ross and Spengler, 2007), suggesting that these 
differences could be due to epigenetic reasons. 
N-type cells are characterized by small rounded body shape with limited cytoplasm and short 
neuritic processes and grow as weakly attached cell aggregates. These cells represent the majority 
of SH-SY5Y population and bear neuronal biochemical properties such as neurotransmission 
enzyme activity (Biedler et al., 1978; Ciccarone et al., 1989; Walton et al., 2004). 
S-type cells are characterized by larger body size, expansive cytoplasm, flattened appearance, 
stronger attachment properties, and epithelial-like morphology (Ross et al., 1983; Walton et al., 
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2004). These cells do not behave as neuronal cells, rather they show features of Schwann, glial, 
and melanocytic cells (Ciccarone et al., 1989; Ross et al., 1995).                                                        
I-type cells represent an intermediate state between N- and S-type. These cells show morphological 
and phenotypical characteristics of both N- and S- type, and have moderate features with respect 
to cytoplasm level, attachment properties, and neuritic processes (Ross et al., 1995; Walton et al., 
2004). I-type cells might either be a progenitor cells that can give rise to either S- or N-type (Ross 
et al., 1995), or it represents an intermediate stage in the process of trans-differentiation between 
the N and S phenotypes. N- and S-type cells have the ability to switch into each other directly (Ross 
et al., 1983; Ross and Spengler, 2007). 
SH-SY5Y cells represent a well-defined model for neuronal differentiation in culture. These cells 
can be induced to differentiate using different agents (Teppola et al., 2016) with retinoic acid (RA) 
representing the most prevalent agent used in differentiation protocols of SH-SY5Y cells 
(Kovalevich and Langford, 2013). Upon RA-induced differentiation, SH-SY5Y cells show small 
rounded cell body with long, straight, and less branched neurite outgrowth (Bell et al., 2013; 
Teppola et al., 2016)      
Retinoic acid (RA) is an oxidation derivative of vitamin A (retinol) that plays a key role in various 
biological contexts including growth, development, transcriptional regulation, and differentiation 
(Chambon, 1996; Ross et al., 2000). RA has several isoforms that either occur naturally such as 
all-trans-retinoic acid (ATRA), 9-cis-retinoic acid (9cRA) or synthetic such as 13-cis-retinoic acid 
(13cRA) (Redfern et al., 1995; Ross et al., 2000; Reynolds et al., 2003). 
Signalling pathways by which retinoic acid (RA) acts in transcriptional regulation starts upon the 
introduction of RA into the cell where it becomes bound by cellular retinoic acid-binding proteins 
1 or 2 (CRABP1 or CRABP2) which renders RA soluble and protected in the aqueous environment 
of cytoplasm. CRABP1 introduces RA to the 26 subfamily of cytochrome P450 superfamily 
enzymes (CYP26A1, CYP26B1 and CYP26C1) which control RA level by catalysing oxidative 
metabolism reactions. On the other hand, CRABP2 transfers RA into the nucleus and delivers it to 
the retinoid receptors by direct protein-protein interactions (Rhinn and Dollé, 2012).  
Within the nucleus, RA binds to two families of retinoid receptor: the retinoic acid receptors 
(RARs) and the retinoid X receptors (RXRs) which act together as heterodimers. Both families 
have three different isotypes: α, β and γ, which are encoded by a unique gene and each isotype has 
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at least two different isoforms (Bastien and Rochette-Egly, 2004; Rhinn and Dollé, 2012). In the 
absence of RA, these RAR/RXR heterodimeric nuclear receptors bind specific DNA sequences at 
the RA-sensitive genes called retinoic acid response elements (RAREs) and repress transcriptional 
activation of target gene by recruiting repressing complexes. Upon RA binding to the RAR/RXR 
heterodimer receptor, a conformational change occurs leading to dissociation of co-repressors and 
recruitment of co-activators. These activities result in chromatin decompaction which allow 
transcription machinery to assemble at gene promoters and hence activate gene transcription. The 
extent and time of RA response is controlled by degrading of RAR RXR retinoid receptors through 
an ubiquitin-proteasome-dependent mechanism (Bastien and Rochette-Egly, 2004; Rhinn and 
Dollé, 2012).  
6.2 Aims 
As mentioned in the introduction, TOP2β was shown to be required for neuronal development in 
animal models. The first aim of this chapter was to test the role of TOP2β in a human neuronal cell 
model. SH-SY5Y cell line was used for this purpose. SH-SY5Y can be induced to neuronal 
differentiation by ATRA. So far, no data is available about the differentiation and gene expression 
in a TOP2B knockout model of this cell line. On the other hand, TOP2β has been shown to be 
involved in regulation of RA-targeted genes in two different cell lines (Ju et al., 2006; McNamara 
et al., 2008). This suggests that TOP2β might be involved in transcriptional activities induced by 
RA in other cells as well. For these reasons, SH-SY5Y represents a suitable model to test these two 
aspects of TOP2β roles. To address this, the following experimental objectives were followed:  
• Generate a TOP2B Knockout model in the human neuroblastoma SH-SY5Y cell line using 
CRISPR technique. 
• Study the effect of the TOP2B knockout on ATRA-induced differentiation in SH-SY5Y 
cells by determining neurite outgrowth formation using phase-contrast microscopy as well 
as using BCL gene expression as a molecular marker of differentiation. 
• Study the effect of knocking out of TOP2B on the induction of CYP26A1, RARB, 
CRABP2, and RET (genes involve in ATRA-induced differentiation pathway). 
• Investigate the effect of a TOP2B knockout on whole genome expression in SH-SY5Y cells 
in the presence and absence of ATRA treatment using RNA-seq. 
• Perform gene enrichment analysis to highlight the biological functions and molecular 




6.3.1 Generating TOP2B knockout clones by CRISPR  
TOP2B knockout was performed by CRISPR technology as described in detail in the materials and 
methods chapter (section 2.15). As no one was using the CRISPR technique in our lab, there was 
a need to optimize this technique. The generation of knockout clones was not straightforward and 
different reagents were used through the experimental workflow before optimizing conditions for 
nuclefection, selection, and screening for knockout clones. The CRISPR timeline is outlined in 
(Figure 6.1). Once conditions were optimized, differernt TOP2B knockout clones of SH-SY5Y 
were successfully generated and used in this chapter as well as different TOP2B knockout clones 
of both Nalm6 and K562 cells which were used in the previous chapter. 
Work was started by genomic editing design which includes: designing guide RNA (gRNA) 
oligonucleotides, bioinformatical testing of their predicted off-target effects, and designing a 
primer required for genotyping (TOPKO1 primer) (Figure 6.1, step 1). Transfection efficiency 
using nucleofection reagents was then tested using PmaxGFP plasmid as a positive control (Figure 
6.1, step 2). Then I cloned the gRNA in PX459 vector (see Appendix table 16 for sequence), a 
plasmid encoding both cas9 system and puromycin resistance as a selection marker (Figure 6.1, 
steps 3 and 4). Then I established a puromycin kill curve to determine the lowest dose that killed 
all the cells to use it for selection of transfected cells (Figure 6.1, step 5). Cells were then transfected 
by nuceofection as described in the materials and methods (section 2.15.3) and treated with 
puromycin for selection (Figure 6.1, steps 6 and 7). The kill was very high and there was no 
difference between transfected and non-transfected cells in terms of survival achieved. I decided 
to test the transfection efficiency by immunoflouresent staining of flag (see PX459 strucure, figure 
2.4) using anti-flag M2 antibody (table 2.1) (Figure 6.1, step 8). Immunoflouresence results showed 
very low transfection efficiency (Appendix figure 19). 
Subsequently, I decided to use PX458, a cloning vector that uses GFP expression as a selection 
marker in order to select and sort cells using FACS which enables sorting of enough cells for 
cloning even if the transfection efficency was low (Figure 6.1, steps 9-18). Steps 9-18 are explained 






Figure 6-1 CRISPR timeline 
This figure shows all successful and unsuccessful CRISPR steps followed in this study. Step (1) is described 
in section (2.15.1), (2) is described in section (6.3.1.1). Steps (3 and 8) are described in section (2.15.2) and 
(Appendix figure 19 and Appendix table 16). Step (8) is presented in Appendix figure 20. Steps (9-18) are 
described in section (2.15) and respective results are presented in in this chapter (for SH-SY5Y), chapter 
five (for Nalm6), and the appendix (for K562). 
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Figure 6-2 Transfection efficiency (%) in SH-SY5Y cells transfected with 
PmaxGFP plasmid. 
6.3.1.1 Determining the transfection efficiency in SH-SY5Y cells using nucleofection 
The transfection efficiency (%) was determined by transfecting SH-SY5Y cells with a plasmid 
encoding the enhanced green fluorescent protein eGFP (PmaxGFP) which was provided with the 
nucleofection kit as a positive control. SH-SY5Y cells were transfected with 2 µg PmaxGFP as 
suggested by the Lonza optimized protocol for these cells. The ratio of GFP expressing cells was 














SH-SY5Y was transfected with 2 µg PmaxGFP plasmid using Nucleofector II device (Lonza, UK) with two 






















SH-SY5Y cells were transfected with 2 µg PmaxGFP plasmid for 48 hrs. Images were captured using a TiE 
fluorescence wide field inverted microscope (Nikon) (20X magnification). 
 
Transfection efficiency (%) with the PX458 vector was then determined by transfecting SH-SY5Y 
cells with six different doses (2, 4, 6, 8, 10, and 12 µg) for 48 hrs under the same condition. Cells 
which were transfected with 6 µg showed the best transfection efficiency of ~10% as presented in 
(Figure 6.4). The 6 µg dose therefore was used in further experiments. GFP expression was 
visualised by live cell imaging (Figure 6.5). Lower transfection efficiency with PX458 vector might 
be because PX458 and PmaxGFP vectors have different promoters. PmaxGFP uses the CMV 
promoter while PX458 uses the U6 promoter. In addition, PX458 size is (~ 9.3 Kb) compared with 









Figure 6-4 Transfection efficiency (%) in SH-SY5Y cells transfected with different 
doses of PX458 vector. 


























SH-SY5Y cells were transfected with 6 µg PX458 plasmid for 48 hrs. Images were captured using a TiE 





Figure 6-6 Digestion test to verify gRNA cloning into PX458 vector 
6.3.1.2 Verifying gRNA cloning with restriction digests and Sanger sequencing   
Cloning of gRNA into PX458 vector is described in section (2.15.2). PX458 vector has a pair of 
BbsI restriction sites. Successful gRNA insertion should destroy the BbsI restriction site. In 
addition, PX458 has a unique EcoRV restriction site. Therefore, a digestion test using these two 
restriction enzymes should give a single band for successful insertion and two bands for 
unsuccessful insertion (Figure 6.6). For successful insertions, samples were sent for Sanger 
sequencing at (GATC Biotech) according to their sample requirements (see Table 6.1). The 
forward primer of Human U6 promoter, LKO.1 5’ was used. Verified plasmid samples were 
purified again to provide sufficient quantity by midiprep using Qiagen Plasmid Midi Kit according 








































































Figure 6-7   T7 Endonuclease I digestion test to determine gRNA efficiency. 
6.3.1.3 Determining the efficiency of gRNA in generating genome editing   













Samples were prepared for (2%) agarose gel electrophoresis as described in (section 2.15.5). Briefly, successfully transfected cells were selected as a pool 
and DNA was extracted. The genomic region which is targeted by CRISPR was amplified by PCR. This was followed by denaturation and reannealing to 
produce heteroduplex DNA fragments. These duplexes were then digested with T7 Endonuclease I, a DNA nuclease that targets any mismatch of more 
than one base pair. Digestion products were visualized by gel electrophoresis which allows determination of the ratio of edited fragments. (*) Gel did not 
show a modified amplification products which might be because the difference between wild type and genetically modified species was very small and 
below the agarose gel resolution (2%). This is because the TOPKO19 reverse primer was only five bases long from gRNA5 due to primer design limitations 
in this genomic region. 
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6.3.1.4 Screening for TOP2B knockout clones 
Out of about 168 clones which were isolated and expanded, 64 clones were checked for TOP2β 
expression before genotyping because they were confluent and ready to be checked at Christmas 
time and I could not use Sanger sequencing service for 2 weeks. Immunofluorescence was used, 
as it does not need as many cells as western blotting.    
6.3.1.4.1 Immunofluorescence  
Immunofluorescence was performed as described in (section 2.15.7.2) using anti-TOP2B antibody 
(4555) (Table 2.1). Nalm6B-/- cells, which was previously described, were included in the screening 
process as a negative control. Out of the 64 clones under screening, fifteen clones were negative 
for TOP2B. In addition, one clone gave weak signal (clone 142) so it was included in the further 













































Cells were prepared for immunofluorescence as described in section (2.15.7.2) and stained with TOP2B 
(4555) antibody followed by Alexa fluor®488 secondary antibodies then immunofluorescence signal was 
captured via FITC channel. 
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Figure 6-9 Agarose gel electrophoresis of suspected knockout clones. 
6.3.1.4.2 Genotyping 
The 16 clones were further analysed by performing DNA extraction and PCR amplification of 
targeted genomic region using TOPKO1 primer as described in (section 2.15.7.1). Clone bands 
which were different from the wild type were extracted from the gel and sent for sequencing (Figure 




















Samples were prepared for genotyping as described in section (2.15.7.1) and run on (3 %) agarose gels to 




Clone gRNA Mutation 
26 5 Wild:     CGGCGGCAACGGGGCACTGACCTGGGTGGTAAGTGGCTGGA Clone:    CGGCGGCAACGGGGCACT...ACCTGGGTGGTAAGTGGCTGGA 
34 6 Wild:    ACTCGCCATGGCCAAGTCGGGTGGCTGCGGCGCGGGAG Clone:  ACTCGCCATGGCCA…..TCGGGTGGCTGCGGCGCGGGAG 
41 6 Wild:  GCACTCGCCATGGCCAAGTCGGGTGGCTGCGGCGCGGG Clone: GCACTCGCCATGGC…………………………………GCGGG 
70 5 Wild:     GCGGCGGCAACGGGGCACTGACCTGGGTGGTAAGTGGCTGG Clone:   GCGGCGGCAAC…………………...CTGGGTGGTAAGTGGCTGG 
82 6 Mutation sequence could not be confirmed. 
98 6 Wild:    AGGCACTCGCCATGGCCAAGTCGGGTGGCTGCGGCGCGGGAG Clone:   AGGCACTCGCCATGGCCAA……….GTGGCTGCGGCGCGGGAG 
112 6 Wild:   AGGCACTCGCCATGGCCAAGTCGGGTGGCTGCGGCGCGGGAG Clone: AGGCACTCGC……………………..GGGTGGCTGCGGCGCGGGAG 
123 7 Wild:   TGGCCAAGTCGGGTGGCTGCGGCGCGGGAGCCGGCGTGGGCG Clone: TGGCCAAGTCGGGTGGCTGC….…….GGGAGCCGGCGTGGGCG 
129 7 Wild: TCGCCATGGCCAAGTCGGGTGGCTGCGGCGCGGGAGCCG Clone: TCGCCATGGCCAAGTCGGGTGGCTGC……….GGGAGCCG 
 













Figure 6-10 TOP2B western blotting of candidate knockout clones (first group). 
6.3.1.4.3 Western blotting 
In addition to immunofluorescence, clones were then tested for TOP2β expression using western 
blotting as described in section (2.15.7.2). Western blotting results were consistent with 






















Clone protein samples (5 µg of WCE / lane) were probed with (A) TOP2B (30400) (B) TOP2B (4557) or 
(C) TOP2B (MAB6348) antibodies. 
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Figure 6-11 TOP2B western blotting of candidate knockout clones (second group). 
 
  















Clone protein samples (5 µg of WCE / lane) were probed with (A) TOP2B (4557) and (B) TOP2B 
(MAB6348) antibodies. 
 
In summary, Clones no. (26, 34, 41, 70, 98, 112, 123, and 129) were confirmed for both absence 








6.3.2 Effect of TOP2B knockout on SH-SY5Y cells 
6.3.2.1 Effect of TOP2B knockout on ATRA-induced differentiation of SH-SY5Y cells 
To determine the effect of TOP2β absence on ATRA-induced differentiation of SH-SY5Y, three 
TOP2B knockout clones (70, 98, and 129) were compared with the wild type for neurite outgrowth 
formation induced by ATRA. These clones were selected for this assay and further analysis as they 
derived from different gRNAs as shown in (Table 6.2). ATRA treatment reduces growth of SH-
SY5Y cells compared with the untreated cells (observation confirmed in lab). As overconfluency 
of cells prevents accurate counting of neurite bearing cells, the initial number of seeded cells was 
optimized in such a way that both ATRA-treated and untreated cells have a comparable confluency 
by the end of time-course of differentiation (7 days). This was to ensure a comparable number of 
cells that can be counted in both samples. For differentiation induction, cells were treated with 
either (10 μM) ATRA or ethanol (0.01 % V/V) for 7 consecutive days and media was replaced 
every 2 days to keep ATRA concentration consistent over differentiation period. Cells were then 
imaged by phase-contrast microscopy using a TiE fluorescence wide field inverted microscope 
(Nikon). Random fields were captured for each sample and the ratio of cells showing neurite 
outgrowth of more than 50 μm long were determined for each sample.  
Results showed that TOP2B knockout clones showed significant reduction in the ratio of neurite 
outgrowth bearing cells. Representative fields and quantification analysis of neurite outgrowth 
bearing cells are shown in (Figure 6.12). 
In addition to morphological characterization of differentiation by neurite outgrowth assay, 
differentiation level was also determined biochemically by measuring the level of BCL2, a proto-
oncogene that has been shown to be associated with neuronal development (Garcia et al., 1992; 
Merry et al., 1994) and increased in SH-SY5Y upon retinoic acid-induced differentiation (Hanada 
et al., 1993; Lasorella et al., 1995; Riddoch et al., 2007; Bell et al., 2013). BCL2 level was 
determined at the molecular level by measuring mRNA using RT-qPCR in the presence or absence 
of differentiation induction for 24 hrs. 
Results showed marked reduction of BCL2 expression in TOP2B knockout clones compared with 



































Figure 6-12 Morphological differentiation in wild type and TOP2B knockout SH-
SY5Y clones induced by ATRA. 
SH-SY5Y Cells were treated with either vehicle EtOH or 10 μM ATRA for 7 consecutive days. Cells were 
seeded at initial number of 4000 cells/well for control (ATRA (-)) cells, and at 8000 cells/well for ATRA 
treated (ATRA (+)) cells in order to have a comparable number of cells that can be counted in both samples 
after 7 days (A) Phase-contrast images of cells were captured at the end of treatment using a TiE 
fluorescence wide field inverted microscope (Nikon). Differentiated cells (ATRA treated) exhibit neurite 
extensions (arrow). Cells that exhibited neurites of ≥ 50 μm in length were counted as differentiated. Images 
shown are representative of at least three independent replicates. Scale bars represent 50 μm. (B) 
Differentiated-to-total cells ratio per field were calculated for both control and treated groups. Mean ratio 
of several random fields per sample were calculated. Basal ratio of differentiated cells in control groups 
were then subtracted. Data presented here is the mean of at least three independent experiments with error 



















Figure 6-13 Relative BCL2 gene induction by ATRA treatment for 24 hours. 
Relative gene expression was determined by RT-qPCR analysis as described in section (2.14.3). PP1A gene 
was used as a reference gene for data normalization. Cells were treated with or without 1 μM ATRA for 24 
hrs and ΔΔCt method was used to calculate fold change induction above control for each clone. Data 
presented here is the mean of at least three independent experiments with error bars representing the SEM.  
(*P≤0.05, **P≤0.01, and ***P≤0.001), Significance of difference was tested using unpaired t-test. 
 
6.3.2.2 Effect of TOP2B on genes involved in the ATRA-induced differentiation pathway 
Results above showed that the absence of TOP2β affected ATRA-induced differentiation of SH-
SY5Y cells. The next step was to test the effect of knocking out TOP2B on the expression of 
(RARB, CYP26A1, CRAPB2 and RET), genes that have been shown to be regulated by retinoic acid 
and to be involved in the retinoic acid-induced differentiation pathway (Perez-Juste and Aranda, 
1999; Brabender et al., 2005; Oppenheimer et al., 2007). The wild type SH-SY5Y cells and the 
knockout clones (BKO-70, BKO-98, and BKO-129) were treated with or without 1 µm of all-trans 
retinoic acid (ATRA) for 24 hours and RNA samples were extracted for RT-qPCR to the determine 
difference between the wild type and knockout clones in the relative induction of these genes 
(Figure 6.14). 
Results showed a significant reduction in ATRA-induced expression of both CRABP2 and 
CYP26A1 genes, while no significant difference were seen between wild type and knockout clones 
in induction of RARB and RET genes (Figure 6.14).  
167 
 



















Relative gene expression was determined by RT-qPCR analysis as described in section (2.14.3). PP1A gene 
was used as a reference gene for data normalization. Cells were treated with or without 1 μM ATRA for 24 
hrs and ΔΔCt method was used to calculate the fold change in induction above control for each clone. Data 
presented here is the mean of at least three independent experiments with error bars representing the SEM. 








6.3.3 Effect of TOP2B knockout on whole transcriptome by RNA sequencing analysis   
The effect of TOP2B knockout on whole genome expression in SH-SY5Y with and without ATRA 
treatment was determined using RNA-seq. The TOP2B knockout (BKO-98) clone was selected for 
RNA-seq experiment as it was generated from gRNA number 6 which was predicted to have the 
least off-target effect (see table 2.7). Four biological replicates of both wild type and BKO-98 clone 
were treated with either (10 μM) ATRA or ethanol (0.01 % V/V) for 24 hours. Cells were then 
harvested and total RNA samples were extracted as described in section (2.14.1). RNA samples 
were then tested for quantity and quality using (Agilent 2100 Bioanalyzer System) as described in 
section (2.14.2.1) and presented in (Table 6.3 and Figure 6.15). Library preparation for sequencing 
and analysis are explained in section (2.14.2). 
 






1 WT (Con) 634 9.9 
WT (RA) 627 9.9 
BKO-98 (Con) 624 10 






2 WT (Con) 660 10 
WT (RA) 630 9.9 
BKO-98 (Con) 612 10 






3 WT (Con) 739 10 
WT (RA) 782 9.9 
BKO-98 (Con) 703 10 






4 WT (Con) 661 10 
WT (RA) 735 10 
BKO-98 (Con) 652 10 
BKO-98 (RA) 590 10 
 








Figure 6-15 Quality of SH-SY5Y RNA samples used in RNA-seq experiment 
This figure shows electropherogram summary with RIN number of RNA samples used in RNA-seq as 







Figure 6-16 PCA analysis of conditions in RNA-seq experiment in SH-SY5Y 
RNA-seq data for the four conditions (WT (Con), WT (RA), BKO-98 (Con), and BKO-98 (RA)) 
were tested for Principal Component Analysis (PCA), a statistical technique used to confirm the 
variation and show the patterns in a dataset. PCA analysis confirmed a consistency between 












PCA analysis of the four conditions used in the RNA-seq experiment in SH-SY5Y cells was performed 
using DESeq2 package in R software (version 4.3). 
 
6.3.3.1 Differential gene analysis 
The differentially expressed genes (DEGs) in the presence or absence of TOP2β with or without 
ATRA were determined by RNA-seq analysis as described in section (2.14.2.3). Four comparisons 
were performed: wild type against BKO-98 without ATRA (WT(C) vs. BKO(C)), wild type against 
BKO-98 with ATRA treatment (WT(R) vs. BKO(R), untreated against treated wild type (WT(C) 
vs. WT(R), untreated against treated BKO-98 (BKO(C) vs. BKO(R). Differential gene analysis 
showed large number of genes which were significantly (padj < 0.05) either up or down regulated 
by more than 1 log2 fold in the four comparisons. Volcano plots of these genes are depicted in 






















Volcano plots show differential gene expression in 4 different comparisons in SH-SY5Y cells. Genes which 
were significantly (padj < 0.05) either up or down regulated by more than 1 log2 fold are labelled. Adjusted 
P value (padj) represents p-value adjusted for multiple testing correction using Benjamini-Hochberg method 
to control the False Discovery Rate (FDR). Plus and minus log2 values correspond to magnitude of change 





Figure 6-18 Differentially expressed genes of 4 conditions of RNA-seq in SH-SY5Y 
For listing the highly regulated genes in a summarized way, the total number of genes which were 
differentially expressed (whether up or down regulated) by more than 1 log2 fold in each 
comparison were analysed for intersection between conditions and presented as Venn diagram with 
genes were categorized as groups from A to O. The full list of these gene groups with padj and 












Venn diagram shows the number of genes which were significantly (padj < 0.05) changed by more than 1 
log2 fold in the four comparisons. Letters represent category allocated to gene groups to identify them in 
(Appendix table 17). The Venn diagram was generated using gplots package in R. the full gene lists are in 
(Appendix table 17).  
 
Generally, RNA-seq analysis for differential gene expression revealed a large number of genes 
changed by more than 1 log2 fold in all comparisons (Figure 6.17). Notably, the number of genes 
which were up or down regulated in the wild type upon ATRA treatment was higher than that in 
the TOP2B knockout cells (1129 vs. 777 up- and 694 vs. 543 down-regulated) respectively (Figure 
6.17). The genes which were regulated by ATRA in the wild type but not in the knockout cells are 




RNA-seq analysis following ATRA treatment for 24 hrs showed different levels of expression of 
a number of neuronal differentiation markers such as BCL2, MAP2 (codes for microtubule 
associated protein 2), SYP (codes for synaptophysin), and GAP43 (codes for growth associated 
protein 43) between wild type and TOP2B knockout cells. These markers have been shown to be 
induced by RA in SH-SY5Y cells in various studies (Hanada et al., 1993; Cheung et al., 2009; Bell 
et al., 2013; Kovalevich and Langford, 2013; Yan et al., 2015). For BCL2, in agreement with the 
previous RT-qPCR results of BCL2 (Figure 6.13), RNA-seq results showed a significant reduction 
in the induction of BCL2 gene in the TOP2B knockout clone by 2.2 log2 fold (padj = 1.85E-118). 
For MAP2, SYP, and GAP43 expression levels, the knockout cells showed reduction (by 1.83, 1.4, 
and 2.5 log2 fold respectively) compared with the wild type. 
Moreover, ATRA treatment led to a remarkable downregulation of MYC, a cell cycle release gene 
that is well known for activating cyclins and cyclin-dependent kinases (CDKs). In addition, MYC 
decreases the level/activity of proteins involved in cell cycle repression such as p21 (encoded by 
CDKN1A gene) (Garcia-Gutierrez et al., 2019). MYC downregulation by ATRA was significantly 
higher in the wild type than the knockout cells (by 2.1 log2 fold, padj = 1.30E-96). This was 
accompanied by up regulation of CDKN1A (by 1.1 log2 fold, padj = 8.35E-36) in wild type cells 
only, and the CCN1A gene (encodes for cyclin A) in both wild and knockout cells with higher 
upregulation in the wild type by 1.2 log2 fold (padj = 3.45E-14). These results support the previous 
microscopic and RT-qPCR results of different levels of differentiation between wild type and 
knockout cells. 
On the other hand, ATRA treatment for 24 hrs did not cause significant change in TOP2α 
expression in either the wild type or the knockout cells nor in TOP2β expression in the wild type, 
suggesting no direct effect of ATRA on both isoform or treatment for 24 hrs was not be enough to 
cause significant change. Longer ATRA treatment (~3-5 days) caused a robust downregulation of 
TOP2A (preliminary lab data).                  
RNA-seq analysis confirmed differential expression of a group of genes involved in metabolism 
and function of RA and regulated by RA at the same time. Differentially expressed genes (DEGs) 
which belong to this group are described in (Table 6.4). These genes are components of RA 
pathway and their induction level is controlled by RA itself (Balmer and Blomhoff, 2002; Rhinn 
and Dollé, 2012). Some of the genes of this group have well defined retinoic acid response elements 
(RAREs) (Balmer and Blomhoff, 2005) as shown in (Table 6.4).  
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Table 6-4 Differential expression of genes involve in RA pathway and regulated by 
RA itself. 
The expression of four genes (RARG, FABP5, AKR1C3, and PDK4) in this group were induced 
only in the wild type cells. In addition, ATRA treatment induced expression of 8 genes in this group 
(RARA, CRABP2, RARB, CYP26A1, CYP26B1, RDH10, DHRS3, and RET) in both the wild type 
and the knockout cells but the induction was much higher in the wild type for 4 genes (CRABP2, 
CYP26A1, CYP26B1, and DHRS3) which were also significantly downregulated in the absence of 
TOP2β even without RA induction (Table 6.4). Reduced induction of two of these genes (CYP26A1 
and CRABP2) were previously shown in the knockout cells using RT-qPCR as shown in (Figure 
6.14). RET oncogene also was remarkably regulated by RA (Table 6.4) and it was included to this 
group as it has been shown to play a key role in transcriptional events related to RA-induced 
differentiation (Oppenheimer et al., 2007). This gene also has been shown to be involved in nervous 












Table shows genes that are involved in RA metabolism and signalling pathway and were differentially 
expressed by (> 1 log2 fold and < 0.05 padj) in the 4 comparisons in SH-SY5Y using RNA-seq. Adjusted 
P values (padj) represents p-value adjusted for multiple testing correction using Benjamini-Hochberg 
method to control the False Discovery Rate (FDR). Padj value of zero means very low value that fall out of 
calculation scale. RARE information was obtained from (Balmer and Blomhoff, 2002; Balmer and 





RNA-seq analysis showed numerous differentially expressed genes (DEGs) with various functions. 
The effect of this differential expression will be discussed in light of respective biological function 
and pathways in which these (DEGs) are involved. DEGs were evaluated for their involvement in 
biological functions and pathways using QIAGEN’s Ingenuity Pathway Analysis (IPA, Spring 
release 2019, QIAGEN Redwood City, USA, www.qiagen.com/ingenuity) as described in 
materials and methods (section 2.14.2.3). Further details about the key genes will be described in 
the discussion. 
6.3.3.2 Ingenuity pathway analysis (IPA) of downstream effects 
IPA analysis involved downstream effects analysis of DEGs for biological function annotations 
and canonical pathways. Functional annotations in IPA are organised into major categories and 
each category contains subcategories of more specific annotations. All the major functional 
annotations for a given comparison are shown in the results. In addition, functional annotations 
which represent a key cellular and molecular events during differentiation were further scrutinized 
for their subcategories annotations. For canonical pathways, all significantly over-represented 
neurological pathways are shown in the results as well as the top 20 significantly over-represented 
pathways of other functions. 
IPA results are presented by divided into two parts. First, shows ATRA effect on SH-SY5Y cells 
and in this part, the function annotations and canonical pathways over-represented in the (WT(C) 
vs. WT(R)) comparison are shown. Second part shows TOP2B knockout effects on ATRA treated 
and untreated SH-SY5Y and in this part, the function annotations and canonical pathways over-
represented in the (WT(C) vs. BKO(C)) and the (WT(R) vs. BKO(R)) comparisons are shown. 
6.3.3.2.1 ATRA effect 
Biological functions and pathways correlated with RA metabolism and signalling pathway 
enriched in the (WT(C) vs. WT(R)) comparison are shown in (Figure 6.19). Results confirmed 
activation of functions and pathways related to biosynthesis and metabolism of RA as well as 
activation of RA receptors like RAR and RXR. ATRA treatment induced enrichment of a wide 
range of annotations associated with cellular, molecular, and physiological processes (Figure 6.20). 
These major categories were further mined for more specific function annotations which are 




Figure 6-19 ATRA effect on functions and pathways involved in RA metabolism 

















IPA analysis of RNA-seq data from wild type SH-SY5Y cells treated with 10 μM ATRA for 24 hrs shows 
(A) Biological function annotations and (B) Canonical pathways related to RA metabolism and signalling 
pathway. Red dots represent –log10 of padj values of a function or pathway and were plotted on upper axis. 
Bars represent percentage of overlapping between DEGs in experiment and total number of genes belong 
to a given function or pathway. Red dashed line represent padj cutoff of 0.05. Padj was calculated by IPA 
algorithm using Benjamini-Hochberg multiple testing correction method. Numbers of DEGs assigned to 
function or pathway are shown in black colour. Z-score values were determined as described in (materials 
and methods, section 2.14.2.3) and represent predicted level and direction (activation or inhibition) of a 
function or pathway. Z-score value of positive (orange), negative (blue), or zero (black) represents 
activation, inhibition, or no change respectively, while (!) function or pathway is “currently ineligible for a 



























IPA analysis of RNA-seq data from wild type SH-SY5Y cells treated with 10 μM ATRA for 24 hrs shows 
all major categories of function annotations enriched. Numbers of DEGs assigned to annotation are shown 
in black colour. Red dashed line represent padj cutoff of 0.05. Padj was calculated by IPA algorithm using 






























IPA analysis of RNA-seq data from wild type SH-SY5Y cells treated with 10 μM ATRA for 24 hrs shows 
subcategories of function annotations related to cellular and morphological changes which associated with 
neurological differentiation. Numbers of DEGs assigned to annotation are shown in black colour. Red 
dashed line represent padj cutoff of 0.05. Padj was calculated by IPA algorithm using Benjamini-Hochberg 
multiple testing correction method. Bars represent minus log10 of padj values. Z-score value of positive 
(orange), negative (blue), or zero (black) represents activation, inhibition, or no change respectively, while 
(!) function or pathway is “currently ineligible for a prediction” by IPA. 
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Overall, results from (Figure 6.21) showed cellular and morphological changes toward neuronal 
differentiation. These changes included inhibition prediction of annotations for proliferation of 
tumor cells (-log10 padj = 7.8, 35 DEGs, z-score = - 0.51) and neuroblastoma cell line (-log10 padj 
= 4.4, 35 DEGs, z-score = - 0.9), colony formation of tumour cell lines (-log10 padj = 5.2, 46 DEGs, 
z-score = -0.71), growth of tumor (-log10 padj = 8.84, 40 DEGs, z-score = - 0.46), central nervous 
system solid tumor (-log10 padj = 7.84, 96 DEGs, z-score = - 1.07), nervous system neoplasm (-
log10 padj = 7.54, 101 DEGs, z-score = - 0.65), development of malignant tumor (-log10 padj = 5.99, 
132 DEGs, z-score = - 1.07), cell transformation (-log10 padj = 3.23, 18 DEGs, z-score = - 0.68) 
and activation prediction of cytostasis annotation (-log10 padj = 3, 25 DEGs, z-score = 1.54).  
This was accompanied by activation prediction of annotations for growth of neurite (-log10 padj = 
3, 12 DEGs, z-score = 0.61), differentiation of tumour cell line (-log10 padj = 4.14, 33 DEGs, z-
score = 1.54), communication of cells (-log10 padj = 9.25, 126 DEGs, z-score = 1.02), adhesion of 
tumor cell lines (-log10 padj = 3.18, 38 DEGs, z-score = 1.79), cell movement (-log10 padj = 6.95, 
181 DEGs, z-score = 2.18) and migration of cells (-log10 padj = 8.58, 172 DEGs, z-score = 1.89) 
(Figure 6.21). Undifferentiated SH-SY5Y cells are characterized by short processes. Once 
differentiated by RA, these short processes disappeared and long neurites formed. This might be 
supported by the inhibition of branching annotations upon ATRA treatment (Figure 6.21).  
IPA analysis showed over-representation of metabolism of neurotransmitter, sensory system 
development, and guidance of axons annotations without directional prediction score as they were 
not eligible for z-score calculation (see section 2.14.2.3). The DEGs involved in growth of neurites 
annotation were (APOE, BCL2, BMP4, CDK5R2, EFNB2, EPHA2, GFRA2, ITGA1, RIT1, SLIT2, 
TGM2, and TNC). BCL2 has been shown to be induced upon neuronal differentiation and was 
induced upon ATRA treatment in this study. Majority of other genes encode for neuronal receptors. 
For instance, CDK5R2 encodes a neuron-specific activator of CDK5 kinase. EFNB2 and EPHA2 
(encodes for Ephrin B2 and Ephrin Type-A Receptor 2 respectively), are members of ephrin 
receptor subfamily which has been shown to be involved in development of nervous system. 
GFRA2 gene product is a receptor for GDNF, a neurotrophic factor has a critical role in the 
differentiation and survival of neuron. ITGA1 encodes for a receptor for laminin and collagen. 
RIT1 product involves in neuron regeneration and development alongside the nerve growth factor. 




The DEGs involved in guidance of axons annotation were (GFRA1, RET, SLIT2, NRXN1, OPHN1, 
SEMA3B, GFRA2, SPTBN2, GFRA3, PRKCA, UNC5A, DOK4, CXCR4, RELN, and ANOS1). 
Products of these genes involved activator proteins, cell surface and neuronal receptors. NRXN1 
gene product is a member of neurexin receptor family which form a complex with neuroligins to 
facilitate neurotransmission at synaptic contacts. SEMA3B encodes for a member of semaphorin 
family which have a well known role in neuronal system via involvement in guidance of growth of 
neuronal cone. SPTBN2 encodes for a member of spectrins which involved in membrane-
cytoskeleton formation. UNC5A encodes for a member of family of receptors to netrin-1 which has 
a chemorepulsion activity to particular axons. RELN (Reelin) has been shown to play a key role in 
controlling cell-to cell interaction that required for neuronal migration. 
Canonical pathways that were mostly enriched from DEGs of (WT(C) vs. WT(R)) comparison are 
presented in (Figure 6.22). Eight neuronal pathways were enriched from the dataset with axon 
guidance signalling pathway the most significant pathway including the largest number of DEGs 
from the comparison dataset (47 genes) among all other pathways. From the 47 DEGs 
encompassing the axonal guidance signalling pathway, 27 genes were significantly upregulated 
(NTRK2, ENPEP, BMP4, ADAM29, PIK3CG, PRKCH, MMP28, ECEL1, SLIT2, GLI1, GNG2, 
MMP11, EPHB3, ADAMTS6, FZD7, ADAMTS2, NTRK1, RRAS, SEMA6C, PLXNA2, GLIS2, 
RAC2, SEMA3B, KALRN, ADAMTS9, PLCD3, and EFNB2) and 20 genes were downregulated 
(PLCH2, PLXNC1, PRKCA, EPHA2, UNC5A, ADAMTS4, SEMA3G, FGFR2, NOTUM, SEMA3C, 
NRP2, PAPPA, KCNJ12, WNT4, CXCR4, NTNG1, UNC5D, NTRK3, ADAMTS17, and NRP1). 
Details for differential expression of these genes are in (Table 6.6). No prediction was made for 
axonal guidance pathway because there is no one activation state for this pathway as explained in 
the materials and methods (section 2.14.2.3). 
In supporting of neuronal commitment, the synaptogenesis signaling pathway was activated upon 
ATRA treatment (-log10 padj = 1.62, 27 DEGs, z-score = 1.57) (Figure 6.22). 
The visual cycle pathway was significantly over-represented with high z-score prediction for 
activation (z-score = 2.24, DEGs = 5). This agreed with well established role of vitamin A in visual 





























IPA analysis of RNA-seq data from wild type SH-SY5Y cells treated with 10 μM ATRA for 24 hrs shows 
canonical pathways enriched. Red dots represent –log10 of padj values of a pathway and were plotted on 
upper axis. Bars represent percentage of overlapping between DEGs in experiment and total number of 
genes belong to a pathway and were plotted on lower axis. Black bars represent neuronal pathways and grey 
bars represent top 20 of other non-neuronal pathways. Numbers of DEGs assigned to a pathway are shown 
in black colour. Red dashed line represent padj cutoff of 0.05. Padj was calculated by IPA algorithm using 
Benjamini-Hochberg multiple testing correction method. Z-score value of positive (orange), negative (blue), 
or zero (black) represents activation, inhibition, or no change respectively, while (!) function or pathway is 
“currently ineligible for a prediction” by IPA. 
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6.3.3.2.2 TOP2B effect 
The effect of TOP2B knockout in SH-SY5Y cells was investigated in this study. IPA analysis was 
performed on DEGs from two comparisons: (WT(C) vs. BKO(C)) and (WT(R) vs. BKO(R) to 
investigate biological functions and pathways affected by absence of TOP2β.  
In untreated SH-SY5Y cells, TOP2B knockout induced over-representation of a range of functional 
annotations (Figure 6.23). Within the cellular molecular and molecular annotations group, 14 major 
functional annotations were over-represented with cellular movement (-log10 = 8.37, 304 DEGs), 
cell-to-cell signaling and interaction (-log10 = 8.37, 217 DEGs), and cell morphology (-log10 = 7.1, 
116 DEGs) the top 3 annotations enriched (Figure 6.23). Interestingly, within the physiological 
annotations group, nervous system development and function annotation was the most significantly 
over-represented (-log10 = 8.37, DEGs = 53). 
The major categories were further investigated into the subcategories for function annotations that 
associated with molecular and cellular events expected to be acquired or changed during neuronal 
cell development (Figure 6.24). Analysis showed over-representation of a range of cellular 
processes associated with morphology and development of neuronal cells. Key cellular processes 
involved in neuronal cell morphology were inhibited upon TOP2B knockout included cell 
spreading, microtubule dynamics, organization of cytoskeleton, assembly of cells, and formations 
of cellular protrusions (Figure 6.24). Moreover, guidance of axons and synaptic transmission were 
significantly over-represented without prediction made by IPA. On the other hand, other 
annotations such as communication of cells and secretion of neurotransmitter were activated. 
Canonical pathway analysis showed the axonal guidance signaling pathway as one of the most 
significant over-represented pathways (-log10 padj = 9.12, DEGs = 82) (Figure 6.25). 
Synaptogenesis signaling pathway showed the highest z-score among all pathways with remarkable 
inhibition prediction (z-score = - 4.24, DEGs = 50). Eleven other neuronal pathways were also 
over-represented (Figure 6.25). Other pathways that showed high inhibition prediction scores 
involved glutamate receptor signaling (z-score = - 2.31, DEGs = 180 calcium signaling (z-score = 
- 2.12, DEGs = 35) super pathway of serine and glycine biosynthesis I (z-score = - 2.24, DEGs = 
5), and eNOS signaling (z-score = - 2.71, DEGs = 26). On the other hand, pathways that showed 
high activation prediction scores involved cardiac hypertrophy signaling (Enhanced) (z-score = 
2.43, DEGs = 61), osteoarthritis pathway (z-score = 1.18, DEGs = 40), protein kinase A signaling 
(z-score = 1.41, DEGs = 54), and notch signaling (z-score = 1.13, DEGs = 9) (Figure 6.25).        
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IPA analysis of DEGs in (WT(C) vs. BKO(C)) comparison shows all major categories of function 
annotations enriched. Numbers of DEGs assigned to annotation are shown in black colour. Red dashed line 
represent padj cutoff of 0.05. Padj was calculated by IPA algorithm using Benjamini-Hochberg multiple 








Figure 6-24 Annotation subcategories which related to neuronal development and 
























IPA analysis of DEGs in (WT(C) vs. BKO(C)) comparison shows subcategories of function annotations 
related to cellular and morphological changes which associated with neurological development. Numbers 
of DEGs assigned to annotation are shown in black colour. Red dashed line represent padj cutoff of 0.05. 
Padj was calculated by IPA algorithm using Benjamini-Hochberg multiple testing correction method. Bars 
represent minus log10 of padj values. Z-score value of positive (orange), negative (blue), or zero (black) 
represents activation, inhibition, or no change respectively, while (!) function or pathway is “currently 
ineligible for a prediction” by IPA. 
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IPA analysis of DEGs in (WT(C) vs. BKO(C)) comparison shows over-represented canonical pathways. 
Red dots represent –log10 of padj values of a pathway and were plotted on upper axis. Bars represent 
percentage of overlapping between DEGs in experiment and total number of genes belong to a pathway and 
were plotted on lower axis. Black bars represent neuronal pathways and grey bars represent top 20 of other 
non-neuronal pathways. Numbers of DEGs assigned to pathway are shown in black colour. Red dashed line 
represent padj cutoff of 0.05. Padj was calculated by IPA algorithm using Benjamini-Hochberg multiple 
testing correction method. Z-score value of positive (orange), negative (blue), or zero (black) represents 
activation, inhibition, or no change respectively, while (!) function or pathway is “currently ineligible for a 
prediction” by IPA. 
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The role of TOP2β was studied in the context of ligand induced transcription and differentiation of 
SH-SY5Y cells. Wild type and TOP2B knockout cells were treated with (10 μM) all-trans-retinoic 
acid for 24 hours then RNA samples from both cell types were extracted and prepared for RNA-
seq as described in (materials and methods, section 2.14.2), then the genes dataset was analysed 
for biological function and canonical pathway over-representation using IPA algorithm. IPA 
analysis showed significant over-representation of various functional annotations with (cell-to-cell 
signaling and interaction) and (nervous system development and function) annotations were the 
most significantly over-represented terms (Figure 6.26).  
Further investigation of subcategories for functional annotations depicted in (Figure 6.26) showed 
over-representation of key events involved in neuronal cell development. For example, results 
showed inhibition predictions for annotations of cell spreading, development of body axis, 
assembly of cells (Figure 6.27). Other neuronal annotations were significantly over-represented 
without z-score prediction involved synaptic transmission, neurotransmission, catabolism of 
neurotransmitter, and guidance of axons (Figure 6.27). 
Canonical pathways that were over-represented in (WT(R) vs. BKO(R)) comparison are presented 
in (Figure 6.28). Axonal guidance signaling pathway again come first in the top of the most 
significantly over-represented pathways (-log padj = 11.2, DEGs = 88) followed by synaptogenesis 
signaling pathway (-log padj = 9.01, DEGs = 62) and the latter showed high inhibition prediction 
score of (z-score = - 3.36) in the TOP2B knockout cells. Endocannabinoid neuronal synapse 
pathway was also significantly over-represented (-log padj = 3.35, DEGs = 23) with high score of 
inhibition prediction of (z-score = - 2.13).  Eleven other neuronal pathways were over-represented 
and are presented in (Figure 6.28).  
Results showed a range of pathways of other functions with cardiac hypertrophy signaling 
(Enhanced) was one of the pathways that showed high activation prediction score (z-score = 2.32, 








Figure 6-26 Function annotations which were over-represented upon ATRA 






















IPA analysis of DEGs in (WT(R) vs. BKO(R)) comparison shows all major categories of function 
annotations enriched. Numbers of DEGs assigned to annotation are shown in black colour. Red dashed line 
represent padj cutoff of 0.05. Padj was calculated by IPA algorithm using Benjamini-Hochberg multiple 






Figure 6-27 Annotation subcategories which related to neuronal development and 
were over-represented upon ATRA treatment in the absence of TOP2β. 
 
  





















IPA analysis of DEGs in (WT(R) vs. BKO(R)) comparison shows subcategories of function annotations 
related to cellular and morphological changes which associated with neurological development. Numbers 
of DEGs assigned to annotation are shown in black colour. Red dashed line represent padj cutoff of 0.05. 
Padj was calculated by IPA algorithm using Benjamini-Hochberg multiple testing correction method. Bars 
represent minus log10 of padj values. Z-score value of positive (orange), negative (blue), or zero (black) 
represents activation, inhibition, or no change respectively, while (!) function or pathway is “currently 
ineligible for a prediction” by IPA. 
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Figure 6-28 Canonical pathways over-represented upon ATRA treatment in the 























IPA analysis of DEGs in (WT(R) vs. BKO(R)) comparison shows over-represented canonical pathways. 
Red dots represent –log10 of padj values of a pathway and were plotted on upper axis. Bars represent 
percentage of overlapping between DEGs in experiment and total number of genes belong to a pathway and 
were plotted on lower axis. Black bars represent neuronal pathways and grey bars represent top 20 of other 
non-neuronal pathways. Numbers of DEGs assigned to pathway are shown in black colour. Red dashed line 
represent padj cutoff of 0.05. Padj was calculated by IPA algorithm using Benjamini-Hochberg multiple 
testing correction method. Z-score value of positive (orange), negative (blue), or zero (black) represents 
activation, inhibition, or no change respectively, while (!) function or pathway is “currently ineligible for a 
prediction” by IPA. 
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Axonal guidance signaling pathway was selected for detailed graph presentation as it was one of 
the crucial pathways in neuronal development and showed the most significant over-representation 
in both (WT(C) vs. BKO(C)) and (WT(R) vs. BKO(R)) comparisons. IPA graph representation of 
axon guidance signaling pathway in (WT(R) vs. BKO(R)) comparisons dataset is depicted in 
(Figure 6.29). This graph presentation includes molecules differential expression, nodes 
relationships, and regulation prediction of nodes as inferred by IPA using molecule activity 
prediction (MAP) option from overlay function in IPA software.  
DEGs belong to this pathway (DEGs = 88) encode for transcription regulators, transmembrane 
receptors, growth factors, kinases and enzymes (Table 6.5) which altogether involve in downstream 
functions associated with alternation between attraction and repulsion of axon as well as other 
functionally related tasks such as cytoskeleton reorganization, axon branching and outgrowth, actin 
filament reorganization, growth cone collapse, microtubule assembly and reorganization (Figure 
6.29). From these 88 DEGs, 54 and 34 genes were significantly down and up regulated respectively 
in the TOP2B knockout clone as compare with wild type (Table 6.5).  
Specifically, downregulated genes in the TOP2B knockout cells involved neuronal growth factors, 
cell surface receptors and other adapter proteins. These include members of family of neurotrophic 
receptor tyrosine kinase NTRK1, NTRK2, and NTRK3 (downregulated by 1.18, 3.63, and 5.11 log2 
fold respectively), Three members of semaphorin family (SEMA4B, SEMA6D, and SEMA7A) were 
downregulated by 2, 1.69, and 1.38 log2 fold respectively with two of semaphorin receptors plexins 
PLXND1 and PLXNA2 (were downregulated by 2.11 and 1.66 log2 fold respectively). In addition, 
member of netrins (NTNG2) and nitrin receptors (UNC5A) were downregulated in the TOP2B 
knockout cells by 1.82 and 5.29 log2 fold respectively. Moreover, two members of slit proteins 
SLIT1 and SLIT2 and one of the related receptors ROBO2 were downregulated in the TOP2B 
knockout cells by 3.77, 3.43, and 1.36 log2 fold respectively. Five members of Eph receptors 
family EPHA10, EPHA8, EPHB3, EPHA6, and EPHB2 (were downregulated by 4.07, 3.63, 3.11, 
1.46, and 1.06 log2 fold respectively). On the other hand, other genes were upregulated and they 
encode for frizzled receptors (FZD1, FZD7, and FZD8), ephrins (EFNA4), netrins (NTN5 and 
NTNG1), semaphorins (SEMA3G and SEMA5A), and Wnt family members (WNT5A, WNT16, and 

























Figure 6-29 IPA graph representation of axonal guidance signaling pathway upon ATRA treatment in the absence of 
TOP2β 















IPA graph of axonal guidance signaling pathway over-represented in (WT(R) vs. BKO(R)) comparison shows both upstream and downstream predicted 





Table 6-5 DEGs involved in axonal guidance signaling pathway regulation upon 
ATRA treatment in the absence of TOP2β 
Padj value of zero means very low value that fall out of the calculation scale. 





padj Location Type(s) 
RAC2 Rac family small GTPase 2 -7.48 8.05E-13 Cytoplasm enzyme 
PAPPA2 pappalysin 2 -7.319 9.76E-11 Extracellular Space peptidase 
ENPEP glutamyl aminopeptidase -6.185 0.0000473 Plasma Membrane peptidase 
UNC5A unc-5 netrin receptor A -5.288 2.58E-59 Plasma Membrane 
transmembrane 
receptor 
NTRK3 neurotrophic receptor tyrosine kinase 3 -5.106 3.13E-23 
Plasma 
Membrane kinase 
KCNJ12 potassium voltage-gated channel subfamily J member 12 -4.614 2.47E-14 
Plasma 
Membrane ion channel 
LINGO1 leucine rich repeat and Ig domain containing 1 -4.592 1.15E-60 
Plasma 
Membrane other 
BMP7 bone morphogenetic protein 7 -4.456 6.11E-10 Extracellular Space growth factor 
EPHA10 EPH receptor A10 -4.066 3.37E-21 Plasma Membrane 
transmembrane 
receptor 
PLCH2 phospholipase C eta 2 -3.789 8.4E-31 Cytoplasm enzyme 
SLIT1 slit guidance ligand 1 -3.768 0.000000317 
Extracellular 
Space other 
SHANK2 SH3 and multiple ankyrin repeat domains 2 -3.675 4.91E-08 
Plasma 
Membrane other 
EPHA8 EPH receptor A8 -3.63 1.63E-23 Plasma Membrane kinase 
NTRK2 neurotrophic receptor tyrosine kinase 2 -3.629 0 
Plasma 
Membrane kinase 
SLIT2 slit guidance ligand 2 -3.434 1.38E-29 Extracellular Space other 
MMP24 matrix metallopeptidase 24 -3.242 1.02E-220 Plasma Membrane peptidase 
L1CAM L1 cell adhesion molecule -3.241 4.44E-174 Plasma Membrane other 
MMP28 matrix metallopeptidase 28 -3.196 1.11E-67 Extracellular Space peptidase 
EPHB3 EPH receptor B3 -3.105 1.42E-43 Plasma Membrane kinase 
ADAMTS17 ADAM metallopeptidase with thrombospondin type 1 motif 17 -2.916 0.0000122 
Extracellular 
Space other 
RASSF5 Ras association domain family member 5 -2.406 1.42E-11 
Plasma 
Membrane other 
ADAM12 ADAM metallopeptidase domain 12 -2.207 9.23E-101 
Plasma 
Membrane peptidase 
ADAMTS7 ADAM metallopeptidase with thrombospondin type 1 motif 7 -2.15 1.86E-32 
Extracellular 
Space peptidase 
PLXND1 plexin D1 -2.114 2.69E-61 Plasma Membrane 
transmembrane 
receptor 
TUBA4A tubulin alpha 4a -2.011 2.64E-14 Cytoplasm other 
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SEMA4B semaphorin 4B -1.997 6.06E-11 Plasma Membrane other 
PLCB2 phospholipase C beta 2 -1.992 0.0000001 Cytoplasm enzyme 
CXCL12 C-X-C motif chemokine ligand 12 -1.989 2.88E-10 
Extracellular 
Space cytokine 
ABLIM2 actin binding LIM protein family member 2 -1.921 2.93E-11 Cytoplasm other 
ADAMTS2 ADAM metallopeptidase with thrombospondin type 1 motif 2 -1.838 2.94E-10 
Extracellular 
Space peptidase 
NTNG2 netrin G2 -1.821 0.000165 Plasma Membrane other 
SEMA6D semaphorin 6D -1.687 2.97E-48 Plasma Membrane other 
PLXNA2 plexin A2 -1.659 2.13E-19 Plasma Membrane 
transmembrane 
receptor 
GNAO1 G protein subunit alpha o1 -1.632 1.62E-59 Plasma Membrane enzyme 
MMP15 matrix metallopeptidase 15 -1.612 6.06E-11 Extracellular Space peptidase 
KIF7 kinesin family member 7 -1.532 2.96E-23 Extracellular Space other 
EPHA6 EPH receptor A6 -1.459 2.88E-16 Plasma Membrane kinase 
MME membrane metalloendopeptidase -1.394 1.18E-16 
Plasma 
Membrane peptidase 







MMP11 matrix metallopeptidase 11 -1.359 1.71E-12 Extracellular Space peptidase 
ROBO2 roundabout guidance receptor 2 -1.356 3.86E-33 Plasma Membrane 
transmembrane 
receptor 
GLIS2 GLIS family zinc finger 2 -1.247 9.04E-09 Nucleus transcription regulator 
PRKCH protein kinase C eta -1.226 1.35E-09 Cytoplasm kinase 
WNT3 Wnt family member 3 -1.221 1.01E-36 Extracellular Space other 
PDGFC platelet derived growth factor C -1.203 0.00143 Extracellular Space growth factor 
NTRK1 neurotrophic receptor tyrosine kinase 1 -1.179 9.11E-12 
Plasma 
Membrane kinase 
TUBB4A tubulin beta 4A class IVa -1.165 2.9E-21 Cytoplasm other 
PLCL1 phospholipase C like 1 (inactive) -1.163 6.08E-11 Cytoplasm enzyme 
ADAM29 ADAM metallopeptidase domain 29 -1.132 0.00354 
Plasma 
Membrane peptidase 
SRGAP1 SLIT-ROBO Rho GTPase activating protein 1 -1.101 0.000373 Cytoplasm other 
EPHB2 EPH receptor B2 -1.061 9.25E-14 Plasma Membrane kinase 
ADAMTS10 ADAM metallopeptidase with thrombospondin type 1 motif 10 -1.05 0.0000223 
Extracellular 
Space peptidase 
ADAM19 ADAM metallopeptidase domain 19 -1.013 4.95E-24 
Plasma 
Membrane peptidase 
PRKCE protein kinase C epsilon -1 0.00000544 Cytoplasm kinase 
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RAP2B RAP2B, member of RAS oncogene family 1.029 7.58E-23 
Plasma 
Membrane enzyme 
PDGFD platelet derived growth factor D 1.031 3.84E-17 Extracellular Space growth factor 




IRS2 insulin receptor substrate 2 1.111 2.59E-102 Cytoplasm enzyme 
ADAMTS20 ADAM metallopeptidase with thrombospondin type 1 motif 20 1.127 4.93E-10 
Extracellular 
Space peptidase 
EFNA3 ephrin A3 1.252 1.07E-12 Plasma Membrane kinase 
PRKCA protein kinase C alpha 1.272 1.14E-170 Cytoplasm kinase 
PLXNB3 plexin B3 1.31 0.0000432 Plasma Membrane 
transmembrane 
receptor 
ADAMTS12 ADAM metallopeptidase with thrombospondin type 1 motif 12 1.385 8.36E-10 
Extracellular 
Space peptidase 
GDF7 growth differentiation factor 7 1.392 0.000000066 
Extracellular 
Space growth factor 
ADAMTS19 ADAM metallopeptidase with thrombospondin type 1 motif 19 1.463 2.26E-58 
Extracellular 
Space peptidase 
PRKCD protein kinase C delta 1.545 4.31E-18 Cytoplasm kinase 
NGFR nerve growth factor receptor 1.549 9.66E-10 Plasma Membrane 
transmembrane 
receptor 




SEMA3G semaphorin 3G 1.685 0.0000339 Cytoplasm other 
FGFR2 fibroblast growth factor receptor 2 1.686 2.92E-10 
Plasma 
Membrane kinase 
ADAMTS5 ADAM metallopeptidase with thrombospondin type 1 motif 5 1.773 1.8E-19 
Extracellular 
Space peptidase 
WNT5A Wnt family member 5A 1.808 0.00000742 
Extracellular 
Space cytokine 
EFNA4 ephrin A4 1.836 3.35E-34 Plasma Membrane kinase 
NFATC4 nuclear factor of activated T cells 4 1.857 1.81E-50 Nucleus 
transcription 
regulator 
ADAM21 ADAM metallopeptidase domain 21 1.867 0.000729 
Plasma 
Membrane peptidase 
NTN5 netrin 5 1.957 0.00949 Other other 
EPHB4 EPH receptor B4 2.063 8.04E-46 Plasma Membrane kinase 




NTNG1 netrin G1 2.273 2.99E-11 Extracellular Space other 
PAPPA pappalysin 1 2.454 2.41E-08 Extracellular Space peptidase 
SEMA5A semaphorin 5A 2.541 1.36E-158 Plasma Membrane 
transmembrane 
receptor 
WNT16 Wnt family member 16 2.796 2.6E-13 Extracellular Space other 





ADAMTS4 ADAM metallopeptidase with thrombospondin type 1 motif 4 3.396 2.48E-26 
Extracellular 
Space peptidase 
GLI1 GLI family zinc finger 1 3.752 1.65E-09 Nucleus transcription regulator 
WNT7B Wnt family member 7B 4.35 0.000463 Extracellular Space other 
BMP4 bone morphogenetic protein 4 4.574 2.33E-27 Extracellular Space growth factor 
PRKD1 protein kinase D1 4.93 9.61E-34 Cytoplasm kinase 
 
The differentially expressed genes (DEGs) that belong to axonal guidance signaling pathway in 
WT(C) vs. WT(R), WT(C) vs. BKO(C), and WT(R) vs. BKO(R) comparisons are shown in (Table 




















































































Table shows differential expression of the DEGs which were assigned to axonal guidance signaling pathway 
in the 3 comparisons of this study: WT(C) vs. WT(R), WT(C) vs. BKO(R), and WT(R) vs. BKO(R). Padj 
value of zero means very low value that fall out of the calculation scale.    
 
6.3.3.3 Ingenuity pathway analysis (IPA) of upstream effects 
Results above showed downstream effect of regulation of genes in the datasets. Using a literature-
based database, IPA also provides a prediction of upstream factors that may have caused the effects 
observed in the datasets. This part of results show the predicted upstream regulators of each 
previously described comparisons. Factors that are significantly over-represented with -1 < z-score 
> 1 are shown. Target molecules associated with an upstream regulator within the datasets are not 
shown. 









ATF4  transcription regulator -2.611 0.000451 
SATB1  transcription regulator -2.578 0.0132 
IDO1  Enzyme -2.236 0.0000586 
EGLN  Group -2.222 0.000851 
EFNA2  Kinase -2.121 0.00727 
CDK2  Kinase -2 0.0016 
BRD4  Kinase -1.995 4.35E-09 
BMI1  transcription regulator -1.969 0.00917 
FN1  enzyme -1.941 0.0278 
26s Proteasome  complex -1.907 0.0341 
EFNA4  Kinase -1.89 0.00844 
EFNA3  Kinase -1.89 0.00844 
EFNA1  Other -1.89 0.00917 
AR  ligand-dependent nuclear receptor -1.823 0.0182 
MYC -4.24 transcription regulator -1.81 0.0292 
estrogen receptor  group -1.651 0.00000335 
Mek  group -1.548 0.0000185 
COL18A1  Other -1.387 0.0000673 
TAB1  enzyme -1.387 0.00663 
mir-29  microRNA -1.3 0.00408 
E2F3  transcription regulator -1.265 0.00893 
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EFNA5  Kinase -1.238 0.00179 
PDLIM2  Other -1.155 0.00414 
NEUROG1  transcription regulator -1.069 0.00000453 
MAP3K7  Kinase -1.069 0.00961 
TERT -1.165 Enzyme -1.067 0.0138 
Akt  Group -1.056 0.000000598 
ZNF217  transcription regulator -1 0.0000298 
RBPJ  transcription regulator -1 0.00208 
NONO  transcription regulator -1 0.0132 
TLR7/8  Group 1 0.00031 
PAF1  Other 1 0.00127 
TRPC1  ion channel 1 0.00344 
PPARG 4.651 ligand-dependent nuclear receptor 1 0.015 
THRB  ligand-dependent nuclear receptor 1 0.0292 
BMP2  growth factor 1 0.0325 
UHRF2  Enzyme 1 0.0433 
PRL  Cytokine 1.021 0.000904 
MAPK1  Kinase 1.054 0.00289 
GH1  growth factor 1.091 0.00475 
CSF3  Cytokine 1.091 0.0163 
RARA 1.714 ligand-dependent nuclear receptor 1.095 0.0000187 





 mature microRNA 1.131 0.00475 
PPARA  ligand-dependent nuclear receptor 1.131 0.0369 
NCOA2  transcription regulator 1.131 0.0433 
mir-15  microRNA 1.154 0.0433 
BMP4 4.22 growth factor 1.185 0.000267 
IRF3  transcription regulator 1.223 0.0262 
PRKCD  Kinase 1.252 0.000301 
ERBB2  Kinase 1.271 0.001 
Interferon alpha  Group 1.356 0.000268 
EGR1  transcription regulator 1.392 0.0154 
TRIB3  Kinase 1.406 0.00105 
TP73  transcription regulator 1.408 0.000125 
SMARCA4  transcription regulator 1.451 0.000000712 
PI3K (family)  Group 1.5 0.000142 
PRNP  Other 1.503 0.0319 
IL13  Cytokine 1.504 0.000306 
STAT1  transcription regulator 1.573 0.0000458 
SREBF1 1.372 transcription regulator 1.589 0.0111 
RARB 4.849 ligand-dependent nuclear receptor 1.673 0.00177 
IL15  Cytokine 1.693 0.021 
GATA6  transcription regulator 1.965 0.00127 
FOXO4  transcription regulator 1.969 0.0163 
TCF3  transcription regulator 1.974 0.00108 
IGF1  growth factor 1.989 0.0188 
PNN  Other 2 0.00829 
ERG  transcription regulator 2.086 0.000224 
NOTCH3  transcription regulator 2.148 0.00337 
MXI1  transcription regulator 2.236 0.000734 
IFNA2  Cytokine 2.266 0.0495 
HSPA9  Other 2.813 4.03E-09 
CST5  Other 3.128 0.0396 
201 
 
TGM2 4.906 enzyme 3.174 0.0103 
RXRA  ligand-dependent nuclear receptor 3.293 2.56E-08 
TGFB1  growth factor 3.337 0.00000608 
 









ATF4 -1.207 transcription regulator -2.88 4.35E-08 
WISP2  growth factor -2.61 0.0446 
IL13  cytokine -2.59 0.0000907 
MYOCD  transcription regulator -2.39 0.0000305 
HDAC4  transcription regulator -2.23 0.00213 
ESR1  ligand-dependent nuclear receptor -2.06 0.00000363 
PCGF2  transcription regulator -2.00 0.00468 
SPARC  other -1.99 0.00468 
SPDEF  transcription regulator -1.80 0.000995 
estrogen receptor  group -1.72 4.81E-08 
CIP2A  other -1.66 0.000347 
HAND2  transcription regulator -1.60 0.000136 
DNMT3B  enzyme -1.51 0.00651 
TAL1  transcription regulator -1.50 0.00018 
NUPR1  transcription regulator -1.48 0.0267 
FOXA1  transcription regulator -1.46 0.0221 
NR3C1  ligand-dependent nuclear receptor -1.46 0.0125 
IDO1  enzyme -1.41 0.0000255 
RXRA  ligand-dependent nuclear receptor -1.41 0.00522 
TCF7L2  transcription regulator -1.34 0.00323 
VHL  transcription regulator -1.34 0.0237 
TBX5  transcription regulator -1.31 0.0000471 
Interferon alpha  group -1.29 0.00434 
MAPK1  kinase -1.26 0.000289 
TREM1  transmembrane receptor -1.22 0.00233 
GATA4  transcription regulator -1.21 0.00271 
MDM4  enzyme -1.18 0.0263 
TOPBP1  other -1.18 0.00468 








CCND1  transcription regulator -1.07 0.0272 
CBX7  other -1.07 0.0335 
BMP2  growth factor -1.07 0.0347 
PAK1  kinase -1.03 0.0116 
IL17F  cytokine -1.00 0.00727 
IFN Beta  group -1.00 0.00958 
ITGB1  transmembrane receptor 1.00 0.00365 
CSF1 1.329 cytokine 1.00 0.0383 
CTNNB1  transcription regulator 1.04 0.00165 
S1PR3  G-protein coupled receptor 1.07 0.000687 
ERG  transcription regulator 1.11 0.0133 
PTTG1  transcription regulator 1.13 0.00322 
Jnk  group 1.14 0.0383 
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TWIST1 1.045 transcription regulator 1.17 0.00126 
PDGF BB  Complex 1.18 0.0293 
TGM2  Enzyme 1.20 0.038 
Pkc(s)  Group 1.26 0.0326 
EZR  Other 1.29 0.00466 
CEBPA -1.256 transcription regulator 1.34 0.0104 
RARB  ligand-dependent nuclear receptor 1.34 0.0134 
FOXC2  transcription regulator 1.45 0.000784 
TNF  cytokine 1.45 0.0000276 
SMARCA4  transcription regulator 1.46 2.96E-08 
CYR61 3.016 Other 1.49 0.00451 
SMAD3  transcription regulator 1.54 0.00025 
RELA  transcription regulator 1.55 0.00186 
BRD7  transcription regulator 1.56 0.00144 
PRKCD  kinase 1.60 0.00117 
KLF6 1.485 transcription regulator 1.60 0.00775 
SMARCD3  transcription regulator 1.63 0.000971 
TBXT -3.495 transcription regulator 1.63 0.000971 
NOTCH1 3.122 transcription regulator 1.90 0.0132 
SHC1  Other 1.91 0.0302 
MUC4  Other 1.95 0.0263 
JAK  group 1.98 0.0347 
PTAFR  G-protein coupled receptor 1.98 0.0418 
POSTN  other 1.98 0.000687 
SSTR2 -1.649 G-protein coupled receptor 1.98 0.00279 
PRL  cytokine 1.99 0.0124 
GNE  kinase 2.00 0.000246 
RLIM  enzyme 2.00 0.00468 
mir-322  microRNA 2.00 0.0149 
STAT1  transcription regulator 2.09 0.0141 
PIN1  enzyme 2.18 0.0413 
IFNL1  cytokine 2.34 0.000695 
REST  transcription regulator 2.60 0.000361 
TWIST2  transcription regulator 2.80 0.0000552 
IFNG  cytokine 2.81 0.000244 
TRIB3 -1.387 kinase 2.95 0.000000727 
TGFB1 1.235 growth factor 3.11 0.000172 
 
 









IL1RN  cytokine -2.813 0.294 
EGLN  group -2.56 0.00713 
MAFB  transcription regulator -2.449 0.261 
IRF3  transcription regulator -2.433 0.0595 
AZGP1  transporter -2.401 0.000672 
SPDEF  transcription regulator -2.221 0.0000876 
NR1H4  ligand-dependent nuclear receptor -2.219 0.244 
IL13  cytokine -2.082 0.00249 










PCGF2  transcription regulator -1.997 0.000447 
UPF2  other -1.982 0.238 
TCF3  transcription regulator -1.98 0.00602 
ASAH1  enzyme -1.98 0.182 
MYOCD  transcription regulator -1.975 0.00000163 
SPARC  other -1.963 0.0049 
PRNP -1.47 other -1.88 0.000246 
MAPK1  kinase -1.758 0.0000275 
WISP2  growth factor -1.757 0.00513 
TAL1  transcription regulator -1.749 0.000227 
PTPN6  phosphatase -1.715 0.0049 
SLC9A3R1  other -1.486 0.000831 
BMP4 4.574 growth factor -1.472 0.0137 
BMP2  growth factor -1.432 0.00916 
RXRA  ligand-dependent nuclear receptor -1.408 0.00185 
HLX  transcription regulator -1.387 0.0433 
NANOG  transcription regulator -1.373 0.0133 
TP73  transcription regulator -1.332 0.000335 
EOMES 3.228 transcription regulator -1.291 8.03E-08 
PDCD4  other -1.214 0.0275 
TOPBP1  other -1.192 0.0049 
RHOA  enzyme -1.192 0.0112 
EHF  transcription regulator -1.175 0.00125 
ESR1  ligand-dependent nuclear receptor -1.17 0.0000444 
COL18A1  other -1.155 0.0102 
HAND2  transcription regulator -1.097 0.00000493 
SMARCE1  transcription regulator -1.091 0.0349 
CBX7  other -1.067 0.0349 
OGA  enzyme -1.061 0.00376 
HDAC4  transcription regulator -1.057 0.0156 
ESR2  ligand-dependent nuclear receptor -1.028 0.01 
RGCC  other -1 0.0000554 
PARP1  enzyme -1 0.0205 
DNMT3B  enzyme -1 0.0403 
PPID  enzyme 1 0.000721 
FOXD2-AS1  other 1 0.00157 
ROR1  kinase 1 0.00157 
RLIM  enzyme 1 0.0049 
SMARCD3  transcription regulator 1 0.0349 
TBXT -3.808 transcription regulator 1 0.0349 
TWIST1 1.112 transcription regulator 1.016 0.0472 
F7  peptidase 1.029 0.021 
NRG1 -1.784 growth factor 1.046 0.0083 
MYB  transcription regulator 1.054 0.000115 
SDCBP  enzyme 1.057 0.0156 
MAP2K1/2  group 1.065 0.0161 
S1PR3 1.926 G-protein coupled receptor 1.067 0.000721 
SOX9  transcription regulator 1.067 0.0435 
ECM1  transporter 1.068 0.0112 
PI3K (family)  group 1.099 0.000834 
FOXL2  transcription regulator 1.103 0.0108 
ST6GALNAC1  enzyme 1.131 0.00157 
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JAK  group 1.131 0.0364 
NFkB (complex)  complex 1.161 0.0449 
NOTCH1 2.16 transcription regulator 1.221 0.000162 
PTTG1  transcription regulator 1.231 0.00341 
LGALS1  other 1.231 0.0122 
Lh  complex 1.234 0.0132 
POU2F2 -3.494 transcription regulator 1.265 0.00331 
MUC4  other 1.383 0.0000705 
ZNF217  transcription regulator 1.387 0.00000114 
DCLK1 -1.061 kinase 1.387 0.000447 
MET  kinase 1.391 0.00209 
FSH  complex 1.406 0.00341 
DEF6  other 1.422 0.000831 
CAV1  transmembrane receptor 1.455 0.00221 
ID1  transcription regulator 1.455 0.00552 
mir-34  microRNA 1.456 0.00866 
SMARCA4  transcription regulator 1.484 9.74E-12 
HGF 5.191 growth factor 1.499 0.0139 
CD44 2.539 other 1.556 0.00352 
Growth hormone  group 1.606 0.000327 
PDGF BB  complex 1.624 0.00578 
PTAFR  G-protein coupled receptor 1.628 0.00154 
MAPK8  kinase 1.633 0.0297 
HIF1A  transcription regulator 1.719 0.000925 
IFNA2  cytokine 1.757 0.454 
IL1A  cytokine 1.771 0.36 
EGF  growth factor 1.781 0.105 
RELA  transcription regulator 1.791 0.178 
IKBKB  kinase 1.934 0.297 
IL1B  cytokine 1.945 0.481 
EPAS1  transcription regulator 1.996 0.0000205 
PI3K (complex)  complex 2 0.148 
MAPK14  kinase 2 0.258 
TNF  cytokine 2.056 0.0028 
SSTR2  G-protein coupled receptor 2.219 0.000214 
TWIST2  transcription regulator 2.233 0.0000605 
mir-322  microRNA 2.236 0.00225 
TGFB1  growth factor 2.238 0.000000793 
REST  transcription regulator 2.241 0.0000104 
NEDD9 1.693 other 2.333 0.00352 
STAT3  transcription regulator 2.35 0.0128 
SYVN1  transporter 2.4 0.00496 
EIF2AK2  kinase 2.433 0.386 
CYR61 3.875 other 2.529 0.000246 
PIN1  enzyme 2.588 0.00252 
IFNL1  cytokine 2.744 0.016 
EGFR 3.175 kinase 2.757 0.00502 
PCDH11Y  other 2.804 0.000222 





6.4 Discussion  
In this chapter, the CRISPR technique was optimized to generate several TOP2B knockout clones 
of the SH-SY5Y cell line. CRISPR was performed using a plasmid based method of guide RNA 
(gRNA) and CAS9 introduction into cells by transfection. A plasmid with a GFP-expression 
selection marker (PX458) was used for two reasons. Firstly, FACS selection of transfected cells is 
rapid and more robust than antibiotic selection especially when cells showed low transfection 
efficiency as was the case with the SH-SY5Y cell line in this study. Secondly, rapid and highly 
efficient single cell cloning can be performed using GFP-based cell sorting. Several TOP2B 
knockout clones were successfully generated and verified for the absence of TOP2β protein using 
both western blotting and immunofluorescence (Figures 6.8, 6.9, 6.10, 9.11, and Table 6.2). From 
those clones, three clones (BKO-70, BKO-98, and BKO-129) were selected for studying the role 
of TOP2β in gene expression and differentiation of SH-SY5Y cells. These 3 clones were generated 
from 3 different gRNAs targeting exon 1 of the TOP2B gene. 
The SH-SY5Y cell line is a neuroblastoma cell line that retains the capacity to undergo neuronal 
differentiation by retinoic acid (RA), and/or other neural differentiation factors (Påhlman et al., 
1984; Encinas et al., 2000; Dwane et al., 2013; Teppola et al., 2016). Upon RA treatment, these 
cells reduce proliferation and undergo morphological changes toward neuronal characteristics such 
as neuronal cell body and formation of extended neurites which eventually form cell axons 
(Constantinescu et al., 2007; Bell et al., 2013; Teppola et al., 2016).  
SH-SY5Y cells are widely used in neuronal studies because these cells retain cellular and 
biochemical characteristics of neuronal cells (Cheung et al., 2009; Krishna et al., 2014). No 
previous reports studied the differentiation of SH-SY5Y cells in a TOP2B stable knockout model. 
Wild type and TOP2B knockout clones were tested for their response to ATRA-induced 
differentiation using microscopic observation of morphological changes particularly neurite 
outgrowth as well as measurement of BCL2 mRNA level as a differentiation marker. Neurite 
outgrowth assay and testing BCL2 level are common assays to evaluate the differentiation of SH-
SY5Y cells (Lasorella et al., 1995; Riddoch et al., 2007; Bell et al., 2013).  
Results showed significant reduction in the ratio of neurite outgrowth bearing cells as well as the 
level of Bcl2 induction in the TOP2B knockout clones. These results agree with previous reports 
that showed neuronal defects in Top2b knockout mice, rats, zebrafish (Yang, 2000; Lyu and Wang, 
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2003; Lyu et al., 2006; Nur et al., 2007; Nevin et al., 2011; Heng et al., 2012; Li et al., 2014) and 
human mesenchymal stem cell-derived neurons (Isik et al., 2015; Zaim and Isik, 2018).  
It has been shown that ATRA treatment of SH-SY5Y cells rapidly induces the expression level of 
a number of genes such as CYP26A1, CRABP2, RARB, and RET (Perez-Juste and Aranda, 1999; 
Brabender et al., 2005; Oppenheimer et al., 2007). These 4 genes were tested for the level of 
induction using RT-qPCR in the wild type and TOP2B knockout clones (Figure 6.14). Results 
revealed a significant decrease in the induction of CRABP2 and CYP26A1 in all 3 TOP2B knockout 
clones compared with wild type. 
Further to these findings, the whole transcriptome profile of SH-SY5Y cells was studied using 
RNA-seq technique and again this was the first study that compares total gene expression of these 
cells in the presence and absence of TOP2β with or without retinoic acid. For this purpose, one of 
the TOP2B knockout clones (BKO-98) was used along with the wild type cells which were 
transfected with empty plasmid. Both cells were grown for 24 hrs in the presence or absence of 
ATRA (10 μM). RNA samples were then extracted, prepared, and sequenced as described in the 
materials and methods (section 2.14.2). Differential gene expression was determined within 4 
comparisons WT(C) vs. WT(R), BKO(C) vs. BKO(R), WT(C) vs. BKO(C), and WT(R) vs. 
BKO(R) (Table 6.3 and Figures 6.15 and 6,16). Results revealed large number of differentially 
expressed genes (DEGs) that were regulated by more than 1 log2 fold (Figures 6.17, 6.18, and 
Appendix table 17). There was no significant change in the expression of all known housekeeping 
genes such as (GAPDH, PP1A, RPL15, ATCB, POLR2F, and POLR2A) in all the 4 comparisons, 
confirming quality and efficiency of calculation of relative abundances of transcripts.  
The effect of retinoic acid on the total transcriptomic profile of differentiated SH-SY5Y cells is 
well established (Oppenheimer et al., 2007; Korecka et al., 2013; Forster et al., 2016; Pezzini et 
al., 2017). However, to our knowledge, less information is present about the early whole genome 
expression changes induced by retinoic acid. This was reported in this study in the differential 
expression profile of the (WT(C) vs. WT(R)) comparison which showed 1202 and 2034 genes were 
down or up regulated respectively (Figure 6.17). RNA-seq results showed induction of the 4 genes 
tested previously (CYP26A1, RARB, CRABP2, and RET) as well as BCL2 by RA. A subset of genes 
that were differentially expressed upon RA are involved in the metabolism and the signaling 
pathway of retinoic acid itself (Table 6.4), suggesting that RA regulates expression of members of 
its own metabolism pathway. For example, the CYP26A1 gene is rapidly induced by RA through 
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two functional RA response elements (RARE) and encodes cytochrome 450 26A1, a catabolizing 
enzyme for RA (Loudig et al., 2005). This shows how RA might take part in regulation of its level 
via feedback loops (White et al., 2007). 
IPA analysis of DEGs from the (WT(C) vs. WT(R)) comparison showed over-representation of 
RA-related pathways and functional annotations. Based on the IPA categorization, ATRA 
treatment induced a wide range of cellular and molecular changes associated with cell morphology 
such as (growth of neurite, guidance of axons, tabulation of cells, branching of cells, and sprouting). 
These changes are pivotal during the differentiation process. Canonical pathway analysis showed 
VDR/RXR activation as the most significant over-represented pathway.  
The axonal guidance pathway was the pathway most affected in terms of the number of genes 
regulated (47 DEGs) (Figure 6.22 and Table 6.6). No activation state prediction was made by IPA 
for this pathway as it is not eligible for z-score calculation because it has more than one activation 
state (see section 2.14.2.3). Axonal guidance (also termed axonal pathfinding) is the process by 
which neuronal cells control the extension of axons towards an appropriate target. Axons extend 
from a part of the cell called growth cone which responds to either chemical or mechanical signals 
called cues and these cues can be either diffusible or nondiffusible. Axonal guidance is controlled 
through balance between attraction/repulsion effects of cues. These cues “instruct” an axon to 
follow the correct route direction through their attractive or repulsive effects. However, some cues 
are bifucntional so there is no single cue-to-effect relationship for these molecules (Tessier-Lavigne 
and Goodman, 1996; Myers et al., 2011; Bearce et al., 2015).  
Genes that are assigned to this pathway and were regulated by ATRA included members of a family 
of neurotrophic receptor tyrosine kinases (NTRK1, NTRK2, and NTRK3). Particularly, NTRK2 (also 
known as TrkB) was the most remarkably induced gene upon ATRA treatment (7.7 log2 fold). 
This agreed with previous reports showing induction of this gene during RA-induced 
differentiation in previous reports involving SH-SY5Y (Shiohira et al., 2012) and NB1643 
(Middlemas et al., 1999) neuroblastoma cells. Other DEGs that were regulated by RA included 
members of the semaphorin family (SEMA6C, SEMA3B, SEMA3G, and SEMA3C) and related 
receptor plexins (PLXNA2 and PLXNC1) and neuropilins (NRP1 and NRP2). Semaphorins act by 
controlling attraction/repulsion balance (Thiede-Stan and Schwab, 2015). In addition, members of 
the ephrin receptor subfamily (EFNB2) and the related receptor (EPHB3 and EPHA2), netrins 
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(NTNG1 and NTNG2) and nitrin receptors (UNC5A and UNC5D), slit proteins (SLIT2), and growth 
factor member (BMP4) were significantly regulated by ATRA.  
These results represent the transcriptional change upon ATRA treatment of wild type SH-SY5Y 
(WT(C) vs. WT(R) comparison which validates our experimental condition and for SH-SY5Y cells 
confirms what is expected from these cells upon RA treatment. 
Next, the role of TOP2β in whole genome expression was investigated in the presence and absence 
of ATRA as shown in the differential gene expression and respective IPA analysis of the two 
comparisons: WT(C) vs. BKO(C) and WT(R) vs. BKO(R). Differential expression analysis 
highlighted regulation of 2554 (1466 down- and 1088 up-regulated) and 2677 (1720 down- and 
957 up-regulated) genes in the TOP2B knockout cells in the absence and presence of ATRA 
respectively (Figure 6.17). Genes with neuronal function represented large proportion (603 genes, 
23.6 %) or (603 genes, 22.5 %) of total regulated genes in WT(C) vs. BKO(C) and WT(R) vs. 
BKO(R) comparisons respectively.  
Interestingly, several of the downregulated genes upon TOP2B knockout were also shown to be 
downregulated in TOP2B mutant models in previous reports. For instance, MYT1L, NELL2, CDH4, 
GABRB3, GRIK2, ANK3, CX3CL1, GPX3, NPY, KCNMA1, HOXA5, RIT2, LPL, and TMEFF2 
genes were shown to be downregulated in the brains of Top2b mutant murine embryos (Lyu et al., 
2006). These genes were all significantly downregulated in the SH-SY5Y cells lacking TOP2β in 
our study. In addition, results showed downregulation of MYT1, CDH8, NELL1, ROBO2, SYT7, 
SYT4, SYT17, SYT11, UNC5A, UNC5D, GRIK3, GRIK4, GRIK5, TAC3, and NCAM1 genes, which 
are closely related to a group of genes (MYT1L, CDH4, NELL2, ROBO1, SYT1, UNC5C, GRIK2, 
TAC1, and NCAM2) in the study mentioned above. These genes have functions of transcription 
regulation, axon guidance, cell adhesion and migration, neuropeptide encoding, synaptic activity, 
and cellular response.        
Further consistency with our result, several of the significantly downregulated genes in the TOP2B 
knockout SH-SY5Y cells in this study were shown to be bound by Top2b (preferentially at 
promoter region) in murine embryonic stem cell-derived postmitotic neurons and were also 
downregulated in the Top2b mutant derivative of these cells (Tiwari et al., 2012) as determined by 
microarray. Gene Ontology (GO) enrichment analysis of these genes performed by the authors 
suggested functions related to neurogenesis. These genes were NTRK3, POU4F2, CNTN5, FSTL5, 
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UNC5D, NELL2, LPL, RALYL, MARCH4, LSAMP, NEFM, AKAP6, ZFP36L1, PRDM8, ROBO2, 
GRIK2, RRM2, ABLIM1, ONECUT1, NRXN1, IRX3, PLCB1, B3GALT2, and CTNNA2. 
Moreover, five of the significantly downregulated genes upon TOP2B knockout in our study 
(DAB1, CPNE9, SGCD, CNTN4, and ADAM19) were shown to be activated by Top2b during rat 
cerebellar differentiation and were supressed upon Top2b inhibition (Sano et al., 2009). Another 4 
downregulated neuronal genes upon TOP2B knockout in our study (VEGFA, GRIK2, NRXN1, and 
NRXN3) were shown to have a role in neural differentiation of mouse retina and were 
downregulated upon conditional Top2b knockout in the retina (Li et al., 2014) as determined by 
RNA-seq. Another 23 genes regulated by Top2b from (Li et al., 2014) study also overlapped with 
our datasets. 
More recent RNA-seq analysis from the same lab for Top2b dependent genes (TDGs) in murine 
photoreceptor cells at two differentiation stages: P0 and P6 revealed a group of key genes in 
differentiation and maturation of these cells (Li et al., 2017). Consistently, group of these genes 
were undergone the same regulation pattern in the knockout cells in our result. In detail, the genes 
that showed significant downregulation in our study and in (Li et al., 2017) were (RBFOX1, FSTL5, 
CARTPT, PCDH7, SPON1, ROBO2, GRIK2, TOP2B, NRXN1, NRXN3, DLG2, and CTNNA2) for 
P0 stage, and (CLVS2, FSTL5, NELL2, CRABP1, SLC7A11, ASNS, MTUS2, MAN2A2, KCNIP1, 
STXBP2, TTC9, PRKCE, HIST1H2BJ, VEGFA, NMB, COX4I2, RRM2, UNC13A, TOP2B, 
GADD45A, DLG2, GNAO1, SCN3A, KIF5A, CTNNA2, and FAM57B) for P6 stage. On the other 
hand, the genes that showed significant upregulation in both datasets were (COL1A1, HSPB1, and 
EDNRB) and (RBP4, ABCG2, CSPG5, ALDH6A1, ITPKB, EFHD1, CD72, LHPP, and TSPO) for 
P0 and P6 stages respectively. 
In further agreement with our data, the requirement for Top2b in expression of a cohort genes of 
neuronal functions in mouse cerebellar granule neurons was shown in another report by (Feng et 
al., 2017a). Interestingly, 37 of those genes (namely DPP6, RBFOX1, DSCAM, CADM3, FSTL5, 
KCNJ3, RUNX1T1, ZMAT4, SH3GL2, PCDH7, GRIA2, CELF4, MMP24, RALYL, NRG3, 
ADARB2, SCG3, GRM1, CPLX1, TNIK, APBA1, EDIL3, GPM6B, FIGN, NTN4, PRKCE, PRDM8, 
GRIK2, NRXN1, NRXN3, TMEM198, DLG2, GNAO1, B3GALT2, SYNE1, ST8SIA4, and PLCL1) 
were also significantly downregulated upon TOP2B knockout in our study.  
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Collectively, these results showed that TOP2β plays a role in the expression of a group of neuronal 
genes. Some of these genes were highlighted in common among the various reports mentioned 
above such as GRIK2, NRXN1, NRXN3, and NELL2. These results correspond to the reduced level 
of differentiation shown in the TOP2B knockout SH-SY5Y cells. 
In this study, the differentially expressed genes in the TOP2B knockout cells might be either 
directly regulated by TOP2β or indirectly by regulation of factors that participate in their activation 
state.  
Chromatin remodelers represent a key factor in regulation of nucleosome positioning and 
accessibility of chromatin and thus play a role in gene activation and silencing (Längst and 
Manelyte, 2015). Chromatin remodelers fall into four families: SWI/SNF, ISWI, INO80, and CHD 
(Tyagi et al., 2016). CHD (Chromodomain-Helicase-DNA binding) is a family of chromodomain-
ATPases that has been shown to play a role in the regulation of gene expression (Murawska and 
Brehm, 2011) particularly of neuronal genes (Egan et al., 2013; Feng et al., 2017a; Feng et al., 
2017b). 
Of particular importance, CHD5 chromodomain remodeler has been shown to be essential during 
neurogenesis and upregulated during neuronal terminal differentiation to facilitate both activation 
of expression of neuronal genes and repression of poly-comb genes that are normally not expressed 
in neuronal tissue (Egan et al., 2013). CHD5 downregulation inhibited differentiation of murine 
neural progenitor cells (NPCs) to neurons and this was accompanied by inhibition of activation of 
key neuronal genes (such as NeuN, Ncam, and Tubb3) and abnormal upregulation of some of the 
poly-comb genes such as Hes7 (Egan et al., 2013).  
Interestingly, CHD5 was downregulated (~10 fold) in the TOP2B knockout SH-SY5Y cells. Visual 
inspection of publically available ENCODE ChIP data in SH-SY5Y cells showed several CTCF 
peaks around the 5’end of CHD5 gene with non-overlapping histone modification activation and 
repression markers around the promoter. Furthermore, several of the downregulated neuronal genes 
in this study (such as NRTK2, NRTK3, and NRXN2) have CHD5 ChIP-seq peaks at or near the 
promoter. On the other hand, other genes that have CHD5 ChIP-seq peaks at or near promoter in 
SH-SY5Y were shown to be significantly induced upon TOP2B knockout. Notably, among those 
induced genes were HES7, VIM, and NGFR (upregulated by ~ 8, 16, and 2.9 fold respectively). 
HES7 was shown to be upregulated upon CHD5 depletion in (Egan et al., 2013) while NGFR was 
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shown to be upregulated in brain of Top2b lacking mouse (Tiwari et al., 2012). Therefore, it is 
plausible that some of the transcriptional effects of TOP2B knockout might occur as a result of 
lower CHD5 expression in the TOP2B knockout cells. 
Mechanistically, as described previously, TOP2β regulates expression of targeted genes either 
through its catalytic activity to modify chromatin supercoiling and change accessibility of 
transcriptional machinery to the susceptible genes (Madabhushi et al., 2015b; Uusküla-Reimand et 
al., 2016; Canela et al., 2017) or via generation of DNA double-stranded breaks at promoters which 
promote gene activation (Ju et al., 2006; Haffner et al., 2010; Madabhushi et al., 2015b; Trotter et 
al., 2015). 
In agreement with TOP2β’s role in expression of many neuronal genes, IPA analysis of 
differentially expressed genes (DEGs) in the knockout cells highlighted the axonal guidance 
signaling pathway as the most significantly over-represented pathway both in the presence and 
absence of ATRA (Figures 6.28 and 6.25) with 88 and 82 DEGs assigned to the pathway 
respectively. DEGs  assigned to this pathway are described with their differential expression log2 
values for all comparisons in (Table 6.6). Other neuronal pathways were also significantly over-
represented, with the synaptogenesis signaling pathway being the second most significantly over-
represented pathway both in the presence (62 DEGs) or absence (51 DEGs) of ATRA. The results 
showed a remarkable inhibition prediction score for this pathway in the knockout cells both with 
and without ATRA (z-score of -3.36 and -4.24 respectively) (Figures 6.28 and 6.25). DEGs 
assigned to this pathway encode for synaptotagmins (SYT2, 3, 4, 5, 7, 9, 11, 14, 16, and 17), 
synapsins (SYN1, SYN2, and SYN3), neurexins (NRXN1, NRXN2, and NRXN3), cadherins (CDH2, 
3, 4, 7, 15, and 22), BDNF, NTRK3, and various other factors such as growth factors and EPH 
receptors encoding genes. 
IPA analysis for the prediction of upstream regulators of observed gene expression patterns in 
WT(C) vs. WT(R), WT(C) vs. BKO(C), and WT(R) vs. BKO(R)  comparisons  showed a cohort 
of various molecules including transcription regulators, kinases, cytokines, growth factors, and 





Overall, the results of this chapter are useful in a number of aspects. Firstly, it shows the 
requirement of TOP2β for neuronal differentiation in a human cell model. Secondly, it uncovers a 
large number of neuronal genes that regulated by TOP2β. A group of these genes are involved in 
canonical neuronal pathways such as axonal guidance signalling. Many of the neuronal genes 
regulated in the knockout cells were previously shown to be regulated by TOP2β in animal studies 
(overlapping with all other studies is mentioned above), suggesting a common group of genes to 
be focused on for more detailed studies in the future. Thirdly, it reports the genes that are regulated 
by retinoic acid and TOP2β at the same time. For example, the genes that were completely 
unchanged by ATRA in the knockout compared to the wild type cells belong to groups A, K, L, 
and O (Figure 6.18), while the genes that are differently regulated by ATRA in the knockout cells 
compared to the wild type cells belong to groups D, N, and M (see figures 6.17 and 6.18, for the 
full list of these genes refer to appendix table 17). These genes can be the basis for further 
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7 Chapter Seven: Discussion  
7.1 Summary of findings 
This study involved investigating of cellular and regulatory roles of TOP2β enzyme. This isoform 
was firstly recognized by (Drake et al., 1987). Since then, many studies aimed at highlighting the 
isoform-specific role of TOP2β. On one hand, it has been suggested that TOP2β involved in 
chromosomal translocations and associated secondary malignancy or therapy-related leukaemia 
(Azarova et al., 2007; Azarova et al., 2010; Haffner et al., 2010; Cowell and Austin, 2012; Cowell 
et al., 2012; Smith et al., 2014).  
In this study, TOP2β was investigated for isoform-specific contribution of cytotoxicity and 
genotoxicity (measured by micronuclei assay by FACS) induced by TOP2 poisons (daunorubicin 
and idarubicin) in Nalm6 cells (Acute lymphoblastic leukaemia). Results showed comparable 
contribution of both isoforms in both cytotoxicity and micronuclei induction. 
This study also involved investigation of cytotoxicity and genotoxicity induced by daunorubicin in 
combination with Ara-C. One interesting finding was the genotoxicity induced by Ara-C was 
significantly lower than that induced by daunorubicin at the same level of cytotoxicity (Figure 
3.13). 
On the other hand, TOP2β isoform has been shown to play a regulatory role in expression of ligand 
inducible and developmentally regulated genes (Austin et al., 2018; Madabhushi, 2018). This study 
aimed at investigating role of TOP2β in gene expression. In Nalm6 cells, two independent RNA-
seq experiments showed a number of genes that differentially expressed in both datasets (see 
chapter 4). RNA-seq and RT-qPCR analysis of expression of selected genes in two different 
knockout Nalm6 models generated by homologous recombination or CRISPR (Nalm6B-/- and 
Nalm6BKO4) highlighted CBR1 as one of the genes that tightly regulated by TOP2β.  
ChIP analysis at CBR1 gene locus showed recruitment and binding of TOP2β at 4 locations. 
Moreover, ChIP showed significant reduction of signals of USF2, c-Myc, and MAX transcription 
factors at CBR1 promoter region in the knockout cells. RT-qPCR analysis of these transcription 
factors showed no reduction in their mRNA level, suggesting reduced recruitment of these 
transcription factors to CBR1 promoter region in a TOP2β dependent mechanism.  
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This is an important finding as although both TOP2β and CBR1 have been reported to be implicated 
in doxorubicin-induced cardiotoxicity (Forrest et al., 2000; Olson et al., 2003; Zhang et al., 2012), 
so far no data suggested that the TOP2β role in doxorubicin-induced cardiotoxicity might be, at 
least in part, due to regulation of CBR1 gene. 
TOP2β has been shown to play a key role in transcriptional regulation of neuronal genes and to be 
required for neuronal development (Austin et al., 2018; Madabhushi, 2018). Studies have shown 
the role of TOP2β in expression of retinoic acid-regulated genes (Ju et al., 2006; McNamara et al., 
2008). SH-SY5Y cells have the ability to differentiate to neuronal phenotype upon retinoic acid 
treatment. Therefore, these cells were chosen in this study to investigate TOP2β role in both RA-
mediated transcription as well as neuronal differentiation. Nine different TOP2B knockout clones 
were successfully generated in SH-SY5Y cell line using CRISPR and verified for TOP2β protein 
absence (Table 6.2 and Figures 6.8, 6.10, and 6.11). 
Investigations involved comparison between wild type SH-SY5Y and three selected knockout 
clones (generated from different gRNAs) for ATRA-induced differentiation as measured by neurite 
outgrowth assay as well as BCL2 expression (Figures 6.12 and 6.13). Results showed significant 
reduction in neurite outgrowth and BCL2 expression in knockout cells compared with the wild 
type. RT-qPCR results also showed significant reduction in ATRA-induced induction of CYP26A1 
and CRABP2, two genes involved in RA signalling pathway and have been shown to be induced 
upon RA-induced differentiation in SH-SY5Y. 
In addition, analysis involved comparison between wild type SH-SY5Y and one of the knockout 
clones for whole genome transcription profile using RNA-seq in the presence and absence of 
ATRA. Results highlighted many genes that were regulated in the TOP2B knockout cells (Figures 
6.17 and 6.18 as well as Appendix table 17). Neuronal genes represent large proportion of total 
genes regulated upon TOP2B knockout in the absence or presence of ATRA (603 genes, 23.6 %) 
or (603 genes, 22.5 %) respectively. IPA analysis showed axonal guidance as the most over-
represented pathway. These findings consistent with previous reports showed TOP2β role in 
neuronal cells (Lyu and Wang, 2003; Nur et al., 2007; Tiwari et al., 2012; Li et al., 2014; Li et al., 
2017). Another functions and pathways were also significantly over-represented (see section 





• TOP2β and TOP2α contribution in cytotoxicity and genotoxicity of daunorubicin and 
idarubicin in Nalm6 cells is comparable. 
• Ara-C induces less micronuclei formation than daunorubicin at the same level of 
cytotoxicity. 
• TOP2β regulates CBR1 gene expression in Nalm6 cell line through mediation of 
recruitment of USF2, c-Myc, and MAX transcription factors to the promoter region. 
• TOP2B deletion in SH-SY5Y significantly reduced ATRA-induced differentiation. 
• TOP2β positively regulates CRABP2 and CYP26A1 genes in SH-SY5Y cells. 
• TOP2B knockout in SH-SY5Y affected expression of a group of genes particularly neuronal 
genes. 
         
7.3 Future work 
• Investigate TOP2β contribution in cytotoxicity and genotoxicity of TOP2 poisons in K562 
and SH-SY5Y cell lines using the newly generated knockout model in these cells. 
• Optimize CBR1 downregulation by siRNA or stable knockout using CRISPR to compare 
the effect of CBR1 inhibition with TOP2B knockout on doxorubicin-induced cytotoxicity. 
• Investigate whole genome binding pattern of TOP2β in Nalm6 and K562 cells using ChIP-
seq to uncover genes that directly bound and regulated by TOP2β. 
• Establish a TOP2B knockout model of human induced pluripotent stem cells then induced 
cardiomyocyte differentiation to test TOP2β role in CBR1 expression in cardiomyocytes. 
• Investigate whole genome binding pattern of TOP2β in SH-SY5Y cells using ChIP-seq to 
uncover genes that directly bound and regulated by TOP2β.     
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Name Source MW Stock Storage 
10 % Paraformaldehyde Sigma  (Cat. P6148)  
Prepare 40 % in 0.1 M 
NaOH, dissolve at 70 °C, 
dilute to 10 % in PBS. 
4 °C 
1.38 M Glycine Melford (Cat. G36050/G0707) 75.07 
Dissolve 5.1798 g in 50 ml 
DW RT 
50 mM PIPES pH 8.0 Sigma  (Cat. 1851) 302.4 
Dissolve 1.512 g in 100 ml 
DW. Adjust pH to 8.0 RT 
850 mM KCl Melford  (P41000) 74.6 Dissolve 6.341 g in 100 ml RT 
5 % NP-40 Calbiochem  (Cat. 492016)  Add 5 ml to 100 ml DW RT 
5 % Na Deoxycholate Sigma  (Cat. D6750)  Dissolve 2.5 g in 50 ml DW 
RT away 
from light 
10 % SDS Sigma  (Cat. L3771)  Dissolve 5 g in 50 ml DW RT 
1.2 M  Tris pH 7.5 Melford  (Cat. T60040) 121.14 
Dissolve 7.2684 g in 50 ml 
DW. Adjust pH to 7.5 RT 
3 M  LiCl Sigma  (Cat. L8895) 42.39 
Dissolve 6.3585 g in 50 ml 
DW RT 
0.1 M  Tris pH 7.5 Melford  (Cat. T60040) 121.14 
Dissolve 0.6057 g in 50 ml 
DW. Adjust pH to 7.5 RT 
10 mM  Na2EDTA Melford  (Cat. E0511) 372.2 
Dissolve 0.1861 g in 50 ml 
DW. RT 
1 M  NaHCO3 Sigma  (Cat. S5761) 84.01 
Dissolve 4.2005 g in 50 ml 
DW. RT 
 












Appendix table 2   RICC values of selected scheduled and concurrent (Ara-C+Daun) 
combinations. 
Cells were incubated with either: Ara-C and daunorubicin at the same time for 48 hours continuously (Ara-
C+Daun), or treated with Ara-C first then daunorubicin 24 hours later (Ara-C→Daun). The cytotoxicity 
was determined as the relative increase in cell count (RICC). Data presented here is the mean of at least 





Treatment (nM)   RICC (%) 
Ara-C Daun Ara-C+Daun SEM 
Ara-
C→Daun SEM 
2   2 70.41 4.96 73.24 2.55 
4 4 46.44 3.52 57.57 4.31 
8 8 16.89 1.55 34.61 6.23 
10 4 30.76 3.19 40.49 5.50 
12 6 19.53 2.34 26.00 5.11 




  Appendix table 3   Relative survival and RICC values of Ara-C, daunorubicin, and idarubicin in Nalm6 cell lines. 
 
Drugs Dose (nM) 
















0 98.6 4.48 103.14 6.37 94.25 9.60 94.91 3.80 89.45 3.25 92.66 2.80 
6 69.23 6.94 89.96 4.45     79.82 1.74 95.83 8.58 
7 56.39 6.35 64.14 7.02         
8.5 55.5 9.97 56.15 7.71 75.68 4.55 85.97 3.41 62.94 2.63 72.27 3.27 
10 39.9 10.45 44.88 11.61 77.68 7.89 85.24 7.97 72.17 3.17 79.32 2.31 
12 24.39 5.77 37.81 7.42 60.56 7.68 69.18 12.45 48.45 4.44 55.74 9.10 
14     49.58 8.96 44.08 3.15 25.50 1.32 32.68 0.63 
18     19.43 5.23 24.83 0.85     
Idarubicin  
0 98.60 4.48 103.14 6.37 94.25 9.60 94.91 3.80 89.45 3.25 92.66 2.80 
1 101.21 6.38 108.20 2.03         
3 64.73 6.02 79.76 10.92 91.57 4.88 91.02 8.59 92.38 3.77 80.64 13.94 
4 49.30 13.64 55.58 10.97         
5 40.15 2.12 43.29 4.70 68.07 8.03 80.82 10.09 67.89 5.18 73.31 4.90 
6         38.58 2.03 45.12 4.45 
7 22.08 9.57 22.44 6.21 54.98 3.91 57.64 9.26 43.54 3.99 41.45 12.59 
10     25.69 3.36 23.88 6.20 10.91 2.41 12.33 3.08 
12     13.67 0.67 14.75 2.12     
Ara-C  
0 94.00 3.24 99.23 6.24 92.43 4.88 109.55 2.52 86.73 2.02 112.91 3.14 
1 103.89 3.21 106.97 6.53 93.41 0.59 89.10 2.81 100.03 5.52 97.45 6.49 
3 65.34 5.32 71.44 3.40 74.35 2.06 79.52 3.75 70.43 3.06 74.22 0.35 
6 45.62 3.31 57.74 2.95 56.75 1.16 60.32 4.96 53.11 5.57 56.34 2.67 
8 36.32 1.89 54.72 2.97 47.81 3.30 53.55 5.70 42.65 2.26 50.08 0.93 




Appendix table 4   Average Micronuclei (MN) and micronuclei fold increase over control induced by TOP2 
poisons and Ara-C in Nalm6 cell lines. 
Drugs Dose (nM) 














0 0.78 0.14 0.95 0.06 1.14 0.15 0.89 0.18 0.98 0.12 0.98 0.07 
6 1.78 0.15 2.43 0.49     2.13 0.27 2.17 0.12 
7 2.29 0.11 3.10 0.46         
8.5 3.00 0.38 4.08 0.84 2.02 0.28 1.90 0.51 2.61 0.11 2.70 0.21 
10 3.58 1.43 7.11 3.91 1.51 0.24 1.42 0.39 1.73 0.13 1.78 0.10 
12 6.21 1.03 8.89 2.93 2.63 0.47 2.48 0.68 3.30 1.12 4.10 0.30 
14     4.27 0.34 3.91 0.64 7.51 1.68 7.57 1.42 
18     9.35 0.47 8.45 0.99     
Idarubicin  
0 0.78 0.14 0.95 0.06 1.14 0.15 0.89 0.18 0.98 0.12 0.98 0.07 
1 1.18 0.24 1.60 0.38         
3 1.57 0.11 2.11 0.29 1.26 0.12 1.17 0.28 1.50 0.29 1.51 0.14 
4 2.41 0.37 3.31 0.81         
5 4.07 0.38 5.64 1.12 1.57 0.13 1.46 0.30 1.43 0.36 1.57 0.49 
6         2.95 0.69 3.13 0.82 
7 6.75 1.51 9.43 3.22 2.51 0.22 2.32 0.52 3.06 0.69 3.37 1.10 
10     7.18 1.04 6.79 1.91 16.34 0.41 17.19 2.49 
12     13.05 2.77 12.55 4.43     
Ara-C  
0 0.55 0.03 0.99 0.06 0.55 0.10 0.92 0.02 0.71 0.01 0.95 0.04 
1 0.57 0.11 1.04 0.19 0.76 0.24 1.31 0.18 1.03 0.14 1.46 0.22 
3 0.59 0.03 1.07 0.05 0.73 0.21 1.30 0.17 1.03 0.17 1.46 0.26 
6 0.71 0.07 1.30 0.17 0.89 0.04 1.73 0.34 1.75 0.19 2.48 0.30 
8 1.35 0.39 2.46 0.69 1.12 0.17 2.19 0.52 2.32 0.17 3.27 0.25 
10 1.94 0.55 3.55 1.02 1.33 0.30 2.72 0.85 3.96 0.60 5.56 0.83 
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Appendix figure 1   Average Micronuclei (%) induced by daunorubicin, idarubicin, 





























Drugs Dose (nM) 
Nalm6WT Nalm6B-/- Nalm6A+/- 
Apoptotic 














0 3.23 0.42 0.99 0.06 3.98 0.12 0.98 0.04 2.80 0.17 0.95 0.05 
6 7.27 0.37 2.30 0.19     4.67 0.13 1.71 0.08 
7 9.22 0.95 2.88 0.08         
8.5 14.42 3.13 4.37 0.43 8.56 0.41 2.15 0.04 6.39 0.13 2.26 0.14 
10 18.29 9.12 5.12 2.11 6.05 0.75 1.51 0.14 3.86 0.10 1.41 0.11 
12 31.29 8.89 9.32 1.47 10.22 0.95 2.56 0.17 10.23 3.64 3.59 1.30 
14     21.98 0.73 5.55 0.35 40.89 6.16 10.28 3.73 
18     49.84 3.37 12.55 0.93     
Idarubicin  
0 3.23 0.42 0.99 0.06 3.98 0.12 0.98 0.04 2.80 0.17 0.95 0.05 
1 3.61 0.24 1.14 0.08         
3 6.82 1.39 2.07 0.17 5.01 0.12 1.26 0.04 7.30 2.70 1.46 0.20 
4 13.69 3.07 4.13 0.44         
5 24.63 2.24 7.97 1.56 7.38 0.39 1.85 0.05 9.31 1.79 2.33 0.33 
6         23.12 3.07 5.75 1.69 
7 60.25 16.91 17.92 2.91 12.44 0.93 3.12 0.15 45.46 29.19 5.19 0.63 
10     48.43 4.60 12.12 0.77 203.17 81.64 35.58 13.71 
12     113.48 26.25 28.24 5.72     
Ara-C  
0 1.99 0.10 1.01 0.07 3.97 0.96 0.93 0.07 2.42 0.11 1.01 0.07 
1 1.90 0.03 0.96 0.07 4.81 1.58 1.17 0.10 2.70 0.07 1.12 0.05 
3 2.08 0.05 1.05 0.07 4.90 1.51 1.20 0.08 2.85 0.06 1.18 0.05 
6 3.57 0.25 1.81 0.19 9.06 3.35 2.16 0.27 5.37 0.23 2.22 0.10 
8 5.93 0.95 3.01 0.55 13.60 5.88 3.15 0.60 7.94 0.58 3.28 0.18 
10 8.05 1.44 4.07 0.79 15.13 5.46 3.63 0.46 11.89 1.22 4.92 0.51 
Appendix table 5   Apoptotic cells (%) and apoptotic cells fold increase over control induced by TOP2 poisons and 




















0 104.92 3.28 97.89 6.52 0.58 0.05 0.98 0.04 3.94 0.24 1.08 0.04 
2nM Ara-C + 2nM 
Daun 73.16 2.48 96.36 12.59 0.80 0.02 1.40 0.14 4.41 0.13 1.12 0.06 
2nM Ara-C + 4nM 
Daun 58.70 8.61 80.05 12.38 1.28 0.05 2.25 0.27 6.63 0.21 1.69 0.06 
2nM Ara-C + 7nM 
Daun 33.31 3.03 54.67 6.17 2.56 0.36 4.59 1.06 14.34 0.25 3.66 0.21 
4nM Ara-C + 4nM 
Daun 42.35 3.74 72.39 7.30 1.43 0.09 2.52 0.32 7.57 0.49 1.92 0.02 
Appendix table 6   Growth inhibition, Micronuclei, and Apoptotic cells data for selected concurrent 
combinations in Nalm6WT 
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Appendix figure 3   RICC at selected (Ara-C+daunorubicin) concurrent 
combinations in Nalm6WT cell line. 
Appendix figure 2   Average Micronuclei (%) induction by selected 



















































0 96.97 5.08 96.62 3.73 0.67 0.11 1.01 0.09 3.63 0.26 0.96 0.02 
Ara-C → Daun (4→4 
nM) 49.24 3.69 71.38 3.40 1.12 0.12 1.81 0.26 5.56 0.43 1.54 0.08 
Daun → Ara-C (4→4 
nM) 50.22 5.59 69.51 3.74 1.69 0.10 2.75 0.39 8.60 0.37 2.41 0.18 
Ara-C+Daun (48) (4+4) 
nM 37.55 3.78 61.76 1.52 1.82 0.21 2.99 0.52 8.92 0.59 2.48 0.15 
Appendix table 7   Growth inhibition, Micronuclei, and Apoptotic cells data for selected scheduled 
combinations in Nalm6WT 
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Appendix figure 4   Average Micronuclei (%) induction by selected 
(Ara-C+daunorubicin) scheduled combinations in Nalm6WT cell line. 
Appendix figure 5   RICC at selected (Ara-C+daunorubicin) scheduled 
combinations in Nalm6WT cell line. 
 

































Nalm6WT Nalm6B-/- Nalm6A+/- 
G1 S G2/M G1 S G2/M G1 S G2/M 









0 35.70 1.69 47.49 1.42 16.81 0.29 34.37 1.22 48.50 1.71 17.12 0.56 34.82 1.51 46.11 1.69 19.07 0.90 
6 41.17 1.72 40.39 1.63 18.43 0.14       38.06 0.10 43.96 0.31 17.97 0.41 
7 42.12 2.75 37.79 2.41 20.09 1.67             
8.5 46.46 1.99 32.58 2.99 20.95 1.29 37.42 1.17 42.83 1.65 19.75 0.56 42.32 0.54 37.92 1.35 19.76 0.81 
10 46.25 5.77 34.07 7.57 19.67 2.01 36.87 1.19 44.60 1.33 18.53 0.27 37.86 0.65 42.60 0.83 19.55 0.19 
12 50.61 1.49 25.08 3.47 24.31 2.31 41.05 1.82 39.83 1.77 19.12 0.06 42.95 3.05 35.91 3.77 21.14 0.78 
14       47.02 1.14 32.48 0.96 20.49 1.01 52.54 2.28 22.81 2.13 24.65 0.37 







0 35.70 1.69 47.49 1.42 16.81 0.29 34.37 1.22 48.50 1.71 17.12 0.56 34.82 1.51 46.11 1.69 19.07 0.90 
1 36.44 0.53 44.94 0.48 18.62 0.07             
3 40.43 1.85 40.83 1.93 18.73 0.59 35.63 1.42 45.71 1.31 18.66 0.41 36.82 2.60 44.91 3.36 18.27 0.78 
4 45.77 2.78 33.42 3.39 20.82 1.41             
5 49.41 0.19 29.92 0.94 20.67 0.75 37.69 0.54 41.78 1.62 20.54 1.60 40.07 1.95 39.55 1.83 20.38 0.18 
6             47.98 0.68 30.84 0.71 21.17 0.84 
7 53.42 1.69 22.56 3.20 24.02 1.74 41.14 1.29 36.74 1.77 22.12 0.49 44.19 1.62 34.61 1.62 21.20 0.05 
10       50.85 2.04 26.43 2.55 22.72 0.90 50.26 0.43 25.16 0.71 24.59 0.55 





0 37.31 2.17 45.14 1.67 17.55 0.51 37.41 2.17 45.68 2.11 16.90 0.31 37.58 0.78 44.43 0.77 17.99 0.10 
1 34.66 3.07 45.87 2.52 19.47 0.62 37.02 1.84 45.03 1.15 17.96 0.87 36.69 0.51 45.20 0.99 18.11 0.95 
3 34.75 2.07 46.25 1.76 19.01 0.48 35.91 1.07 44.89 0.66 19.20 0.42 33.64 0.97 47.35 0.79 19.01 0.76 
6 30.36 1.05 51.37 1.18 18.27 0.31 29.37 2.37 51.36 3.08 19.27 1.06 31.23 0.71 51.11 0.54 17.67 0.79 
8 30.39 1.34 51.25 1.14 18.36 0.45 29.81 1.78 51.65 2.60 18.54 1.25 30.27 0.98 50.45 1.46 19.28 0.93 
10 30.29 0.97 52.27 0.81 17.43 0.16 28.96 2.23 52.75 3.02 18.29 0.98 32.01 1.68 49.59 2.45 18.39 0.99 
Appendix Table 8   Relative cell cycle phase distribution in Nalm6 cell lines treated with 




















combination G1 S G2/M 
mean SEM mean SEM mean SEM 
0 34.79 2.91 45.51 0.63 19.69 2.31 
2nM Ara-C + 2nM 
Daun 33.75 1.73 47.03 2.96 19.22 1.46 
2nM Ara-C + 4nM 
Daun 36.83 1.32 43.94 2.38 19.23 1.07 
2nM Ara-C + 7nM 
Daun 44.46 1.41 33.57 1.18 21.97 0.45 
4nM Ara-C + 4nM 
Daun 34.66 1.34 46.11 2.04 19.22 0.79 
combination G1 S G2/M 
mean SEM mean SEM mean SEM 
0 34.36 0.72 49.53 1.14 16.11 0.78 
Ara-C → Daun (4→4 nM) 38.39 1.33 42.61 1.78 19.01 0.46 
Daun → Ara-C (4→4 nM) 30.43 1.45 47.91 1.82 21.66 0.63 
Ara-C+Daun (48) (4+4) 
nM 37.38 1.07 44.84 1.16 17.79 0.43 
Appendix table 9   Relative cell cycle phase distribution in Nalm6WT cell line treated with 
selected (Ara-C+daunorubicin) concurrent combinations. 
Appendix table 10   Relative cell cycle phase distribution in Nalm6WT cell line treated with 
selected (Ara-C+daunorubicin) scheduled combinations. 
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Appendix figure 6 siRNA knockdown of TOP2B in K562WT cell line 










Samples were probed with TOP2B antibodies. Cells were transfected with 400 nM of either control or 















Volcano plot shows log2 fold change in gene expression. Genes showed more than 2 fold change are 
labelled. Y axis shows adjusted P values (padj) which represent p-value adjusted for multiple testing 
correction using Benjamini-Hochberg method to control the False Discovery Rate (FDR). Genes showed < 
0.05 padj were considered as significantly changed.  
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ZSCAN18 zinc finger and SCAN domain containing 18 4.83 3.53 3.64E-165 
ZNF512B zinc finger protein 512B 3.96 6.42 4.79E-120 
PRKACB protein kinase, cAMP-dependent, catalytic, beta 3.88 6.78 4.90E-124 
YOD1 YOD1 deubiquitinase 3.67 7.83 4.78E-219 
CBR1 carbonyl reductase 1 3.54 8.60 8.09E-75 
TOP2B topoisomerase (DNA) II beta 3.22 10.71 0* 
MIER2 mesoderm induction early response 1, family member 2 3.12 11.53 3.01E-55 
ZNF43 zinc finger protein 43 3.02 12.33 5.87E-171 
ZNF626 zinc finger protein 626 2.59 16.62 3.04E-53 
CTD-
2528L19.6 RNA Gene 2.51 17.58 1.39E-45 
PLAGL1 pleiomorphic adenoma gene-like 1 2.40 18.96 5.10E-32 
ZNF573 zinc finger protein 573 2.15 22.60 4.64E-25 
ZNF585B zinc finger protein 585B 2.09 23.48 5.04E-39 
TIE1 tyrosine kinase with immunoglobulin-like and EGF-like domains 1 2.07 23.78 1.02E-39 
GPER1 G protein-coupled estrogen receptor 1 2.06 23.98 6.29E-75 
ZNF432 zinc finger protein 432 1.94 26.09 1.33E-26 
UAP1L1 UDP-N-acetylglucosamine pyrophosphorylase 1 like 1 1.83 28.16 3.17E-60 
GPR146 G protein-coupled receptor 146 1.82 28.36 2.43E-23 
ABLIM1 actin binding LIM protein 1 1.71 30.55 1.91E-26 
MAP2 microtubule-associated protein 2 1.67 31.32 1.27E-19 
MTMR1 myotubularin related protein 1 1.67 31.44 1.13E-123 
LAMA5 laminin, alpha 5 1.66 31.60 4.91E-30 
GPRASP1 G protein-coupled receptor associated sorting protein 1 1.65 31.91 9.31E-28 
COL8A2 collagen, type VIII, alpha 2 1.62 32.57 2.73E-15 
PTPN21 protein tyrosine phosphatase, non-receptor type 21 1.58 33.50 7.70E-22 
NBPF15 neuroblastoma breakpoint family, member 15 1.56 33.91 2.01E-22 
RAB39B RAB39B, member RAS oncogene family 1.48 35.82 4.27E-12 
PTMS parathymosin [Source:HGNC 1.47 36.02 4.03E-22 
MIOX myo-inositol oxygenase 1.47 36.06 6.67E-12 
IDS iduronate 2-sulfatase  1.46 36.44 3.03E-64 
ARMCX5 armadillo repeat containing, X-linked 5 1.44 36.76 1.59E-81 
METRN meteorin, glial cell differentiation regulator 1.44 36.93 8.21E-48 
GP5 glycoprotein V (platelet) 1.43 37.01 2.08E-12 
MIR4442 microRNA 4442 1.40 37.97 1.03E-10 
PYCARD PYD and CARD domain containing 1.39 38.09 4.74E-11 
RPL22L1 ribosomal protein L22-like 1 1.39 38.13 5.53E-25 
RP4-
769N13.6 novel transcript, ARMCX5-GPRASP2 readthrough 1.38 38.53 2.06E-20 
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ZNF737 zinc finger protein 737 1.37 38.60 9.60E-11 
RYK receptor-like tyrosine kinase 1.37 38.71 3.27E-31 
RIBC2 RIB43A domain with coiled-coils 2 1.35 39.27 1.23E-15 
SPP1 secreted phosphoprotein 1 1.33 39.91 3.17E-25 
SLC9A3R2 solute carrier family 9, subfamily A (NHE3, cation proton antiporter 3), member 3 regulator 2 1.29 40.76 5.21E-10 
ST6GAL2 ST6 beta-galactosamide alpha-2,6-sialyltranferase 2 1.29 40.91 1.21E-09 
CD34 CD34 molecule 1.27 41.56 1.35E-10 
TPCN1 two pore segment channel 1 1.22 42.98 1.31E-34 
BTBD6 BTB (POZ) domain containing 6 1.20 43.41 3.21E-17 
ZNF841 zinc finger protein 841 1.15 45.10 1.15E-07 
PCDH18 protocadherin 18 1.15 45.13 2.03E-07 
LA16c-
312E8.4 Uncategorized gene. 1.15 45.15 4.65E-11 
RP11-
108H9.1 RNA Gene 1.14 45.25 1.89E-07 
GJA3 gap junction protein, alpha 3, 46kDa 1.14 45.27 2.50E-23 
RP11-
557L19.1 RNA Gene 1.14 45.51 2.10E-07 
CD4 CD4 molecule 1.14 45.51 7.70E-08 
ENOX1 ecto-NOX disulfide-thiol exchanger 1 1.13 45.54 2.52E-07 
TMPRSS3 transmembrane protease, serine 3 1.12 45.88 2.48E-12 
DENND6B DENN/MADD domain containing 6B 1.12 46.11 5.38E-15 
FAM78A family with sequence similarity 78, member A 1.08 47.30 1.13E-36 
BHLHB9 basic helix-loop-helix domain containing, class B, 9 1.08 47.43 4.92E-08 
C22orf34 chromosome 22 open reading frame 34 1.07 47.63 7.44E-12 
TMEM150A transmembrane protein 150A 1.03 49.00 1.37E-15 
FKBP4 FK506 binding protein 4, 59kDa 1.03 49.07 7.16E-41 
SLC30A1 solute carrier family 30 (zinc transporter), member 1 1.02 49.25 9.92E-45 
PLCH2 phospholipase C, eta 2 1.01 49.76 4.48E-07 
ZFYVE28 zinc finger, FYVE domain containing 28 1.00 49.90 2.68E-06 
ABCA2 ATP-binding cassette, sub-family A (ABC1), member 2 1.00 49.98 8.44E-21 
FAM221A family with sequence similarity 221, member A 1.00 50.00 5.66E-06 
WBP5 WW domain binding protein 5 1.00 50.03 1.44E-06 
* The control (Nalm6WT) corresponds to 100% 
 
Genes are listed from the highest to the lowest log2 fold change value. (*) TOP2B gene showed such a very 
low (padj) value that the machine rounded it to zero as the smallest non-zero normalized floating-point 

















LILRB1 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1 2.89 740.83 1.31E-84 
EVPL envoplakin 2.35 509.94 5.30E-38 
LGALS9 lectin, galactoside-binding, soluble, 9 2.35 508.41 2.58E-69 
SEPT3 septin 3 2.27 482.53 1.44E-44 
MVB12B multivesicular body subunit 12B 2.25 476.29 5.87E-40 
LILRA2 leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 2 1.94 383.28 1.19E-58 
GPRC5C G protein-coupled receptor, class C, group 5, member C 1.93 381.05 7.59E-29 
CLMP CXADR-like membrane protein 1.91 375.07 6.39E-23 
CC2D2A coiled-coil and C2 domain containing 2A 1.89 371.92 6.91E-23 
ROR2 receptor tyrosine kinase-like orphan receptor 2 1.82 352.11 3.24E-23 
C7orf57 chromosome 7 open reading frame 57 1.82 351.99 3.32E-34 
GDNF glial cell derived neurotrophic factor 1.74 334.47 1.02E-29 
OSCAR osteoclast associated, immunoglobulin-like receptor 1.73 332.45 1.13E-45 
TNS3 tensin 3 1.71 327.43 9.74E-22 
CD300LF CD300 molecule-like family member f 1.71 326.79 2.96E-27 
ARL4C ADP-ribosylation factor-like 4C 1.71 326.58 9.19E-24 
IL1B interleukin 1, beta 1.70 325.29 6.77E-29 
STK32B serine/threonine kinase 32B 1.70 324.80 1.01E-58 
NKG7 natural killer cell granule protein 7 1.66 316.56 3.82E-49 
GZMA granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) 1.66 315.00 1.51E-38 
EIF4E3 eukaryotic translation initiation factor 4E family member 3 1.65 313.49 8.74E-43 
FLT1 fms-related tyrosine kinase 1 1.63 308.52 2.35E-62 
EMP2 epithelial membrane protein 2 1.62 306.56 8.76E-50 
CRAT carnitine O-acetyltransferase 1.61 304.22 2.26E-18 
CSMD1 CUB and Sushi multiple domains 1 1.56 295.86 2.30E-48 
DCLK2 doublecortin-like kinase 2 1.56 294.84 4.04E-14 
CTB-83J4.2 RNA gene 1.53 289.51 8.45E-13 
CMPK2 cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial 1.50 283.63 2.35E-37 
CTSG cathepsin G 1.50 283.37 1.15E-12 
AC004009.3 UnchAra-Cterized LOC105375207 (RNA gene) 1.48 279.18 1.62E-12 
SOD1P3 superoxide dismutase 1, soluble pseudogene 3 1.47 276.34 1.57E-12 
MPEG1 macrophage expressed 1 1.46 275.44 1.95E-16 
TUB tubby bipartite transcription factor 1.43 269.64 1.55E-27 
ADAM19 ADAM metallopeptidase domain 19 1.42 267.72 2.08E-16 
ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 1.40 263.47 2.34E-11 
TSC22D3 TSC22 domain family, member 3 1.40 263.22 8.82E-13 
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SPNS3 spinster homolog 3 (Drosophila) 1.39 261.80 2.79E-11 
DTX4 deltex 4, E3 ubiquitin ligase 1.38 260.98 2.06E-78 
TANC1 tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1 1.38 259.53 6.48E-19 
IGFBP4 insulin-like growth factor binding protein 4 1.37 258.45 3.76E-24 
MROH3P maestro heat-like repeat family member 3, pseudogene 1.37 258.22 6.51E-13 
HSH2D hematopoietic SH2 domain containing 1.37 257.92 1.53E-84 
SLC26A9 solute carrier family 26 (anion exchanger), member 9 1.36 256.80 4.42E-20 
NSUN7 NOP2/Sun domain family, member 7 1.35 254.71 2.41E-10 
CD1C CD1c molecule 1.34 252.82 2.33E-12 
SULF2 sulfatase 2 1.33 252.11 4.50E-28 
KALRN kalirin, RhoGEF kinase 1.32 249.75 2.58E-22 
LINC00963 long intergenic non-protein coding RNA 963 1.30 247.02 1.08E-12 
MRC2 mannose receptor, C type 2 1.30 246.97 1.06E-72 
RP3-416J7.4 UnchAra-Cterized LOC285766 (RNA Gene) 1.30 246.40 1.32E-18 
ALOX12P2 Ara-Chidonate 12-lipoxygenase pseudogene 2 1.30 246.03 1.50E-10 
BACE2 beta-site APP-cleaving enzyme 2 1.30 245.58 1.06E-17 
CGNL1 cingulin-like 1 1.28 242.79 2.00E-16 
ITIH3 inter-alpha-trypsin inhibitor heavy chain 3 1.28 242.43 2.76E-19 
FHIT fragile histidine triad 1.27 241.47 7.06E-11 
RP4-639J15.3 RNA Gene 1.26 239.69 8.14E-09 
HHIP-AS1 HHIP antisense RNA 1 1.26 238.98 2.71E-15 
SMIM24 small integral membrane protein 24 1.25 238.48 3.74E-18 
C1orf54 chromosome 1 open reading frame 54 1.25 238.41 1.87E-33 
EBF4 early B-cell factor 4 1.25 237.86 1.07E-08 
TREML2 triggering receptor expressed on myeloid cells-like 2 1.24 236.52 8.98E-11 
EFEMP1 EGF containing fibulin-like extracellular matrix protein 1 1.24 236.34 7.49E-27 
CTD-
2313F11.1 RNA Gene 1.23 234.07 1.38E-21 
MUC19 mucin 19, oligomeric 1.21 232.03 2.49E-08 
ATP9A ATPase, class II, type 9A 1.21 231.50 3.04E-08 
APOBEC3B apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B 1.21 231.28 1.13E-31 
TNFSF4 tumor necrosis factor (ligand) superfamily, member 4 1.21 230.82 8.19E-37 
ANKRD18DP ankyrin repeat domain 18D, pseudogene 1.20 229.13 6.58E-24 
CCDC3 coiled-coil domain containing 3 1.20 229.02 2.33E-11 
RP11-
87G24.3 RNA Gene 1.19 228.41 2.68E-14 
CTD-
3035K23.7 RNA Gene 1.19 228.31 2.65E-08 
CHD5 chromodomain helicase DNA binding protein 5 1.19 228.01 8.49E-19 
SYNJ2 synaptojanin 2 1.19 227.85 3.88E-10 
STAT5A signal transducer and activator of transcription 5A 1.19 227.49 1.82E-30 
GSN gelsolin 1.18 226.25 2.58E-30 
C1orf228 chromosome 1 open reading frame 228 1.18 226.15 2.11E-08 
PHACTR3 phosphatase and actin regulator 3 1.18 225.92 1.14E-29 
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CIART circadian associated repressor of transcription 1.17 225.61 8.54E-20 
ZNF283 zinc finger protein 283 1.17 224.57 2.01E-18 
SYPL1 synaptophysin-like 1 1.16 223.05 1.81E-23 
ZNF93 zinc finger protein 93 1.15 222.01 8.45E-52 
SIGLEC17P sialic acid binding Ig-like lectin 17, pseudogene 1.15 221.58 3.24E-08 
ESM1 endothelial cell-specific molecule 1 1.15 221.57 5.69E-08 
RAB27B RAB27B, member RAS oncogene family 1.15 221.30 1.70E-09 
GOLGA8S golgin A8 family, member S 1.15 221.22 1.48E-18 
ME3 malic enzyme 3, NADP(+)-dependent, mitochondrial 1.14 220.76 1.12E-26 
SYT11 synaptotagmin XI 1.14 220.36 3.83E-32 
SYNPO synaptopodin 1.13 219.55 8.57E-09 
NCF2 neutrophil cytosolic factor 2 1.13 219.30 3.18E-08 
HR hair growth associated 1.13 218.91 1.14E-10 
PVRL1 poliovirus receptor-related 1 (herpesvirus entry mediator C) 1.13 218.80 6.71E-27 
NOS3 nitric oxide synthase 3 (endothelial cell) 1.13 218.74 1.95E-09 
LPXN leupaxin 1.11 216.15 2.62E-46 
LRG1 leucine-rich alpha-2-glycoprotein 1 1.11 215.79 1.45E-08 
RGS9 regulator of G-protein signaling 9 1.11 215.60 1.07E-13 
CTC-
251I16.1 TEC (To be Experimentally Confirmed) gene 1.10 214.57 1.42E-11 
LRRC2 leucine rich repeat containing 2 1.10 213.98 4.62E-12 
SLC16A2 solute carrier family 16, member 2 (thyroid hormone transporter) 1.10 213.87 2.18E-18 
ZNF114 zinc finger protein 114 1.10 213.85 7.37E-25 
GDNF-AS1 GDNF antisense RNA 1 1.09 213.58 3.32E-07 
RP1-45N11.1 UnchAra-Cterized LOC105377891 (RNA gene) 1.08 211.59 1.28E-12 
CCM2L cerebral cavernous malformation 2-like 1.08 211.51 1.16E-13 
RP5-
1028K7.2 RNA Gene 1.08 211.44 1.13E-17 
CTD-
3035K23.3 Uncategorized gene. 1.08 211.23 4.73E-07 
TNS1 tensin 1 1.08 211.18 1.51E-12 
MGAT5B mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase, isozyme B 1.07 210.58 3.68E-20 
CTD-
2368P22.1 UnchAra-Cterized LOC100128398 (RNA gene) 1.07 210.56 3.59E-13 
TNFRSF8 tumor necrosis factor receptor superfamily, member 8 1.07 210.52 1.80E-08 
COL5A1 collagen, type V, alpha 1 1.07 210.45 6.15E-15 
SPSB1 splA/ryanodine receptor domain and SOCS box containing 1 1.07 210.36 2.46E-19 
TBC1D27 TBC1 domain family, member 27 1.07 210.17 1.83E-09 
LIMCH1 LIM and calponin homology domains 1 1.07 210.11 7.25E-16 
CELF5 CUGBP, Elav-like family member 5 1.07 209.37 6.58E-10 
LRFN2 leucine rich repeat and fibronectin type III domain containing 2 1.07 209.26 3.84E-07 
CMAHP cytidine monophospho-N-acetylneuraminic acid hydroxylase, pseudogene 1.07 209.26 5.47E-44 
RNF182 ring finger protein 182 1.06 209.11 6.56E-17 
ZNF831 zinc finger protein 831 1.06 209.04 2.85E-10 
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KLK1 kallikrein 1 1.06 208.63 1.83E-06 
LST1 leukocyte specific transcript 1 1.06 208.49 1.95E-06 
ULK2 unc-51 like autophagy activating kinase 2 1.06 208.34 3.99E-31 
SOX13 SRY (sex determining region Y)-box 13 1.06 208.34 1.35E-33 
PIK3R5 phosphoinositide-3-kinase, regulatory subunit 5 1.05 207.05 1.46E-25 
VDR vitamin D (1,25- dihydroxyvitamin D3) receptor 1.05 207.04 4.24E-24 
TMSB4Y thymosin beta 4, Y-linked 1.05 206.46 4.13E-28 
GFRA1 GDNF family receptor alpha 1 1.04 205.90 2.84E-31 
LINC01588 long intergenic non-protein coding RNA 1588 1.04 205.80 1.86E-06 
MYO7A myosin VIIA 1.04 205.75 1.60E-07 
ETV7 ets variant 7 1.03 204.71 3.45E-06 
FBLN7 fibulin 7 1.03 204.56 4.42E-12 
GZMK granzyme K (granzyme 3; tryptase II) 1.03 203.88 6.37E-22 
CD96 CD96 molecule 1.03 203.77 3.89E-73 
ADAMTS10 ADAM metallopeptidase with thrombospondin type 1 motif, 10 1.03 203.70 6.53E-24 
AMPD3 adenosine monophosphate deaminase 3 1.02 203.45 1.54E-12 
CSPG4 chondroitin sulfate proteoglycan 4 1.02 202.86 1.43E-09 
RP1-
310O13.7 RNA gene 1.02 202.57 7.24E-08 
RP11-
13K12.1 UnchAra-Cterized LOC100507351 (RNA gene) 1.02 202.14 5.90E-06 
KCNK10 potassium channel, two pore domain subfamily K, member 10 1.02 202.13 8.23E-15 
DUSP4 dual specificity phosphatase 4 1.01 201.98 2.91E-13 
LINC00937 long intergenic non-protein coding RNA 937 1.01 201.91 1.25E-16 
C1R complement component 1, r subcomponent 1.01 201.81 1.75E-07 
ECM1 extracellular matrix protein 1 1.01 201.76 2.92E-21 
S100A10 S100 calcium binding protein A10 1.01 201.74 1.80E-08 
C19orf57 chromosome 19 open reading frame 57 1.01 201.42 1.38E-20 
RP11-
114H23.1 RNA gene 1.01 201.17 1.61E-06 
OBSCN obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF 1.00 200.40 6.76E-13 
C1RL complement component 1, r subcomponent-like 1.00 200.34 7.02E-12 
RP11-
889L3.1 Ribosomal Protein L19 Pseudogene 9 1.00 199.98 6.40E-09 
LINC00689 long intergenic non-protein coding RNA 689 1.00 199.74 2.13E-11 
* The control (Nalm6WT) corresponds to 100% 
 
























Volcano plot shows log2 fold change in gene expression. Genes showed more than 2 fold change are 
labelled. Y axis shows adjusted P values (padj) which represent p-value adjusted for multiple testing 
correction using Benjamini-Hochberg method to control the False Discovery Rate (FDR). Genes showed < 


















S100A16 S100 calcium binding protein A16 4.54 4.30 1.32E-300 
ME3 malic enzyme 3, NADP(+)-dependent, mitochondrial 3.28 10.33 1.11E-129 
LDOC1L leucine zipper, down-regulated in cancer 1-like 2.39 19.13 5.60E-62 
TMEM132A transmembrane protein 132A 2.16 22.44 6.65E-135 
GSTK1 glutathione S-transferase kappa 1 2.15 22.50 5.35E-148 
NKD2 naked cuticle homolog 2 (Drosophila) 1.93 26.20 1.66E-60 
PPM1E protein phosphatase, Mg2+/Mn2+ dependent, 1E 1.93 26.31 1.59E-69 
ZNF512B zinc finger protein 512B 1.91 26.64 2.57E-69 
MMADHC methylmalonic aciduria (cobalamin deficiency) cblD type, with homocystinuria 1.86 27.45 4.28E-249 
ELFN2 extracellular leucine-rich repeat and fibronectin type III domain containing 2 1.72 30.31 5.37E-68 
PADI4 peptidyl arginine deiminase, type IV 1.50 35.30 4.22E-27 
XAF1 XIAP associated factor 1 1.43 37.03 1.28E-44 
MT1H metallothionein 1H 1.39 38.09 3.83E-21 
RP11-
762L8.6 Uncategorized gene 1.24 42.32 1.85E-18 
SIKE1 suppressor of IKBKE 1 1.23 42.57 4.81E-208 
MID1 midline 1 1.19 43.92 5.34E-27 
COL8A2 collagen, type VIII, alpha 2 1.19 43.93 1.67E-15 
LAMA5 laminin, alpha 5 1.11 46.46 2.91E-25 
GNPDA1 glucosamine-6-phosphate deaminase 1 1.09 47.12 5.50E-16 
BCAM basal cell adhesion molecule (Lutheran blood group) 1.06 47.84 6.22E-14 
ELK3 ELK3, ETS-domain protein (SRF accessory protein 2) 1.05 48.39 8.20E-58 
MPV17L MPV17 mitochondrial membrane protein-like 1.03 49.06 8.81E-13 
TUB tubby bipartite transcription factor 1.03 49.12 4.90E-18 
CHST15 carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) sulfotransferase 15 1.02 49.19 5.27E-114 
RP3-
431P23.5 RNA gene 1.01 49.53 4.22E-14 
MT1G metallothionein 1G 1.01 49.63 4.11E-76 
ABLIM1 actin binding LIM protein 1 1.00 50.06 2.73E-23 
TOP2A topoisomerase (DNA) II alpha 0.76 59.06 1.11E-129 
* The control (Nalm6WT) corresponds to 100% 
 
Appendix table 13 Down regulated genes in Nalm6A+/- compared to Nalm6WT (AROS 
data). 














RP11-557L19.1 RNA Gene 1.90 374.30 1.00E-54 
RP11-291B21.2 UnchAra-Cterized LOC101060038 (RNA gene) 1.72 329.83 7.60E-34 
RP3-380B4.1 Long Intergenic Non-Protein Coding RNA 1758 1.69 323.27 5.47E-70 
RP11-61L19.2 RNA Gene 1.68 319.68 1.39E-41 
LINC00861 long intergenic non-protein coding RNA 861 1.67 317.88 4.29E-31 
CSMD1 CUB and Sushi multiple domains 1 1.65 314.24 1.39E-230 
SDK2 sidekick cell adhesion molecule 2 1.61 305.00 2.06E-100 
SPP1 secreted phosphoprotein 1 1.59 300.18 1.54E-191 
ADAMTS9 ADAM metallopeptidase with thrombospondin type 1 motif, 9 1.56 294.26 1.39E-75 
LIMCH1 LIM and calponin homology domains 1 1.49 281.44 2.53E-52 
LILRB1 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1 1.47 277.53 1.43E-41 
SEPT3 septin 3 1.43 270.30 2.76E-28 
CLEC12B C-type lectin domain family 12, member B 1.39 261.40 9.58E-41 
PARVG parvin, gamma 1.37 258.92 3.38E-28 
RP5-887A10.1 Long Intergenic Non-Protein Coding RNA 1781 1.35 255.12 6.60E-24 
ROR2 receptor tyrosine kinase-like orphan receptor 2 1.35 254.76 3.67E-21 
ARHGAP24 Rho GTPase activating protein 24 1.33 251.70 1.69E-28 
OSCAR osteoclast associated, immunoglobulin-like receptor 1.33 250.86 2.54E-32 
LINC00504 long intergenic non-protein coding RNA 504 1.32 250.04 4.35E-19 
CLEC14A C-type lectin domain family 14, member A 1.30 246.10 1.80E-159 
RGMB-AS1 RGMB antisense RNA 1 1.29 244.85 5.48E-43 
EBF3 early B-cell factor 3 1.28 242.41 1.29E-24 
ABR active BCR-related 1.22 233.63 1.15E-71 
RP11-744O11.2 DEAD-Box Helicase 5 (Pseudogene) 1.21 231.71 1.89E-17 
SPINK4 serine peptidase inhibitor, Kazal type 4 1.18 226.65 4.48E-37 
MGAT5B mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase, isozyme B 1.17 225.03 7.30E-31 
GDNF glial cell derived neurotrophic factor 1.17 224.96 8.78E-19 
SOD1P3 superoxide dismutase 1, soluble pseudogene 3 1.17 224.28 5.75E-15 
IL2RG interleukin 2 receptor, gamma 1.16 223.52 7.61E-63 
APBA1 amyloid beta (A4) precursor protein-binding, family A, member 1 1.15 222.00 2.45E-69 
SH3PXD2A SH3 and PX domains 2A 1.14 220.84 7.37E-40 
RP11-114H23.1 RNA gene 1.12 217.91 1.97E-14 
LRG1 leucine-rich alpha-2-glycoprotein 1 1.12 216.90 1.55E-14 
CNR1 cannabinoid receptor 1 (brain) 1.11 216.22 1.74E-86 
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FAM13A-AS1 FAM13A antisense RNA 1 1.11 215.70 6.14E-38 
RIBC2 RIB43A domain with coiled-coils 2 1.07 210.64 8.71E-26 
LYZ Lysozyme 1.07 209.27 7.01E-19 
ZIK1 zinc finger protein interacting with K protein 1 1.06 208.74 5.27E-56 
PTMAP5 prothymosin, alpha pseudogene 5 1.06 208.38 7.99E-66 
APELA apelin receptor early endogenous ligand 1.06 208.34 1.43E-19 
CALD1 caldesmon 1 1.06 207.95 5.18E-14 
KIAA1683 KIAA1683 1.06 207.92 7.59E-16 
ZNF737 zinc finger protein 737 1.04 205.27 9.67E-16 
CRMP1 collapsin response mediator protein 1 1.04 205.25 5.04E-20 
ITGA6 integrin, alpha 6 1.04 204.97 3.57E-95 
CLEC12A C-type lectin domain family 12, member A 1.03 204.10 9.69E-84 
NRCAM neuronal cell adhesion molecule 1.01 201.76 4.43E-34 
FAM13A family with sequence similarity 13, member A 1.00 200.67 8.47E-26 
STK33 serine/threonine kinase 33 1.00 199.39 4.98E-12 
* The control (Nalm6WT) corresponds to 100% 
 
















Appendix figure 9 Transfection efficiency in K562 cells. 
(A) Live imaging of Nalm6 cells transfected with positive control (PmaxGFP) and (PX458) plasmids by 
Nucleofection. Images were captured using TiE fluorescence wide field inverted microscope (Nikon) (10X 






















Samples were amplified as described in the Materials and methods and loaded on (3 %) agarose gel 
electrophoresis to allow for small size differences. 
 
Clone gRNA Mutation 
33 6 










42 6 Wild:    GCCATGGCCAAGT…..CGGGTGGCTGCGGCGCGGGAGC Mutant: GCCATGGCCAAGTGCCGGGTGGCTGCGGCGCGGGAGC 
43 6 Mutation sequence could not be confirmed. 
 































Cells were prepared for immunofluorescence as described in (Section 2.15.7.2) then probed with anti 
TOP2B antibodies (4555) followed by Alexa fluor®488 secondary antibodies then immunofluorescence 




Appendix figure 12 Screening for TOP2B knockout clones in K562 cells by 
western blotting. 
Clone protein samples (5 µg / lane) were prepared for western blotting as described in (Section 2.3) and 










































RT-qPCR analysis of genes which were either downregulated (A) or upregulated (B) in knockout Nalm6 
from Adachi (Nam6B-/-). RT-qPCR analysis as described in (section 2.13.4). PP1A gene was used as a 
reference gene for normalizing data. Data presented here is the mean of at least three independent 
















Cells were treated with (10 μM) vitamin D3 or ethanol as control for 48 hours and analysed for cell surface 















































Appendix figure 16 Effect of ATRA on growth of Nalm6 cells at 2 % FBS 
medium. 
Appendix figure 17 Effect of ATRA on growth of Nalm6 cells at 













































































Appendix table 16 Sanger sequencing results of gRNA cloning into PX459. 















































































































































Appendix figure 20 Testing transfection efficiency of PX459 vector in SH-SY5Y 


















Appendix table 17 Completed list of DEGs in SH-SY5Y by RNA-seq   
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